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The SREBP (sterol response element binding proteins) transcription factors are 
central to regulating de novo biosynthesis of cholesterol and fatty acids. The 
SREBPs are regulated by retention or escape from the ER to the Golgi where they 
are proteolytically cleaved into active forms. The SREBP cleavage activating protein 
(SCAP) and the INSIG proteins are essential in this regulatory process. The aim of 
this thesis is to further characterise the molecular and cellular aspects surrounding 
regulation of SREBP processing.  
SREBP and SCAP are known to interact via their carboxy-terminal regulatory 
domains (CTDs) but this interaction is poorly characterised.  Significant steps were 
achieved in this thesis towards specific mapping of the interaction site. These 
included cloning and over expression and partial purification of tagged SREBP1 and 
SREBP2 CTDs and probing of a SCAP peptide array with the CTDs. Results from 
the SREBP2 probing were difficult to interpret due to insolubility issues with the 
protein, however, probing with SREBP1 revealed five potential binding sites which 
were detected reproducibly. Further research is necessary to overcome SREBP2 
insolubility issues and to confirm the identified SREBP1 interaction site(s) on 
SCAP.  
INSIG1 has a central role in regulating SREBP processing and in regulating stability 
of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), a rate limiting 
enzyme in cholesterol biosynthesis. There are two protein isoforms of human 
INSIG1 produced through the use of two in-frame alternative start sites. 
Bioinformatic analysis indicated that the presence of two in-frame start sites within 
iii 
 
the 5-prime region of INSIG1 mRNA is highly conserved and that production of two 
isoforms of INSIG1is likely a conserved event. Functional differences between these 
two isoforms were explored. No difference in either the regulation of SREBP 
processing or HMGCR degradation between the INSIG1 isoforms was observed and 
the functional significance of the two isoforms is as yet unclear. 
The final part of this thesis focused on enhancing the cytotoxicity of statins by 
targeted inhibition of SREBP processing by oxysterols. Statins have significant 
potential as anti-cancer agents as they inhibit the activity of HMGCR leading to a 
deficiency in mevalonate which is essential for cell survival. The levels of HMGCR 
fluctuate widely due to cholesterol feedback of SREBP processing. The relationship 
between sterol feedback and statin mediated cell death was investigated in depth in 
HeLa cells. Down regulation of SREBP processing by sterols significantly enhanced 
the efficacy of statin mediated cell death. Investigation of sterol feedback in 
additional cancer cell lines showed that sterol feedback was absent in cell lines A-
498, DU-145, MCF-7 and MeWo but was present in cell lines HT-29, HepG2 and 
KYSE-70. In the latter inhibition of SREBP processing using oxysterols significantly 
enhanced statin cytotoxicity. The results indicate that this approach is valid to 
enhance statin cytotoxicity in cancer cells, but may be limited by deregulation of 
SREBP processing and off target effects of statins, which were observed for some of 
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Cholesterol is a vital component within the cell. Membrane lipid rafts contain high 
concentrations of cholesterol and are required to maintain membrane structure and 
fluidity (Ikonen 2008). Lipid rafts also function as an anchor for 
glycosylphosphatidylinisotol (GPI)-modified signalling molecules, as well as being 
sites for protein endocytosis (Simons & Toomre 2000; Simons & Ikonen 2000). 
Membranes deplete of cholesterol can display defective membrane receptor 
trafficking through inability of clathrin to induce membrane curvature (Rodal et al. 
1999; Subtil et al. 1999). Cholesterol is also a precursor molecule for oxysterols and 
bile acids which have signalling roles within the cell through LXRs and FXRs, 
respectively. LXR signalling reduces cholesterol absorption and promotes 
cholesterol excretion and conversion to bile acids, to prevent cholesterol build-up 
within the cell (Wójcicka et al. 2007). FXR signalling plays a role in the feed-back 
regulation of bile acid synthesis to increase conjugation and excretion of bile acids, 
also to prevent toxicity (Thomas et al. 2008). Cholesterol availability is also a 
determinant for pregnenolone synthesis which the precursor for natural steroid 
hormones which are indispensible in the body (Miller 1988).  
Cholesterol also plays an important role in the proliferation and survival both normal 
and cancer cells (Gorin et al. 2012). In addition to being essential for new daughter 
cell membrane formation, cholesterol is also tightly linked to the cell cycle (P. Singh 
et al. 2013). Blockade of cholesterol biosynthesis revealed its requirement for G1 to 
S phase transition (Jakóbisiak et al. 1991). Cancer cells have also reported to have 
elevated membrane cholesterol content (Hager et al. 2006a; Gorin et al. 2012; 




cancer studies, although the underlying mechanisms of this protective effect are not 
well understood (Banker et al. 2004; Li et al. 2006). Increased membrane cholesterol 
levels have been correlated with mediating survival in breast, prostate, liver and 
colorectal cancer cell lines, and depletion of cholesterol has been shown to enhance 
cancer cell sensitivity to apoptosis (Li et al. 2006; Hager et al. 2006a; Calleros et al. 
2009). Akt survival signalling is dependent on its localisation to lipid rafts (Zhuang 
et al. 2002). It is proposed that cholesterol depletion disrupts lipid raft organisation 
and this causes Akt inactivation with a subsequent decrease in anti-apoptotic gene 
expression and the absence of Akt-mediated inhibitory phosphorylation on pro-
apoptotic proteins (Zhuang et al. 2005).  
A major source of cholesterol is through dietary uptake. Cholesterol-rich foods 
include meat, eggs and dairy (O Brien et al. 2000). Intestinal cholesterol absorption 
is facilitated by cholesterol forming mixed miscelles with bile salts, as cholesterol is 
a relatively insoluble molecule (Wilson & Rudel 1994). Cholesterol then requires 
cellular uptake, which is mediated by Niemann–Pick C1-Like 1 (NPC1L1) (Altmann 
et al. 2004). NPC1L1 is a polytopic transmembrane protein which contains a sterol-
sensing domain homologous to that present in HMGCR and SCAP (Yu 2008). It is 
highly expressed in enterocytes and NPC1L1 null mice have highly impaired 
intestinal cholesterol absorption (Davis et al. 2004). NPC1L1 primarily resides in the 
endocytic recycling compartment (ERC) but under cholesterol-deplete conditions, 
NPC1L1 is relocated from ERC to PM where it binds cholesterol through its sterol 
sensing domain (Altmann et al. 2004). This cholesterol-bound NPC1L1 protein is 
then internalised via vesicular endocytosis, for which lipid raft localised flotillins 
have been shown to be essential (Ge et al. 2011). Internalised cholesterol is then 




is closely related to NPC1, which is also involved in cholesterol transport, although 
it is located in the late endosome/lysosomal membranes and plays a role in transport 
of low-density lipoprotein (LDL)-derived cholesterol (Wang & Song 2012). Serum 
cholesterol is transported in esterified form complexed with LDL (Liscum & Munn 
1999). LDL-cholesterol is bound by specific LDL-receptors and internalised via 
endocytosis (Simons & Ikonen 2000). Cholesterol esters are then released from LDL 
by hydrolysis within the lysosomal compartments and distributed to cellular 
membranes, facilitated by NPC1 (Liscum 2000). Cholesterol can also be synthesised 
de novo within the cell via a multi-enzymatic process, the expression of the enzymes 
involved is regulated by the sterol-response element binding protein 2 (SREBP-2) 
(Sakakura et al. 2001; Horton et al. 1998) (Figure 1.1).  
 
The Sterol Response Element Binding Protein (SREBP) Pathway 
Both biosynthesis and uptake of lipid and cholesterol are highly regulated processes, 
a regulation which is necessary to maintain the balance required for viability and to 
prevent toxicity. A main point of regulation for the proteins involved is at the 
transcriptional level. Expression of genes within these pathways are maintained by 
the actions of ubiquitous transcription factors such as SP-1 and NF-Y, but expression 
also has the capacity to be enhanced through the action of a family of transcription 
factors; the Sterol Response Element Binding Proteins (SREBPs) (Amemiya-kudo et 







Figure 1.1. SREBP-2 mediated activation of the entire pathway for cholesterol synthesis in 
mammalian cells. Key biosynthetic intermediates are highlighted in yellow. Red italics 
denote the fold increase in mRNA levels for each enzyme in TgSREBP-2 liver. Each value 
is the average of the two microarray hybridizations listed in Tables 1 and 3. *, Desmosterol 
reductase was not represented on the microarray. The fold-increase value is from real-time 
PCR. †, 17_-Hydroxysteroid dehydrogenase-7 has not been confirmed as a cholesterol 










 The SREBPs were first discovered in 1993 in the laboratory of Michael Brown and 
Joseph Goldstein and were found to bind to inverted E-box motifs referred to as SRE 
elements within the promoter regions of such genes (Hua et al. 1993a; Wang et al. 
1994).  There are three main isoforms of SREBPs which differ in their affinity for 
variations of this SRE motif, although there are more than 3 SRE elements 
recognised and there is some cross-over in transcriptional activation capabilities 
(Edwards et al. 2000). All SREBP transcription factor domains are basic-helix-loop-
helix leucine zipper motifs (Figure 1.2). SREBP 1a and SREBP 1c are two proteins 
produced from the same gene located on chromosome 17p11.2 through use of 
independent transcriptional start sites (Yokoyama et al. 1993). As a result, SREBP 
1a and SREBP 1c are encoded by different first exons and the result is a 1c 
transcription factor which is a weaker activator than 1a (Shimano, Horton, et al. 
1997). This weaker activation capacity is owing to its shorter trans-activation 
domain. SREBP2 is encoded on chromosome 22q13 (Hua et al. 1995). SREBP1c 
preferentially regulates genes involved in fatty acid biosynthesis, SREBP2 
preferentially regulates genes involved in cholesterol biosynthesis while SREBP1a is 
believed to have crossover between both areas (Amemiya-kudo et al. 2002). This is 
highlighted in nSREBP transgenic and knockout animal studies (Table 1.1).  Overall, 
the human SREBPs share 71% identity in their transcription factor domains, and this 
is reflected in homologous mammalian SREBP proteins. More recent studies are 
revealing roles for SREBP/SREs outside of the lipogenic pathways. Microarray 
analyses in a human skeletal muscle cell model over-expressing SREBP1 has 
revealed roles for the SREBPs in mitochondrial metabolism, the immune response, 
carbohydrate metabolism and hypoxia, in addition to the lipogenic pathways (Rome 








                       
Figure 1.2. Domains and identity of the SREBP isoforms (May 2008), modified from (Hua 
et al. 1993b); Domain structure of SREBP-2 and -la with numbers corresponding to the 
amino acid residues (5). The bHLH region is denoted by the green box, the leucine zipper 
region by the purple box, and the COOH-terminal domain by the blue box. Regions rich in 
particular amino acids are indicated. The percent identities in the three most homologous 





















                                                                                                                
 
      Table 1.1 (Horton et al. 2002a) 





The SREBPs differ from most other transcription factors in that they are synthesised 
as inactive precursor proteins located in the endoplasmic reticulum (ER) (Hua et al. 
1993a; Hoppe et al. 2001). The SREBPs share a common protein structure composed 
of the transcription factor domain at the amino terminus (NTD), a central 
transmembrane (TM) loop, and a large regulatory domain at the carboxy terminus 
(CTD) (Sato et al. 1994). From the moment of their synthesis, SREBPs are bound by 
the SREBP Cleavage Activating Protein (SCAP), and in the absence of SCAP, 
SREBP proteins are rapidly degraded (Sakai et al. 1997). The gene encoding SCAP 
is localised to chromosome 3p21.3 and this encodes a multipass ER-resident 
transmembrane protein with 8 TM regions and a large CTD (Nakajima et al. 1999a).  
SCAP contains a multipass transmembrane region which in which TM2-7 has been 
identified as a sterol-sensing domain (SSD) (Radhakrishnan et al. 2004) (Figure 1.3). 
The interaction between SCAP and SREBP has been localised to their respective 
CTDs, which each are sufficient to immunoprecipitate the corresponding full-length 
interacting protein (Sakai et al. 1997). The CTD of SCAP contains WD40 repeat 
motifs which are believed to mediate its interaction with SREBP (Hua et al. 1996). 
WD40 domain proteins are known to facilitate binding of multiple interacting 
proteins. For example, RACK1 contains 7 WD40 repeats, forms a beta-propeller 
structure and influences a variety of cellular signalling cascades through interaction 
with a variety of protein partners (Adams, Ron & P. a Kiely 2011). To date, the 
SREBPs are the only proteins reported to interact with the WD domain of SCAP. 
Interestingly, progesterone receptor membrane component 1 (PGRMC1) was 
identified as interacting with SCAP directly (Suchanek et al. 2005). It would be 






Figure 1.3. Topology model of the membrane domain of hamster SCAP, showing its three 
functional domains and the sites of three point mutations (Y234A, D428A, and Y640S) that 
confer a constitutive cholesterol-bound conformation, even in the absence of sterols. Amino 
acids (aa) 40–284 correspond to the sequence of luminal Loop 1, the cholesterol-binding domain of 
Scap. The three hydrophobic patches in the Loop 1 sequence are shaded in purple, and the N-linked 
glycosylation site is denoted by the red box. The Insig-binding domain is localized to transmembrane 
helices 2–6, shown by the blue bracket. The COPII-binding site is localized to the MELADL 
sequence in Loop 6, shaded in orange. Amino acids 538–710 correspond to the sequence of luminal 
Loop 7; its twoN-linked glycosylation sites are denoted by the red boxes. In membranes from sterol-
deprived cells, trypsin cleaves Scap on itsNH2-terminal side at Arg-496; in sterol-replete membranes, 
trypsin cleaves at Arg-503/Arg-505. The trypsin-cleavage site on the COOH-terminal side of Scap in 
both the absence and the presence of sterols occurs within a cluster of arginines (Arg-747–Arg-750). 










WD40 motifs follow a loose consensus sequence of X6–94-[GH-X23–41-WD]N4–8 
(where N is the number of repeats) (Neer et al. 1994). Each motif folds in a beta-
sheet conformation such that the repeats come together to form a propeller-like 
structure, with each blade of the propeller comprising of strand A-C of one repeat, 
and strand D of the next repeat (Smith et al. 1999). Strand D is believed to be the 
most accessible region of each WD40 repeat. This propeller-like structure then acts 
as a platform in mediating protein-protein interactions.  To date, all proteins 
containing WD40 repeats which have had their crystal structures solved indeed show 
this to be the case (Renault et al. 1998; Voegtli et al. 2003; Cheng et al. 2004; 
Adams, Ron & P. a Kiely 2011). However, although the consensus sequence says 
four to eight repeats can be present, all WD40 proteins that have crystal structures 
solved have seven to eight repeats forming the propeller, with the optimal beta 
propeller fold described as a seven bladed structure (Smith 2008). 
As well as being essential for stability of the SREBPs, the CTD interaction with 
SCAP is also required to mediate the transport of the SREBP precursor proteins to 
the Golgi where a 2-step proteolytic cleavage event results in release of the active 
transcription factor domain (L.-P. Sun et al. 2007; Duncan et al. 1997a; Duncan et al. 
1998).  Compartmentalisation of the precursor protein within the ER and the 
proteases in the Golgi is the only thing preventing unregulated activation of SREBP 
(DeBose-Boyd et al. 1999). Thus, SCAP-mediated transportation from the ER to the 
Golgi is the key step for SREBP activation. This transportation event is a highly 
regulated process. Activation of the SREBP pathway is regulated in a negative 
feedback manner by biosynthetic products produced by the pathway (Brown & 
Goldstein 2009).  The best characterised is cholesterol-based regulation of the 




pathway was discovered almost entirely through the works of one group based in 
Texas, under the direction of Michael S Brown and Joseph L Goldstein.  They began 
pioneering works on identification of regulators of the LDL receptor and their 
primary area of research was in cholesterol and atherosclerosis (Goldstein & Brown 
2009). SCAP is a key regulatory protein in this process, and has been highly studied 
in this regard.  
When cellular sterol levels are low, SCAP is in a conformation which facilitates 
binding of COPII vesicle packaging proteins, beginning with Sec24 binding to a 
hexapeptide sequence, Met–Glu–Leu–Ala–Asp–Leu, which is commonly referred to 
as MELADL (L.-P. Sun et al. 2007). The MELADL sequence is localised to cytosol 
facing loop 6 of SCAP (Sun et al. 2005). Following vesicle assembly around the 
SCAP-SREBP complex, it is retrogradedly transported from the ER to the Golgi. 
The Golgi houses the two proteases required for release of the SREBP transcription 
factor domain. First, site-1 protease cleaves at Arginine-X-X-Leucine (RXXL) motif 
site in the luminal loop of the precursor protein, and this is followed by cleavage at a 
site in the middle of the first transmembrane helix, and this results in a liberated 
active transcription factor domain (Duncan et al. 1997a; Duncan et al. 1998). These 
two proteases are not specific to SREBP cleavage and are also known to cleave 
ATF6 and CREBH ER-stress response proteins (Ye et al. 2000; Zhang et al. 2006). 
Cleavage by S2P is dependent on S1P cleavage (Sakai et al. 1996). The liberated 
NTD then requires transport into the nucleus which is facilitated by importin beta 
(Nagoshi et al. 1999; Nagoshi & Yoneda 2001). Once in the nucleus the NTD 





Figure 1.4. Cholesterol-mediated regulation of SREBP processing. High cholesterol 
conditions are sensed by the SCAP (blue) component of the SCAP-SREBP (blue-red, 
respectively) complex. This renders SCAP in a confirmation that prevents binding of COPII-
associated proteins to the MELADL sequence in SCAP and facilitates binding of INSIG1 
(yellow).  Thus, the SCAP-SREBP complex is retained in the ER under high cholesterol 
conditions. Under low cholesterol conditions, SCAP is in a confirmation that allows binding 
of COPII-associated proteins. The SCAP-SREBP complex is packaged into COPII-coated 
vesicles and transported to the Golgi where SREBP undergoes a two-step proteolytic 
cleavage event, mediated by two Golgi-resident proteases. This cleavage releases the active 
N-terminal transcription factor domain (nSREBP) which is transported into the nucleus by 
importin-β. nSREBP binds to SRE elements within promoters of target genes, resulting in 





However, as mentioned, this transport dependent activation is a tightly regulated 
process and is regulated in a negative feedback manner. When ER membrane 
cholesterol levels exceed 5%, SCAP undergoes a conformational change in loop 6 
that alters the proximity of the MELADL sequence in relation to the ER membrane 
such that sec24 can no longer bind (Radhakrishnan et al. 2008). This conformational 
change was demonstrated by a change in pattern of trypsin cleavage bands, where a 
previously obscured trypsin cleavage site is revealed in low sterol conditions. 
Cholesterol has been shown to elicit this effect by binding to a region within luminal 
loop 1 of SCAP (Motamed et al. 2011). A point mutation of Y234A within this loop 
alters the conformation of  loop six, mimicking the effect of bound cholesterol, and 
SREBP processing does not occur even in sterol deplete conditions (Motamed et al. 
2011). This mutant retains the ability to bind SREBPs however and prevent their 
degradation. A potential mechanism as to how cholesterol binding to loop 1 
influences the conformation of loop 6 has recently been proposed. Zhang et al 
identified a critical residue in luminal loop 7 of SCAP which when mutated to serine 
(Y640S) has the same effect as the Y234A mutation (Y. Zhang et al. 2013). These 
studies revealed that an interaction between loop 1 and loop 7 of SCAP keeps loop 6 
in a conformation with MELADL accessible. Cholesterol binding prevents this 
interaction from occurring and that this results in the altered conformation of loop6. 
The mutations in loop 1 or 7 also block this interaction, thus mimicking the effect of 
cholesterol binding (Y. Zhang et al. 2013).  
The conformational change in SCAP also facilitates binding of another ER resident 
protein called insulin induced gene (INSIG) (Sun et al. 2007). INSIG is also 
commonly referred to as the ER-retention protein for the SCAP-SREBP complex, 




(Sun et al. 2005). Two paralogs of INSIG exist in the vertebrate genome; INSIG1 
and INSIG2. INSIG1 is located at 7q36 and INSIG2 is located at 2q14.1 (Peng et al. 
1997; Bressler et al. 2009). These INSIG proteins have six-transmembrane helices 
with short cytosolic extensions at both the amino and carboxy termini (Feramisco et 
al. 2004) (Figure 1.5). They share 56% overall sequence identity (Yabe et al. 2002). 
Both INSIG proteins have demonstrated the capability to mediate the ER-retention 
of the SCAP-SREBP complex (Yabe et al. 2002). Knockout studies of each have 
shown that in the absence of INSIG1, INSIG2 compensates, and vice-versa 
(Engelking et al. 2005).  
Also, over-expression of each isoform has the same inhibitory effect in the presence 
of sterols (Yabe et al. 2002). The two INSIG proteins do however differ in their 
modes of regulation. INSIG2 is constitutively expressed and is not subject to sterol-
regulated degradation (Lee, Gong, et al. 2006; Gong, Lee, Lee, et al. 2006a). 
Conversely, INSIG1 expression is induced by the SREBP transcription factors, 
which themselves are activated in response to low sterol availability (Lee & Ye 
2004). INSIG protein is then stabilised through sterol-mediated binding to SCAP, 
which displaces the E3 ligase gp78 and prevents degradation of INSIG (Ye & 
Debose-boyd 2011). INSIG essentially functions to negatively regulate cholesterol 
biosynthesis through inhibition of cholesterogenic gene expression via ER retention 
of SREBP-SCAP. Both SCAP and INSIG act to negatively regulate SREBP 
transport in the presence of sterols. Insig binds within TM 2-6 of SCAP, and three 
sterol-resistant mutants of SCAP (D443N, Y298C, and L315F) fail to bind INSIG 
(Yang et al. 2002). INSIG is essential to sterol-regulated retention of SCAP-SREBP 
processing as in the absence of INSIG, SREBP processing is not regulated by 




sufficient to inhibit sec23/24 binding (Sun et al. 2005). INSIG is also essential for 
oxysterol-mediated regulation of SREBP processing as oxysterols bind to INSIG, not 




Figure 1.5. Membrane topology of human INSIG proteins. (A) Proposed membrane 
topology of INSIG-1 (modified from(Gong, Lee, Brown, et al. 2006)). (B) Proposed 









Cholesterol is not the only regulator of SREBP activation. In 2007, Radhakrishnan et 
al showed using radio-labelled sterols in competition assays that cholesterol bound 
the sterol sensing domain of SCAP (Radhakrishnan et al. 2007b). In the same study, 
other sterols shown to interact with SCAP and prevent SREBP processing included 
dihydrocholesterol, desmosterol, androstenol and androstanol. They showed using 
the same methods that other sterols, including 7α-hydroxycholesterol (7α-OHC), 27-
hydroxycholesterol (27-OHC), 24S-hydroxycholesterol (24S-OHC), 25-
hydroxycholesterol (25-OHC), 22R-hydroxycholesterol (22R-OHC), and 24,25-
hydroxycholesterol (24,25-OHC) competitively bound INSIG. Oxysterols stabilise 
INSIG and prevent its ubiquitin-dependent degradation by displacing gp-78. Sterols 
that were found to bind either of these two proteins demonstrated the ability to 
prevent SREBP cleavage (Radhakrishnan et al. 2007b). However, not all sterol based 
molecules displayed these characteristics and were not recognised as regulators of 
SREBP activity. 25-OHC was identified as the most potent inhibitor of SREBP 
activation; due to its ease of transport across the membrane, and is commonly used 
in experiments investigating molecular aspects of SREBP activity and regulation, 
and as a positive control when identifying novel regulators of the pathway (Figure 
1.7). 
The mechanisms of fatty acid regulation of the SREBP pathway are less clear, but 
work in the area is growing. However, it had been shown that poly unsaturated fatty 
acids (PUFAs) down regulate SREBP1 isoforms at the processing level, and that this 
inhibitory effect increased with chain length and unsaturation of the FAs (Xu et al. 
1999). This was later linked to PUFA binding to and stabilising INSIG, to facilitate 
ER-retention of SREBP (Lee et al. 2008). Insulin regulation of SREBP1 processing 




Yellaturu, Deng, Park, et al. 2009). The mechanism by which PUFAs and sterols 
differentially regulate processing of SREBP1 and SREBP2 isoforms, respectively, 
has not yet been elucidated.  
Non-sterol regulators have also been identified that inhibit SREBP processing. 
Betulin is a naturally occurring triterpenoid isolated from birch bark (Alakurtti et al. 
2006) (Figure 1.7). Betulin has been investigated in relation to cancer cell 
cytotoxicity but has shown limited beneficial effects (Li et al. 2010; Cichewicz & 
Kouzi 2004; Rzeski et al. 2009). However, in 2009, treatment of cancer cells with 
betulin in the presence of cholesterol significantly enhanced cell death beyond that 
induced by treatment with betulin alone (Mullauer et al. 2009). The authors could 
not propose a potential mechanism for the enhancing effect of cholesterol on betulin, 
but suggested it was linked to an effect of cholesterol on membrane integrity 
enhancing betulin uptake into the cell. In 2010 it was demonstrated that betulin 
inhibited SREBP processing by promoting the association between SCAP and 
INSIG (Tang et al. 2011). Thus it is possible that the combined action of betulin and 
cholesterol on the SREBP pathway resulted in the observed effects. 
Recently, a synthetic small molecule inhibitor called Fatostatin was identified as an 
inhibitor of adipogenesis and also blocked body weight increase and hepatic fat 
accumulation in obese mice (Kamisuki et al. 2009). Fatostatin was shown to elicit 
this effect through blocking the ER-Golgi transport of SREBP by binding to SCAP. 
This effect was shown to be independent of INSIG-mediated ER retention and did 
not affect SCAP interaction with SREBP, and thus it was proposed to interfere with 
the binding of COPII associated proteins to SCAP, although this would require 




have high anti-cancer activity in prostate cancer (Li et al. 2014). Treatment with 
Fatostatin induced apoptosis, reduced invasion and migration in prostate cancer cell 
lines, and inhibited tumour growth and serum PSA levels in mouse models of 
prostate cancer. Prostate cancer is strongly linked to aberrant lipogenesis and the 
effects of Fatostatin were attributed to its modulation of the SREBP pathway and 
androgen receptor signalling (Li et al. 2014).  
Mechanisms for activation of SREBP processing have also been reported. Inhibition 
of the Akt/PI3K pathway has been reported to negatively impact on cholesterol and 
fatty acid synthesis by disrupting SCAP transport form the ER to the Golgi (Du et al. 
2006; Krycer et al. 2010). Insulin has also been shown to enhance processing of 
SREBP-1c by promoting Akt-mediated phosphorylation of the precursor protein 
which led to an increased affinity of the SCAP-SREBP complex for COPII 
packaging proteins (Yellaturu, Deng, Cagen, et al. 2009). However, the same 
experiment showed insulin to have no effect on SREBP-2 processing. This, taken 
together with initial reports indicating that Akt inhibition affects both cholesterol and 
fatty acid synthesis, suggests that the PI3K/Akt pathway has the capability to 
differentially enhance the processing of SREBPs under different conditions. 
Androgen regulation of SREBP processing has also been reported in the prostate 
cancer cell line, LNCaP, mediated by androgen-induced up-regulation of SCAP 
(Heemers et al. 2006; Heemers et al. 2001). SCAP was found to contain an androgen 
response element in intron 8, which allowed androgen receptor mediated regulation 




Surprisingly, SREBP processing has also reported to be activated by cysteine 
proteases that have a role in apoptosis, although a role for active SREBP in apoptosis 
is unclear (Pai et al. 1996). 
 
Oxysterols: Synthesis and Functions 
The SREBP pathway governs cholesterol biosynthesis and is subject to end-product 
feedback regulation, as described above. However, certain cholesterol-derived 
molecules have also displayed a regulatory influence over SREBP activation. 
Oxysterols are derivatives of cholesterol which are produced through enzymatic 
oxidation and also through non-enzymic oxidation processes (Otaegui-Arrazola et al. 
2010).  The main enzymes involved in the oxidation of cholesterol are Cytochrome 
P450 family members (Figure 1.6). (CYP7A1), (CYP27A1), (CYP46A1) catalyse 
the conversion of cholesterol to 7α-OHC, 27-OHC, 24S-OHC, respectively (Otaegui-
Arrazola et al. 2010). A small percentage of 25-OHC is reported to be produced 
through the actions of the aforementioned P450 enzymes, and also through the 
specific 25-hydroxylase enzyme (Diczfalusy 2013). The distribution and levels of 
oxysterols vary across tissues, dependent on the expression of a given P450 enzyme. 
For example, 7α-OHC and 27-OHC levels are high in the liver as they are precursors 
for bile acids production, while 24S-OHC is high in the brain (Garenc et al. 2010). 
25-OHC is lowly expressed in comparison.   
Non-enzymatic oxidation of cholesterol is also reported. There are two pathways by 
which this enzyme-independent process can occur, distinguished by the involvement 






Figure 1.6. Structure and origin of common oxysterols. Most of the oxysterol species 
displayed are generated by enzymes that belong to the Cytochrome P450 family (CYP). 
CH25H, cholesterol 25-hydroxylase, is a di-iron enzyme. The enzymatically derived species 
are indicated with green, products of cholesterol autoxidation with red, and a species derived 
from a shunt of the cholesterol biosynthetic process with blue print (Olkkonen et al. 2012).  
  
Oxysterols are also available from dietary sources. High cholesterol foods such as 
meats, eggs and dairy products are also rich in oxysterols, including 7α-OHC, 7β-
OHC, 7-ketocholesterol, alpha-epoxycholesterol (α-epox), beta-epoxycholesterol (β-
epox), 19-hydroxycholesterol (19-OHC) and 25-OHC (O Brien et al. 2000). 
Oxysterols modified at the C7 position are usually the highest concentration 
oxysterol detected in such foods, but limited data exists to determine plasma 
concentrations achieved following ingestion. Heating cholesterol-rich foods, 
however, has been shown to significantly increase their oxysterol content (Savage et 




A number of the oxysterols have been screened for their capacity to regulate SREBP 
activation.  Competitive binding assays revealed that 25-OHC, 22R-OHC, 24S-OHC, 
27-OHC, and 24,25-OHC negatively regulate SREBP processing through binding 
INSIG (Radhakrishnan et al. 2007b). 7α-OHC, 7β-OHC and 7-ketocholesterol 
displayed moderate regulatory capacity, although binding to INSIG or SCAP as 
mechanism was unclear. This study demonstrated that not all oxysterols were 
capable of regulation, one of which was 19-OHC (Figure 1.7). This group 
subsequently used 19-OHC as a negative control for many SREBP pathway 
mechanistic studies, which appeared to confirm that this is the case (Brown et al. 




Figure 1.7. Structures of some commonly used regulators (cholesterol, 25-OHC and betulin) 





In addition to regulation of SREBP cleavage and being precursor molecules for bile 
acid synthesis, oxysterols also function as signalling molecules (Olkkonen et al. 
2012). Oxysterol production is proportional to the available cholesterol for 
modification within the cell. In instances of excess cholesterol, oxysterols signal 
within the cell to adjust accordingly to the excess of cholesterol present. LXRs are 
ligand-activated transcription factors which function as heterodimers with RXRs 
(another ligand-activated TF) (Wójcicka et al. 2007).  Oxysterols are the natural 
ligands for LXR (activation at the micromolar levels (as is in plasma)), and include 
4β-OHC, 25- OHC, 22ROHC, 24S-OHC, 27-OHC, and 24,25-OHC, although  25-
OHC and 27-OHC are reported as being relatively weak activators. Activated LXRs 
stimulate expression of multiple genes involved in removal of excess cholesterol 
from the cell (Li & Glass 2004; Yoshikawa et al. 2010). LXRs increase expression of 
Niemann-Pick C1 (NPC1) proteins and ABC transporters which regulate transfer of 
cholesterols from endosomes to the plasma membrane, followed by their efflux to 
HDL particles, respectively (Ory 2004; Ma et al. 2009; Repa et al. 2002). 
Interestingly, cholesterol efflux is actively suppressed through the actions of 
SREBP2. SREBP2 is transcriptionally regulated by itself, thus in sterol depleted 
conditions its expression in increased (Sato et al. 1996). An evolutionarily conserved 
mir-33 was recently identified within intron 16 of the human SREBP2 gene and was 
found to be co-expressed with SREBP2 mRNA levels. Mir-33 negatively regulates 
ABC transporters and decreases circulating HDL-cholesterol levels (Marquart et al. 
2010; Rayner et al. 2010). Thus SREBP2 acts to co-ordinate increased cholesterol 
synthesis and decreased cholesterol efflux to raise cellular sterol levels. LXRs also 
regulate expression of the rate limiting step of bile acid synthesis, CYP7A1, which 




LXRs also limit intestinal cholesterol absorption by increasing ABCG5 and ABCG8 
transporter expression in enterocytes, although this is believed to be of minor 
importance in relation to increasing cholesterol efflux (Repa et al. 2002). Thus, 
oxysterols function at multiple levels to maintain the tight balance of intra-cellular 
cholesterol.  
Activated LXRs also have roles outside of cholesterol regulation, including in 
inducing inflammatory mediators, contributing to atherosclerotic plaque formation, 
and potentiating neurodegenerative diseases (Jamroz-wiśniewska et al. 2007).  
Oxysterols have also demonstrated apoptotic effects in a variety of non-malignant 
and cancer cell lines (Lordan et al. 2009).  These effects together with their pro-
inflammatory links have also linked oxysterols to disease such as irritable bowel 
syndrome and age-related macular degeneration (Poli et al. 2013). Recently, 27-
OHC was identified as a linking factor between hypercholesterolemia and breast 
cancer (Nelson et al. 2013). 27-OHC was shown to be a ligand for the oestrogen 
receptor and 27-OHC binding to this receptor increased cell growth. Increased 
expression of CYP27A1, which converts cholesterol to 27-OHC, was found to be 
associated with high-grade tumours (Nelson et al. 2013).  
 
HMGCR          
The rate limiting step of cholesterol biosynthesis is the conversion of HMG CoA to 
mevalonate in the presence of NADPH, which is catalysed by HMGCR (Brown et al. 
1973; Rétey et al. 1970). The HMGCR gene is localised to chromosome 5q13 and 
encodes an ER-localised protein with an 8 TM region containing an SSD and a 






Figure 1.8. Domain structure of hamster HMG CoA reductase. (A) HMG CoA reductase 
consists of two distinct domains: a hydrophobic N-terminal domain with eight membrane-
spanning segments that anchor the protein to ER membranes, and a hydrophilic C-terminal 
domain that projects into the cytosol and exhibits all of the enzyme's catalytic activity. (B) 
Amino acid sequence and topology of the membrane domain of hamster HMG CoA 
reductase. The lysine residues implicated as sites of Insig-dependent, sterol-regulated 
ubiquitination are highlighted in red and denoted by arrows. The YIYF sequence in the 






As well as being required as the precursor for de novo cholesterol synthesis; the 
essential nature of which is highlighted earlier, mevalonate production is also 
essential to maintain cell viability (Ikonen 2008). Mevalonate itself has an essential 
role in DNA replication, with an increase in HMGCR expression linked to cell cycle 
S-phase (Quesney-huneeus et al. 1979; Tatsuno et al. 1997). Mevalonate production 
is also an absolute requirement for the synthesis of farnesyl pyrophosphate and 
geranylgeranyl pyrophosphate intermediates of the cholesterol biosynthesis pathway, 
which are essential for post-translational modification of proteins essential 
throughout the cell cycle (Sebti & Hamilton 2000; Rilling et al. 1993).  
Cellular mevalonate levels are controlled through tight regulation of HMGCR which 
is centred on the sterol requirements of the cell (Vallett et al. 1996; Horton et al. 
2002a). In response to changes in cellular sterol levels, HMGCR is altered at the 
transcriptional and protein levels (Vallett et al. 1996; Sever et al. 2003a). Low 
cellular sterol levels activate SREBP transcription factors, as described above, which 
regulates HMGCR at the transcriptional level (Vallett et al. 1996). Sterols also play a 
role in regulating HMGCR protein stability, to exert a more immediate stop to 
mevalonate production under high sterol conditions (Sever et al. 2003a). In the 
presence of oxysterols, including 25-OHC 24,25-dihydrolanosterol, INSIG binds 
HMGCR (Lange et al. 2008). This binding event recruits INSIG-associated E3 
ubiquitin ligases to HMGCR, resulting in the ubiquitin-dependant degradation of the 
protein (DeBose-Boyd 2008). Both INSIG isoforms can mediate the degradation of 
HMGCR, although they do so through distinct E3 ligases. INSIG1 recruits gp78, 
INSIG2 recruits TRC8 (Jo et al. 2011; Che et al. 2012). It is also reported that 
HMGCR catalytic activity is regulated at the post-translational modification level, 




phosphorylate Ser872 (human) in the HMGCR active site (Clarke & Hardie 1990). 
This phosphorylation inhibits HMGCR activity and is reversed upon de-
phosphorylation by PP2A.  
The role of mevalonate in proliferating cells has been established. Unsurprisingly, 
the mevalonate pathway has also demonstrated links to cancer cell survival and 
progression (Gorin et al. 2012; Yokomizo et al. 2011; Swanson & Hohl 2006; 
Wächtershäuser et al. 2001). Constitutively active HMGCR was sufficient to 
enhance the cancer phenotype of MCF-7 cells, and to induce transformation of their 
non-malignant counterparts, MCF-10A (Clendening, Aleks Pandyra, et al. 2010). In 
the same study the authors discuss the correlation between high mRNA levels of 
HMGCR and other mevalonate pathway genes with poor prognosis for breast cancer 
patients. Brain and prostate cancers have also been reported as having elevated levels 
of cholesterol synthesis and cholesterogenic gene expression (Rudling et al. 1990; 
Hager et al. 2006b). Sterol-feedback regulation of SREBP processing and 
cholesterogenic gene expression has also been reported for a subset of prostate 
cancers (Chen & Hughes-Fulford 2001). Studies have also shown an association 
between statin resistance in a subset of AML cell lines and up-regulation of HMGCR 
(Clendening, Aleksandra Pandyra, et al. 2010). HMGCR has therefore been 
proposed as a metabolic oncogene, which would fit within one of the emerging 
hallmarks of cancer; reprogramming of cellular energy metabolism in order to 
support continuous cell growth and proliferation (Hanahan & Weinberg 2011). Thus, 
this further makes HMGCR an attractive target in the treatment of cancer.  
The activity of HMGCR is effectively inhibited by a family of drugs known as 




cholesterol-related disease (Istvan & Deisenhofer 2001; Law et al. 2002; Vaughan et 
al. 2000). These drugs competitively bind the catalytic site of HMGCR, decrease 
mevalonate production, and the cell compensates by increasing cholesterol 
biosynthesis and uptake genes (Istvan & Deisenhofer 2001; Sheng et al. 1995). 
HMGCR is reported to undergo alternative splicing, with the resultant HMGCR 
isoform lacking exon 13 (HMGCR-D13) (Medina et al. 2008). Initial reports 
indicated that this isoform was not catalytically active, but subsequent studies show 
that this isoform is indeed capable of producing mevalonate (Burkhardt et al. 2008). 
The key residues for substrate binding are 684 to 692, and are located in exon 16, 
and thus are not affected by the absence of exon 13, which encodes residues 522 to 
574 (Medina et al. 2008). In fact studies have shown both HMGCR and 
HMGCRD13 transcripts to be up-regulated in response to statin treatment, and that 
HMGCR-D13 does not display any impaired ability to promote proliferation of 
HepG2 cells compared to the full length isoform (Clendening, Aleks Pandyra, et al. 
2010). It is suggested that the possibility of a heterodimer formation between 
isoforms may have confounded the first study (Medina & Krauss 2009). However, 
there are reports that the D13 isoform is less sensitive to statin mediated inhibition of 
HMGCR enzymatic activity compared to the full length isoform (Medina & Krauss 
2009). There has also been reports correlating elevated levels of the HMGCR-D13 
isoform in patients with a decreased response to statin-induced plasma LDL-
cholesterol lowering, resulting from reduced upregulation of LDLR (Medina et al. 
2008; Krauss et al. 2008).  Together these data would suggest that the HMGCR-D13 
isoform is functional to produce mevalonate but that statins have reduced binding 
capacity, possible linked to the altered active site conformation, and thus statin-




proposed that statins form van der Waals interactions with multiple residues encoded 
by exon 13 and that loss of these interactions may affect statin action, although this 
requires further investigation (Istvan & Deisenhofer 2001).  
 
Statins  
Statins refer to a group of drugs which competitively bind to the catalytic pocket of 
HMGCR and effectively prevent the enzymatic conversion of HMG-CoA to 
Mevalonate (Istvan & Deisenhofer 2001). Statins were originally identified as fungal 
metabolites which effectively and competitively inhibited cholesterol synthesis in 
mammalian cells. The pioneering statin, compactin, was discovered in the mid-
1970s, isolated from Penicillium citrinium, followed closely by the identification of 
another naturally occurring statin from Aspergillus terreus, lovastatin (Brown et al. 
1978; Alberts et al. 1980; Brown & Goldstein 2004). Natural statins which are 
currently clinically available are Lovastatin, Pravastatin and Simvastatin (Tobert 
2003). Compactin failed to pass clinical trials but is routinely used in the laboratory 
setting in studies of the SREBP and mevalonate pathways (Kita et al. 1980; Sever et 
al. 2003a; Goldstein et al. 1979).  Synthetic statins are also clinically available; 
Atorvastatin, Cerivastatin and Fluvastatin, which contain the HMG-like moiety 
present in all of the naturally occurring statins central to their inhibitory action 
(Tobert 2003).    
Members of the statin family all competitively bind HMGCR and effectively reduce 
serum cholesterol levels. However they differ in a number of their properties, a 
comprehensive review by Schachter et al, 2004 gives more detail on this aspect 




bioavailability. Statins differ in their potency at achieving plasma cholesterol 
reduction, with evidence suggesting atorvastatin and simvastatin represent the most 
effective statins at the recommended daily doses (Solomon & Freeman 2008). These 
differing effects have been linked to the influence of their chemical structures on 
solubility and half-lives. Despite their rapid absorption following administration,  
statins suffer from a high level of first-pass metabolism in the liver (Schachter 2004). 
However, they differ in the extent to which their bioavailability is affected, ranging 
from 5-60%. This difference is linked to the P450 enzymes which metabolise each 
statin differing (Schachter 2004). This issue of bioavailability does not affect statin 
inhibition of HMGCR in the liver as site of action for serum cholesterol lowering, 
but requires consideration for possible alternative therapeutic uses of statins.  
The primary use of statins is to lower circulating plasma LDL-cholesterol through 
increasing cell surface LDLR expression, which is triggered upon HMGCR 
inhibition (Law et al. 2002).  The majority of clinical benefits observed with statin 
use are attributable to cholesterol reduction, however there is emerging evidence to 
support non-LDL-cholesterol linked or pleiotropic effects of statins (Bonetti et al. 
2003; Zhou & Liao 2010). Atherosclerosis is complex disease involving lipid plaque 
formation combined with chronic inflammation in arterial walls (Fan & Watanabe 
2003). In addition to the beneficial impact of cholesterol lowering on this disease, 
statins are believed to also contribute to a reduction in the associated inflammation 
(Jain & Ridker 2005). Statins have been shown to modulate the immune system in a 
number of ways. Statins have been shown to directly decrease the expression of 
ICAM-1, VCAM-1 and E-selectin endothelial adhesion molecules (Jain & Ridker 
2005).  Statins have also been shown to indirectly repress major histocompatibility 




expression of a MHC-II transactivator (CIITA) (Kwak et al. 2000). Activated T-
lymphocytes play an important role in the pathogenesis of atherosclerosis (Fan & 
Watanabe 2003). These anti-inflammatory traits of statin use have led to interest in 
their use for reduced transplant rejection (Lakkis & Billiar 2013). Statins are also 
currently used for the prevention and treatment of stroke (Prinz & Endres 2011). 
There is little evidence to connect elevated cholesterol levels with stroke incidence 
and the anti-inflammatory pleiotropic effect of statins are attributed with the 
beneficial effects (Prinz & Endres 2011). Such pleiotropic effects are evidence that 
statins can act systemically, outside of hepatic LDL-cholesterol clearance, despite 
their high first-pass clearance rate. 
Although the clinical tolerance and benefits of statins are apparent, adverse side 
effects to statin treatment are reported in a portion of patients. The most common 
reported side effect among statin users is myopathy (Needham & Mastaglia 2014; 
Joy & Hegele 2009). Patients on high dose statin regimes are more likely to 
experience myopathic events, although it is also dependant on patient risk factors 
including age, nutrition, exercise levels and other medications (Escobar et al. 2008; 
Egan & Colman 2011). A recent clinical trial investigating the effects of statins on 
skeletal muscle function revealed that high-dose statin treatment over a six month 
period did produce mild muscle injury in patients, but did not decrease muscle 
strength or exercise performance (Parker, Capizzi, et al. 2013). The mechanism of 
statin effect on muscle is not clear. Possible proposed mechanisms include the effect 
of reduced protein prenylation on the activation capacity of pathways involved in 
maintaining skeletal muscle homeostasis during exercise (Stark et al. 1998). Reduced 
isoprenoid synthesis also impacts on ubiquinone production, which may lead to 




Johnson et al. 2004). Another attractive possibility is the reported effects of statins 
on cell proliferation, apoptosis, and on the immune system and that these may be 
linked to skeletal muscle damage (Wong et al. 2002; Jain & Ridker 2005). Statin-
associated myopathy is a further indicator of extra-hepatic effects of statin use and 
may serve as evidence that HMGCR inhibition can occur beyond the liver despite 
the high level of first-pass clearance. A recent review also discusses genetic 
susceptibility factors for statin myotoxicity (Needham & Mastaglia 2014). Other less 
frequent reported statin side effects include hepatotoxicity and diabetes (Wilkinson 
et al. 2014). It is believed that these effects are likely secondary to the lipid lowering 
effect of statins.  
Statins are one of the most extensively used drugs across the world in the treatment 
of cholesterol-related disease. Their mechanism of action is well understood and 
their side-effects are minimal under the recommended dose range (40 mg/day). 
However, given the pathway that they manipulate to achieve their therapeutic effect 
and that they influence serum cholesterol levels, there has been significant interest in 
the effect of statin usage on both cancer risk and prevention (Boudreau et al. 2010; 
Browning & Martin 2007; Demierre et al. 2005). While early studies on statin users 
in a clinical trial for coronary heart disease reported an increased cancer incidence 
among statin users as a secondary finding (Sacks et al. 1996), subsequent meta-
analyses of a wide variety of randomised clinical trials taking into account trial size, 
follow up dates and removal of confounding factors gave a more comprehensive 
insight (Boudreau et al. 2010; Dale et al. 2006; Browning & Martin 2007; Graaf et 
al. 2004; Alsheikh-Ali et al. 2008; Liu et al. 2014; X.-L. Zhang et al. 2013; Wang et 
al. 2013; Chan et al. 2013; X. Zhang et al. 2013). The consensus from a variety of 




increased risk of cancer overall or at specific sites, among statin users. In fact, there 
is a growing body of evidence to support a chemoprotective effect of statin use 
(Nielsen et al. 2012). Atorvastatin has been shown to inhibit both pancreatic and 
intestinal tumourigeneis (Gbelcová et al. 2008; Swamy et al. 2006; Reddy et al. 
2006). Simvastatin has been shown to inhibit growth of malignant gliomas (Kikuchi 
et al. 1997). Lovastatin has been shown to suppress the formation of lung tumours in 
mice (Feleszko et al. 2000; Hawk et al. 1996). Epidemiological studies on statin use 
have reported a decreased incidence in a variety of cancer types among statin users 
(S. Singh et al. 2013; Yi et al. 2014; Mucci & Stampfer 2014). It is important to 
note, however, that this was not a universal effect observed among patients, and 
conclusive evidence for an established link between statin use and a reduced 
incidence of cancer is not yet available. Clinical trials on cancer prevention with 
statins are underway (Table 1.2).   
 
Table 1.2. Statins in Cancer Prevention (www.clinicaltrials.gov) 
Identifier:  
NCT01349881 S0820, Adenoma and Second Primary Prevention Trial (PACES) 
NCT00334542 Simvastatin in Preventing a New Breast Cancer in Women at High 
Risk for a New Breast Cancer  
 
NCT00285857 Phase II Trial - Breast Cancer Chemoprevention by Lovastatin 
NCT00637481 A Phase I Prevention Study of Atorvastatin in Women at Increased 
Risk for Breast Cancer 
NCT01992042 Novel Window of Opportunity Trial to Evaluate the Impact of Statins 
to Oppose Prostate Cancer 
NCT01821404 Atorvastatin and Prostate Cancer (ESTO1) 
NCT00335504 Atorvastatin Calcium, Oligofructose-Enriched Insulin, or Sulindac in 
Preventing Cancer in Patients at Increased Risk of Developing 
Colorectal Neoplasia 





Based on the cholesterol and isoprenoid requirements of the proliferating cell, statins 
are attractive adjuvants to reduce cholesterol and mevalonate availability to tumours. 
In vitro studies have demonstrated the effects of statins on current chemotherapeutic 
strategies. Lovastatin was shown to synergistically act with cytosine arabinoside to 
induce cytotoxicity in leukemic cell lines (Holstein & Hohl 2001).  Mevastatin was 
shown to enhance the sensitivity of AML cell line to radiochemotherapy (Li et al. 
2003). Fluvastatin has been shown to enhance the anti-proliferative effect of the 
cytosine arabinoside analogue gemcitabine in a cell line model of pancreatic cancer 
(Bocci et al. 2005). In vivo studies also support such findings. Lovastatin was shown 
to potentiate the anti-tumour activity of doxorubicin in mouse models of colon 
cancer, sarcoma and lung carcinoma (Feleszko et al. 2000). Lovastatin had a similar 
effect on the anti-tumour activity of cisplatin in a mouse melanoma model (Feleszko 
et al. 1998).  Atorvastatin was shown to enhance the chemo-preventive efficacy of 
celecoxib in a mouse model of colorectal cancer (Reddy et al. 2006). A phase 1 
study showed pravastatin enhanced the chemotherapeutic effect of a regimen 
commonly used in the treatment of AML (Kornblau et al. 2007). Statins are also 
under investigation in a number of clinical trials for use as adjuvants to current 









Table 1.3. Statins as  Adjuvants to Chemotherapeutics (www.clinicaltrials.gov) 
Identifier:  
NCT00816244  Study of Statin as Neo-Adjuvant Therapy in Postmenopausal Breast 
Cancer 
NCT01418729 Efficacy and Safety Study of Sorafenib Plus Pravastatin to Treat 
Advanced Hepatocarcinoma (ESTAHEP-2010) 
NCT02029573 Efficacy and Safety of Atorvastatin in Combination With Radiotherapy 
and Temozolomide in Glioblastoma (ART) 
NCT00583102 Dose Escalation Phase I/II Study of Lovastatin With High-Dose 
Cytarabine for Refractory or Relapsed AML 
NCT01772719 Overcoming Chemotherapy Resistance In Refractory Multiple 
Myeloma With Simvastatin and Zoledronic Acid 
NCT00107523 Pravastatin, Idarubicin, and Cytarabine in Treating Patients With Acute 
Myeloid Leukemia 
NCT00490698 Zoledronate With Atorvastatin in Renal Cell Carcinoma 
NCT01831232 Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients 
With Acute Myeloid Leukemia or Myelodysplastic Syndromes 
NCT00313859 Phase II Study of Simvastatin Plus Irinotecan, Fluorouracil, and 
Leucovorin(FOLFIRI) for Metastatic CRC 
NCT01238094 Trial of XELIRI/FOLFIRI + Simvastatin Followed by Simvastatin 
Maintenance in Metastatic Colorectal Cancer 
NCT01281761 Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer 
(CRC) 
NCT02026583 Study of Simvastatin Plus XELOX and Bevacizumab as First-line 
Chemotherapy in Metastatic Colorectal Cancer Patients 
NCT01441349 Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive 
Patients With Extensive Disease-small Cell Lung Cancer 
NCT00944463 Trial of Simvastatin and Gemcitabine in Pancreatic Cancer Patients 
NCT01478828 Pre-Prostatectomy Lovastatin on Prostate Cancer 
NCT00452244 Gefitinib With or Without Simvastatin in Non-Small Cell Lung Cancer 
(NSCLC) 
NCT00433498 Etoposide and Cisplatin or Carboplatin as First-Line Chemotherapy 
With or Without Pravastatin in Treating Patients With Small Cell Lung 
Cancer 
NCT00354640 Simvastatin and Anastrozole in Treating Postmenopausal Women With 
Ductal Carcinoma In Situ or Invasive Breast Cancer 
NCT00584012 A Study of the Proper Dosage of Lovastatin and Docetaxel for Patients 
With Cancer 
NCT00452634 Irinotecan/Cisplatin Plus Simvastatin in Extensive Disease-Small Cell 
Lung Cancer (ED-SCLC) 
NCT00966472 Phase I Study of a Statin + Erlotinib for Advanced Solid Malignancies 
With Focus on Squamous Cell Carcinomas and NSCLC 




Statins have also independently demonstrated anti-cancer effects in a variety of 
cancer cell line models. Statins, including atorvastatin and simvastatin have been 
shown to induce apoptosis in myeloma cell lines in a caspase-dependent manner 
(Cafforio et al. 2005).  Mevastatin has been shown to induce apoptosis in colorectal 
carcinoma cell lines (Wächtershäuser et al. 2001). Lovastatin, mevastatin and 
simvastatin have all been shown to induce apoptosis in melanoma cell lines, as well 
as having inhibitory effects on the migration and invasion of these cancer cells 
(Glynn et al. 2008). Mevastatin and simvastatin have been shown to decrease 
androgen sensitivity and cell proliferation in androgen receptor (AR)-positive 
prostate cancer cells, but not in AR-negative cells (Yokomizo et al. 2011). This 
decrease in proliferation was linked to statin-induced proteolysis of the AR protein, 
which in turn reduced SREBP pathway activation in these cells.  
Tumours of simvastatin treated mice have been shown to have increased levels of 
apoptosis compared to untreated control mice, as measured by immune-
histochemical staining of mammary tumour sections for cleaved caspase-3 
(Campbell et al. 2006). Simvastatin also has demonstrated anti-proliferative effects 
on human glioma cells which was rescuable by mevalonate in a dose dependent 
manner, and thus attributable to inhibition of HMGCR (Kikuchi et al. 1997). Thus, 
the anti-cancer potential of statins in cell culture is quite apparent.  
However, statin resistant cell lines have also been identified, although the 
mechanisms underlying this resistance are not clear. Studies of statin-induced 
apoptosis in a panel of AML cell lines resulted in a group of sensitive and resistant 
lines, with the discerning feature between the two groups being regulation of the 




statin sensitive cell lines were shown to have little or no upregulation of SREBP 
target genes, while in contrast the resistant cell lines displayed a marked increase in 
target genes, including HMGCR. In fact over expression of the catalytic domain of 
HMGCR reduced the statin-sensitivity of the sensitive AML cell lines (Clendening, 
Aleksandra Pandyra, et al. 2010). This suggests a link between statin sensitivity to 
cell death and HMGCR levels, and that increased HMGCR may be advantageous to 
the cancer cell. This finding is consistent with studies from AML patient samples 
which displayed decreased feedback of LDLR in the presence of 25-OHC, a process 
which is mediated by SREBPs which co-ordinately increases cholesterogenic target 
genes, including HMGCR (Tatidis et al. 1997). Interestingly, over-expression of the 
D13 isoform catalytic domain failed to have a protective effect on the statin sensitive 
cancer cell lines, suggesting that HMGCR alternative splicing may be linked to statin 
sensitivity (Clendening, Aleksandra Pandyra, et al. 2010). This possibility has 
recently been discussed in relation to reduced LDL-cholesterol response to statins 
among individuals, and siRNA knockdown studies selective for the full length 
isoform and not the D13 mutant, demonstrated reduced inhibition of HMGCR 
enzymatic activity (Medina et al. 2008). Heterogeneous nuclear ribonucleoprotein 
A1 (HNRNPA1) was recently identified as a sterol-regulated splicing factor involved 
in the regulation of HMGCR alternative splicing (Yu et al. 2014). A CHO-derived 
cell line selected for statin-resistance revealed impaired degradation of HMGCR 
protein as the underlying mechanism for resistance (Ravid et al. 1999). Thus existing 
evidence indicates that statin efficiency is linked to HMGCR levels.  
In addition to varying response to statins, there is also debate as to whether the 
concentrations required to elicit these anti-cancer benefits are achievable in vivo 




potential of statins cannot be ignored and in recent years there are clinical trials 
underway specifically investigating statins as a primary form of treatment (Table 
1.4). Deregulated inflammation is characteristic of cancer, and has been associated 
with the progression and in some cases, the initiation of the disease (Candido & 
Hagemann 2013). The anti-inflammatory effects of statins described earlier also 
have potential chemotherapeutic benefits.  
 
Table 1.4. Statins as Primary Chemotherapeutic (www.clinicaltrials.gov) 
Identifier:  
NCT00281476 The Effect of High Dose Simvastatin on Multiple Myeloma 
NCT00807950 Phase II Study of Simvastatin in Primary Breast Cancer; Test of 
Its Potential Selectivity on Basal Subtype Breast Cancer 
NCT00185731 Phase II Study of Atorvastatin Safety and Antitumor Effects in 
Non-Hodgkin's Lymphoma 














The SREBP pathway has a central role in the regulation of de novo lipid and 
cholesterol biosynthesis. Modulation of this pathway activity is of high interest in the 
context of atherosclerosis, hypercholesterolemia, obesity and cancer (Eberlé et al. 
2004). The activity of this pathway is regulated in response to dietary sterols and 
fatty acids, although novel non-dietary regulators are also emerging (Goldstein et al. 
2006; Lee et al. 2008; Kamisuki et al. 2009; Tang et al. 2011). The SCAP-SREBP 
interaction is essential for SREBP protein stability and for delivery of the SREBP 
precursor protein to the Golgi for proteolytic processing (Rawson et al. 1999). Thus, 
small molecule intervention of this interaction would also allow for inhibition of 
SREBP processing. Also, the SREBPs share approximately 60% identity in their 
CTD regions and are both bound by SCAP, of which there exists only one isoform. It 
is not known how SCAP differentially regulates processing of SREBP1 and SREBP2 
proteins. Knowing the precise residues involved in the SCAP-SREBP1 and SCAP-
SREBP2 interaction would give further insight into this regulation.  The aim of this 
thesis was to map the interaction site between SCAP and SREBP, which would 
provide valuable information on the mechanisms regulating this pathway. 
SREBPs are involved in regulating the expression of genes essential for steroid 
hormone biosynthesis, including the rate limiting enzyme steroidogenic acute 
regulatory protein (StAR) and also Steroid 5α-reducate isotype 2 (Srd5a2) which is 
involved in the conversion of testosterone to dihydrotestosterone (Shea-eaton et al. 
2014). Steroid hormone production is also dependent on cholesterol availability, and 
thus is dependent on SREBP activity (Miller 1988). However, feedback regulation of 




activation of SREBP processing has been demonstrated (Heemers et al. 2006).  In 
early studies in the lab of Brown and Goldstein, progesterone was shown to have 
little or no effect on processing of SREBP1 (Wang et al. 1994). However, 
progesterone membrane receptor component 1 (PGRMC1) has been identified as an 
interacting partner of SCAP (Suchanek et al. 2005). PGRMC1 is believed to bind 
progesterone, and also to positively affect its synthesis (Peluso et al. 2006). We 
hypothesised that PGRMC1 may elicit a regulatory effect on the SREBP pathway, 
namely on SREBP processing, through its interaction with SCAP. As PGRMC1 is 
reported to mediate effects of P4, it is possible that progesterone may be required for 
this regulation. A regulatory effect of P4 on SREBP processing would be in keeping 
with cholesterol derived molecules regulating SREBP processing. The aim of this 
thesis was to investigate the regulatory effect of PGRMC1 on SREBP processing, 
and the requirement of P4 in this potential regulatory role.  
INSIG is a key protein involved in the regulation of SREBP processing (L.-P. Sun et 
al. 2007). It is also central to regulating the degradation of HMGCR (Sever et al. 
2003a). There are two isoforms of INSIG1 produced through the use of two 
alternative in-frame translational start sites (Yang et al. 2002). The significance of 
having two isoforms produced has not yet been addressed. The aim of this thesis was 
to investigate the evolutionary conservation of having two INSIG1 isoforms 
expressed, and to investigate if there was a functional difference between the 
isoforms with respect to the two known functions of INSIG1. 
Statins competitively bind the catalytic site of HMGCR and are widely used in the 
treatment of cholesterol-related disease (Schachter 2004). Inhibition of HMGCR 




feed forward response to activate SREBP target genes, including LDLR and 
HMGCR (Law et al. 2002; Sheng et al. 1995; Vallett et al. 1996). Increased LDLR 
expression provides the beneficial reduction in plasma LDL-cholesterol levels, while 
increased HMGCR maintains cell viability in the presence of statins (Law et al. 
2002). However, in the presence of excess statin all HMGCR enzymatic activity is 
inhibited and this has been shown to trigger growth arrest and induce apoptosis in a 
variety of cell lines. This has led to the investigation of the chemotherapeutic 
potential of statins (Sleijfer et al. 2005).  Central to the mechanism of action of 
statins is upregulation of SREBP target genes (Sheng et al. 1995). However, this 
results in statins essentially upregulating their own target. We hypothesised that 
blocking the HMGCR increase which occurs upon statin treatment would reduce the 
concentrations required to induce cell death. Statins are subject to high first pass 
clearance in the liver, resulting in low circulating statin concentrations (Schachter 
2004). Extra-hepatic effects of statins are limited by this. Reducing the concentration 
required to induce statin cell death would be valuable for the potential use of statins 
as chemotherapeutics, especially outside of hepatocellular carcinomas. The aim of 
this thesis was to investigate the combined effect of inhibiting SREBP processing in 









Summary of Thesis Aims 
The aims of this thesis were to characterise molecular and cellular aspects of the 
SREBP pathway, as outlined below. 
The SREBP isoforms are differentially activated in response to low cellular fatty 
acid and cholesterol levels. It is possible that the SREBPs bind to distinct sites within 
the CTD of SCAP and that this contributes to their differential activation by SCAP. 
To investigate this possibility we sought to map the interaction site of each SREBP 
on SCAP. In addition, mapping the precise interaction site of the SREBPs with 
SCAP is the first step towards small molecule inhibition of SREBP activation.  
Proteolytic activaton of the SREBPs is a highly regulated event. Understanding the 
factors involved in this regulation is key to furthering our understanding of the roles 
of the SREBPs. The aim was to investigate the role of a potential SREBP regulatory 
protein PGRMC1, and also to further characterise the role of a known SREBP 
regulator INSIG1, with respect to regulation of SREBP activation.  
The chemotherapeutic potential of statins is limited by failure to achieve serum 
concentrations of statins sufficient to induce cancer cell death. The final aim of this 
thesis was to investigate inhibition of the SREBP pathway as a mechanism to lower 
the concentration of statin required to induce cancer cell death. Expression of the 
target of statins HMGCR is known to be increased under lipid depleted conditions. 
This investigation was performed under high and low lipid conditions to investigate 
potential dietary influences on cancer cells to statin induced cell death. 





























Unless where stated, all products were purchase from Sigma Aldrich, Dublin, Ireland 
Bioinformatic analysis of SCAP CTD 
Sequences homologous to the human SCAP protein sequence were retrieved from 
the NCBI database using their protein-protein basic local alignment search tool 
(pBLAST). Sequences were loaded into the alignment explorer function within 
Molecular Evolutionary Genetics Analysis (MEGA) v4.0 and aligned using 
ClustalW (Tamura et al. 2007; Higgins et al. 1994). Phylogenetic tree was generated 
based on the multiple sequence alignment using the Neighbor-Joining method in 
MEGA, and tree topology confidence scores were calculated using the Bootstrap test 
of phylogeny. Alignments were saved in FASTA format to allow analysis of 
conserved regions of interest using GeneDoc multiple sequence alignment editor. 
Alignments were then transferred to Microsoft Word by saving the alignment blocks 
in rich text format (.rtf), to facilitate annotation of residues of interest.  
 
Cloning of GST-SREBPCTD Proteins 
The carboxy-terminal domain (CTD) of human SREBP-2 (amino acid 556 to 1142) 
was PCR amplified from plasmid template (IMAGE ID 5498684, Geneservices) 
using Taq DNA Polymerase (New England Biolabs (NEB) ) using the following 
primer sets;  
Forward: 5‘ GCAACTAgtcgaCTGCTGGTTCATGGGGAGCCAGTGAT 3‘ 
Reverse:       5‘        GTCAAGTgcggccgcTCAGGAGGCGGCAATGGCAGT     3‘  
The resulting PCR product was digested with SalI and NotI restriction enzymes 
(NEB) and ligated into pGEX-6p1 vector (GE Lifesciences) using T4 DNA Ligase 




cells (c2525, NEB), as per manufacturer‘s guidelines. The PCR product was cloned 
into pEBG mammalian GST expression vector (Addgene) in the same way. 
The CTD of human SREBP-1 (amino acid 559 to 1148) was PCR amplified from 
plasmid template (I.M.A.G.E. ID 5786483, Geneservices) using Taq DNA 
Polymerase using the following primer sets;  
Forward: 5‘ GCAACTAggatccGTCTCCTTGGTGCTTCTCTTTGTCTA 3‘ 
Reverse:           5‘ GTCAAGTgcggccgcCGGGGTCTAGCTGGAAGTGACAGT  3‘  
The resulting PCR product was digested with BamHI and NotI restriction enzymes 
(NEB) and ligated into pGEX-6p1 vector using T4 DNA Ligase. Ligations were 
transformed into chemically competent BL21 E. coli cells, as per manufacturer‘s 
guidelines. The PCR product was cloned into pEBG mammalian GST expression 
vector (Addgene) in the same way. 
Positive transformants were identified by restriction digest screens, followed by 
sequence verification by Sanger sequencing (Lifesource Bioscience). 
 
Induction of GST-fusion proteins 
Induced expression of GST alone and GST- SREBP1CTD GST- SREBP2CTD fusion 
proteins from BL21 E. coli was optimised for IPTG concentration, length of 
induction time, and temperature. Induction of GST-proteins was confirmed by SDS-
PAGE and specificity of the band of interest was confirmed by western blot analysis 
(Anti-GST, 1:1000 dilution, Cell Signalling). Briefly, LB-Ampicillin (50 μg/ml) 
broth was inoculated 1:100 with an overnight starter culture and grown to an O.D.600 




and incubated for a further 4 hours, 16hours or 40hours at 37
o
C, as indicated.  
Bacterial cells were pelleted by centrifugation at 7,700 x g for 10 minutes at 4
o
C. 
Pellets were stored at -20
o
C. 
Classical Solubilisation of GST-fusion proteins 
Bacterial pellets were resuspended in cold 1X PBS containing lysozyme at 100 
μg/ml and sonicated on ice for 8 x 10 second bursts using a probe sonicator at half 
max intensity (Soniprep 150). Samples were brought to a final concentration of 1% 
Triton X-100 and incubated for 30 minutes gently rocking at room temperature. 
Samples were then clarified by centrifugation at 12 000 x g for 10 minutes at 4
o
C. 
The supernatant was designated the soluble protein fraction, while he pellet was 
designated the insoluble protein fraction. 
 
Purification of GST-fusion proteins 
GST proteins were purified according to the batch/column purification using 
Glutathione Sepharose 4B (GS4B, Amersham Biosciences), as per manufacturer‘s 
guidelines. Briefly, equilibrated 50% GS4B slurry was prepared from the stock 
EtOH solution suspension, then added to soluble protein fractions and incubated for 
overnight at 4
o
C. The flow through was collected by centrifugation at 500 x g for 5 
minutes, the resin was washed 3 times with cold 1X PBS, then incubated for 30 
minutes with elution buffer (50 mM  reduced-glutathione in 50 mM Tris-HCl, pH8). 
Eluted protein was collected in fractions, and samples from all fractions were 
analysed by SDS-PAGE or immunoblot with anti-GST (#2624, Cell Signalling 






Purifying Inclusion Bodies  
Inclusion bodies were purified from bacteria as previously described (Rodríguez-
Carmona et al. 2010). Briefly, bacterial Pellets were resuspended in 1X Sodium 
chloride-Tris-EDTA (STE) buffer (10 mM Tris pH8, 150 mM NaCl, 1 mM EDTA) 
and freeze-thawed for 4 cycles in liquid nitrogen. A bacterial protease inhibitor 
cocktail and lysozyme (1 mg/ml final) were added and lysates were incubated for 2 
hours at 37
o
C. Lysates were then brought to 0.5% Triton X-100 and incubated 
rocking for 1 hour at room temperature (RT). Cell suspensions were then sonicated 
on ice for 5 x 10 second bursts. NP-40 was then added to a concentration of 0.025% 
and lysates were incubated at 4
o
C for 1 hour. Samples were then brought to 750 μM 
MgSO4 and DNAse was added. Samples were incubated at 37
o
C for 45 minutes, 
followed by centrifugation at 15000 x g for 15 minutes at 4
o
C. The pellet contains 
inclusion bodies. IBs were washed once in STE buffer containing 0.5% Triton X-
100, then centrifuged again. Pellets were resuspended in 1X Laemmli buffer and 
analysed by SDS-PAGE and immunoblot to confirm presence of the fusion protein. 
Solubilisation of IBs was optimised, as described below.  
 
Solubilisation of Inclusion Bodies 
IBs were solubilised based on methods previously described (Frangioni & Neel 
1993). Briefly, IB pellets were re-suspended in STE buffer containing lysozyme at 
100μg/ml, incubated for 15 minutes on ice, and then adjusted to 5 mM DTT. Cells 
were lysed by addition of 10% or 1 % sarkosyl, as indicated, then sonicated on ice 
for 10 x 2 second bursts on Soniprep 150, setting 6. Lysates were clarified by 
centrifugation at 10 000 x g for 5 minutes at 4
o
C. The soluble fractions were then 




the presence of sarkosyl (Tao et al. 2010). Detergent combinations used ranged from 
1-4% Triton X-100 ± 10-40 mM CHAPS, gently rocking for 30 minutes at RT, prior 
to incubation with GS4B affinity resin. 
 
Cloning of His6-Fusion Proteins 
The CTD of human SREBP-2 (amino acid 556 to 1142) was PCR amplified  from 
plasmid template (I.M.A.G.E. ID 5498684, Geneservices) using Taq DNA 
Polymerase (NEB) using the following primer sets;  
Forward:            5’ CTGCTGGTTCATGGGGAGCCAGTGAT 3’ 
Reverse:                   5’ CCAGGAGGCGGCAATGGCAGT 3’. 
The resulting PCR product was ligated into pBADtopo TA expression vector 
(Invitrogen) as per manufacturer‘s guidelines. Ligations were transformed into 
Top10 chemically competent cells, supplied with the vector, as per manufacturer‘s 
guidelines.   
The CTD of human SREBP-1 (amino acid 559 to 1148) was PCR amplified from 
plasmid template (I.M.A.G.E. ID 5786483, Geneservices) using Taq DNA 
Polymerase (NEB) using the following primer sets;  
Forward:            5’ GTCTCCTTGGTGCTTCTCTTTGTCTA 3’ 
Reverse:             5’ CGGGGTGTAGCTGGAAGTGACAGT 3’  
The resulting PCR product was ligated into pBADtopo TA expression vector as per 
manufacturer‘s guidelines. Ligations were transformed into Top10 chemically 
competent cells, as per manufacturer‘s guidelines.   
Positive transformants were identified by restriction digest screens, followed by 





Induction and Lysis of His-Fusion Proteins 
Overnight cultures containing E.coli expressing His-fusion proteins were inoculated 
1:100 in pre-warmed LB media containing ampicillin at 75 μg/ml (either 500 ml or 
5L (5 x 1L) of LB, as indicated). Cultures were grown to an OD600=0.5 (37
o
C, 200 
rpm), at which point L-arabinose was added to a final concentration of 0.02%. 
Cultures were induced for a period of 4 hours. Bacteria were pelleted by 
centrifugation at 7700 x g for 15 minutes at 10
o
C. Pellets were stored at -20
o
C until 
ready for affinity purification.  
For lysis prior to purification, bacterial pellets were thawed on ice and re-suspended 
in 1X His-Native Loading Buffer (50 mM NaH2PO4 pH 8, 500 mM NaCl, solution 
adjusted to pH 8) (50 ml per 5L pellet). Lysozyme was added to a concentration of 1 
mg/ml and samples were incubated on ice for 30 minutes. Samples were then 
sonicated on ice for 10 x 40 second bursts on 75% intensity, with minimum of 1 
minute rests on ice in between (Soniprep 150). Cell debris was removed by 
centrifugation at 3000 x g for 15 minutes at 4
o
C. Supernatants contained the soluble 
protein fraction and could be stored at -20
o
C prior to nickel-affinity purification. 
 
Purification of His-Fusion Proteins 
Probond nickel affinity resin (Invitrogen) was equilibrated in 1X His-Native Loading 
Buffer from the EtOH storage solution, as per manufacturer‘s guidelines. 5 ml resin 
was added per 50 ml soluble protein fraction and incubated for 1.5 hours, gently 
rocking at 4
o
C. Resin was sedimented by centrifugation at 800 x g for 1 minute and 
the supernatant was designated the flow through fraction. The resin was washed by 
gentle re-suspension in 1X His-Native Wash Buffer (50 mM NaH2PO4 pH 8, 500 




followed by centrifugation at 800 x g for 1 minute. The resin was washed a total of 3 
times. 1X His Elution Buffer (50 mM NaH2PO4 pH 8, 500 mM NaCl, 250 mM 
Imidazole, solution adjusted to pH 8) was then incubated with the resin for 1 hour, 
gently rocking at 4
o
C. This suspension was then loaded onto a disposable column 
(PD-10), the resin was allowed to settle by gravity for 20 minutes at 4
o
C, and then 
elution fractions were collected, also at 4
o
C. Fractions were analysed by SDS-PAGE, 
immunoblot with anti-His (A00186-100, Genescript (1:2500 dilution)), or subject to 
fast protein liquid chromatography (FPLC), as indicated.  
 
SDS-PAGE and Immunoblot Analysis of Bacterial Proteins 
Bacterial cell pellets were resuspended in  1X Laemmli buffer for analysis (4% SDS, 
10% 2-mercaptoehtanol, 20% glycerol, 0.004% bromophenol blue, 0.125 M Tris-
HCl, pH to 6.8), while soluble fractions was mixed in a 1:1 ratio with the 2X 
Laemmli buffer. All samples were boiled for 5 minutes in a water bath. Sample 
volumes of 15 μl were loaded onto a 0.75 mm SDS-PAGE gel in all cases. Samples 
were run through the stacking gel (5% acrylamide) at 75V and through the resolving 
gel (10% acrylamide) at 150V. The 1X SDS-PAGE running buffer (25 mM Tris, 250 
mM Glycine (pH 8.3), 0.1% SDS) was ice-cold prior to use. Separated protein 
samples were transferred to Whatman Protran nitrocellulose membranes 
nitrocellulose membrane using wet transfer conditions (1X Transfer Buffer: 25 mM 
Tris, 192 mM Glycine, 20% methanol, 0.1% SDS) and running at 100V for 1 hour. 
Sponges, filter paper and membranes were all equilibrated in transfer buffer for 10 
minutes prior to cassette assembly and transfer. An ice pack was included during 
transfer and the buffer was ice-cold prior to use. Successful transfer was confirmed 




Membranes were then gently washed in 1X TBS-T (50 mM Tris-Cl, pH 7.6; 150 
mM NaCl, 0.1% Tween) to remove the Ponceau S stain, followed by incubation with 
blocking buffer (5% dry skimmed milk (Marvel) dissolved in 1X TBS-T) for 1 hour 
gently rocking at RT. Blocking buffer was removed and membranes were probed 
with the indicated primary antibodies overnight (16 hours) gently rocking at 4
o
C. 
Primary antibodies were removed and stored at -20
o
C for reuse. Membranes were 
washed 3 x 10 minutes with 1X TBS-T, gently rocking at RT. This was followed by 
incubation with the appropriate infrared (IR)-conjugated secondary antibody for 1 
hour, gently rocking at RT (mouse IRDye680LT (1:20 000), rabbit 1RDye800CW 
(1:15 000), Li-cor). Membranes were washed 3 x 10 minutes with 1X TBS-T, gently 
rocking at RT, followed by detection on the Odyssey IR imaging system (Li-cor).  
 
Gel Filtration Fast protein liquid chromatography (FPLC) 
Analysis was performed on an AKTA purification system (GE Life Sciences), as per 
the recommended guidelines. All buffers were de-gased prior to use. Samples were 
sterile-filtered prior to use using 0.45 micron syringe filter. BSA was used as an 
elution profile control protein. 
The sample was first run through a Hi-Trap desalting column (GE Life Sciences) to 
exchange the eluted proteins from the imidazole containing His Elution Buffer to 1X 
His-Native Loading Buffer. Samples were taken up 0.7 ml at a time into a 1 ml 
needle-syringe, all bubbles were removed and the sample was injected. The flow rate 
was maintained at 0.5 ml per minute and protein concentration was assessed by 
absorbance peaks at a wavelength of 280 nm (A280). All fractions containing high 




The Superdex gel filtration column (GE Life Sciences) was equilibrated with 1X 
His-Native Loading Buffer, as per manufacturer‘s guidelines. Samples were taken up 
0.7 ml at a time into a 1 ml needle-syringe, all bubbles were removed and the sample 
was injected. Fractions were collected at a rate of 0.5 ml per minute. This was 
injection/collection process was repeated until the total sample volume had been 
applied to the column. Fractions were analysed by SDS-PAGE or immunoblot, as 
indicated.  
 
Peptide Array Analysis 
Peptide arrays were provided by Dr Emilie Tresse from the lab of Prof. Rosemary O‘ 
Connor, School of Biochemistry and Cell Biology, UCC. Arrays consisted of the 
amino acid sequence of SCAPCTD immobilised on a cellulose membrane in a series 
of 18-mer peptides with each peptide overlapping with the next by a five amino 
acids. The array was received dried in a sealed plastic bag. 
The array was bathed in 100% ethanol for 5 minutes at RT, and then equilibrated in 
1X TBS-T for 10 minutes. The array was then blocked with a solution of 5% 
milk/1X TBS-T, gently rocking for 1 hour at RT. The membrane was then incubated 
with 6 mLs of the eluted fractions of the indicated fusion protein containing 1% milk 
gently rocking overnight at 4
o
C (16 hours). The array was then washed 3x5 minutes 
in 1X TBS-T, followed by incubation with anti-His primary antibody (A00186-100, 
Genescript (1:2500 dilution in 5% milk/TBS-T)) gently rocking for 2 hours at RT. 
The array was washed 3x5 minutes in 1X-TBS-T, followed by incubation with HRP-
conjugated anti-mouse secondary antibody (NXA931, GE Healthcare (1:1000 




was visualised by ECL.  Peptides with fusion protein positively bound were 
indicated by dark spots, while unbound peptides remained blank.  
Alanine scanning arrays were treated in the same way as peptide arrays, as described 
above.  
Cell Culture 
A-498, DU-145, HeLa, HeLa-PHGL, HT-29, KYSE-70 and MeWo cell lines were 
maintained in RPMI-1640 medium containing 10% foetal bovine serum (FBS), 1% 
Penicillin/Streptomycin (P/S) at 37
o
C, 5%CO2. HepG2 and MCF-7 cell lines were 
maintained in DMEM containing 10% FBS, 1% (P/S) at 37
o
C, 5%CO2. For all cell 
lines, FS culture conditions refer to cells cultured in the aforementioned full-serum 
formulations. For some experimental conditions, cells were incubated with media 
containing 10% lipid-depleted serum (LDS) in place of 10% FBS, and this is 
referred to as LDS culture conditions.  
For all experiments, cells were seeded on day 1 at 40% confluency. In a 24-well 
tissues culture plate (Sarstedt) with a growth surface area of 2 cm
2
, this corresponds 
to the following cell number seeded in 500 μl FS media per well: A-498 (4 x 10
4
), 
DU-145 (7 x 10
4
), HeLa (4 x 10
4
), HepG2 (1.2 x 10
5
), HT-29 (1 x 10
5
), KYSE-70 (1 
x 10
5
), MCF-7 (1 x 10
5




Preparation of LDS 
LDS was prepared by incubating 100 ml of FBS with 2 g fumed silica (Sigma) 
gently swirling overnight at room temperature. The LDS was clarified by 
centrifugation at 2000 x g for 10 minutes at 10
o
C. The supernatant was sterile 
filtered using 0.45 micron filter, aliquoted and stored at -20
o




was assayed using a cholesterol assay kit (Audit Diagnostics, Ireland) and was >99% 
depleted of cholesterol compared to FBS.  
 
Cloning of luciferase gene reporters  
The HMGCR promoter (-270 to +77) was amplified from human DNA by PCR and 
cloned into both the Firefly luciferase reporter plasmid pGL3-Basic (Promega)  and 
the Guassia luciferase plasmid pGLuc-Basic (New England Biolabs) using EcoRI 
and HindIII restriction sites. The LDLR promoter (-590 to +93) was also amplified 
from human DNA by PCR and cloned into pGL3-Basic vector using BglII and 
HindIII restriction sites and into pGLuc-Basic vector using EcoRI and HindIII 
restriction sites. Cloned promoter sequences were verified by DNA sequencing.  
 
DLR Assay 
HeLa cells were seeded at 4 x 10
4 
cells in 500 µL FS media per well in a 24-well 
plate (37
o
C, 5% CO2). After 18-24 hr incubation, cells were transfected for 6-9 hours 
with 450 ng of reporter plasmid and 50 ng of control reporter plasmid (pRL-TK, 
Promega) using 1 µL TurboFect (Thermoscientific) in 100 µL serum-free media, 
according to manufacturer‘s instructions. Following transfection, media was replaced 
with 500 µL LDS media and incubated for a further 6 hours. 25-OHC was then 
added to a final concentration of 1.25 µM and incubation was continued for a further 
16 hours. Cells were harvested by aspirating media, washing once in ice-cold 
phosphate buffered saline (PBS), and incubated shaking for 30 minutes in 100 µL 
Passive Lysis Buffer (Promega) at room temperature. 10 µL of each sample was 
removed and assayed for Firefly and Renilla luciferase activity using a microplate 




Renilla luciferases respectively) were purchased from Nanolight Technology and the 
DLR assay buffers were prepared from individual components essentially as 
described previously (16). 
Firefly luciferase assay buffer contained 25 mM glycylglycine, 15 mM K2PO4 pH8, 
4 mM EGTA, 15mM MgSO4, 0.1 mM coenzyme-A, 1 mM DTT, 2 mM ATP, 75 
µM luciferin. Renilla luciferase assay buffer contained 1.1 M NaCl, 2.2 mM EDTA, 
220 mM K2PO4 pH5.1, 0.44 mg/mL BSA, 1.3 mM NaN3, 1.43 µM coelenterazine. 
Stock solutions for all of the above were prepared in water, except for coelenterazine 
which was prepared in methanol and kept protected from light.  
 
SSLR Assay 
Transfection was as described for the DLR assay. Total amount of plasmid DNA 
transfected was maintained at 500ng and comprised of reporter plasmid or a 
combination of reporter plasmid and empty vector plasmid. Following transfection, 
media was replaced with 500 µL LDS media. Small aliquots of media were removed 
at intervals and stored at -20
o
C until assayed for luciferase activity. 25-OHC 
treatment was as described for the DLR assay. 10 µL samples were assayed for 
Guassia luciferase activity using a microplate luminometer in the Renilla luciferase 
assay buffer. A simple Guassia luciferase assay buffer (PBS with 1.43 µM 
coelenterazine) was also tested and yielded similar results.  
 
HeLa Cell Line Stably Expressing pGLuc-promHMGCR 
 HeLa cells were seeded at 40% confluency in under FS conditions in 10 cm dishes. 
Cells were transfected at 80-90% confluency with 15 µg of pGLuc-promHMGCR 




free media. The transfection mixture was removed and replaced with fresh FS 
medium after 6 hours incubation. Cells were trypsinized 48 hours post-transfection 
and re-seeded at different dilutions in FS media supplemented with 400 µg/ml G-
418. Every 3-4 days G-418/FS media was renewed until individual clones were 
identified. These individual clones were then isolated using cloning discs and grown 
up in 24 well plates. Stable integrants were identified by trypsinizing and re-seeding 
cells and assaying for the highest consistent luciferase activity levels and 
responsiveness to 25-OHC treatment under LDS conditions.  
 
Effect of PGRMC1 and progesterone on SREBP luciferase reporter activity  
On day 1, HeLa-PHGL cells were seeded at 4 x 10
4 
cells in 500 µL FS medium per 
well in a 24-well plate (37
o
C, 5% CO2). On day 2, cells were transfected with 0.5 μg 
of each of the indicated plasmids for a total of 1 μg of plasmid DNA to 2µL of 
TurboFect transfection reagent (Thermoscientific) in 100 µL of serum-free medium, 
per well, according to manufacturer‘s instructions. Following transfection, media 
was replaced with either FS or LDS media, containing progesterone or EtOH only 
control, as indicated in the figure legend. Aliquots of media (25µl) were taken at 24 
and 48 hour timepoints and stored at -20
o
C until ready to be assayed for Gaussia 
luciferase enzyme activity. MTT assay was then performed immediately after the 48 
hour timepoint was taken to determine cell viability in response to the treatments.  
 
Bioinformatic analysis of INSIG1 
Sequences homologous to the human INSIG1 protein sequence were retrieved from 
the NCBI database using their protein-protein basic local alignment search tool 
(pBLAST). mRNA sequences corresponding to each of the INSIG1 homologs were 




All sequences were loaded into the alignment explorer function within Molecular 
Evolutionary Genetics Analysis (MEGA) v4.0 and aligned using ClustalW (Tamura 
et al. 2007; Higgins et al. 1994). Phylogenetic tree was generated based on the 
INSIG1 protein sequence alignment using the Neighbor-Joining method in MEGA, 
and tree topology confidence scores were calculated using the Bootstrap test of 
phylogeny (Nei & Kumar 2000; Saitou & Nei 1987). Alignments were saved in 
FASTA format to allow analysis of conserved regions of interest using GeneDoc 
multiple sequence alignment editor. Alignments were then transferred to Microsoft 
Word by saving the alignment blocks in rich text format (.rtf), to facilitate annotation 
of residues of interest.  
 
Generation of INSIG1 isoform mutants by site directed mutagenesis 
INSIG1 mutants were generated using Stratagene Quikchange II kit (Agilent 
Technologies), as per manufacturer‘s guidelines. pCMV6-AC-HA -INSIG1 was used 
as the template plasmid for mutagenesis. This plasmid was generated by sub-cloning 
the INSIG1 cDNA sequence from pCMV6-AC-Myc/DDK-INSIG1 (RC200312, 
Origene) into the precision shuttle pCMV6-AC-HA destination vector (PS100004, 
Origene).  The primer sets used for mutagenesis were designed using the Stratagene 
custom primer design software programme (http://labtools.stratagene.com/QC).  
INSIG1WT:  
Forward: 5‘ GATCTGCCGCCGCGATCCCGATGCCCAGATTGCACG 3‘  
Reverse: 5‘ CGTGCAATCTGGGCATCGGGATCGCGGCGGCAGATC 3‘ 
INSIG12ND-AAA :  
Forward:    5‘ CGGCCAAGGTTGGGGAGAAAATCAACGTTTCCGTGTCCG 3‘  
Reverse:     5‘ CGGACACGGAAACGTTGATTTTCTCCCCAACCTTGGCCG 3‘ 
INSIG11ST-AAA: 
Forward:  5‘ GCCGCCGCGATCGCCAAACCCAGATTGCACGACC 3‘   




Positive transformants were confirmed by Sanger Sequencing (GATC). 
Comparing the effect of INSIG1 isoform mutants on SREBP luciferase reporter 
activity 
On day 1, HeLa-PHGL cells were seeded at 40% confluency in 500μl in 24-well 
plates. On day 2, cells were transfected with either pCMV6-AC-HA empty vector, or 
the indicated INSIG isoform plasmid. A ratio of 0.5μg of DNA to 1μl TurboFect 
transfection reagent was used, as per manufacturer‘s guidelines, in 100μl of serum-
free media. The total 600μl transfection mixture was removed from cells following a 
six hour incubation and replaced with LDS media with or without 25-OHC (1μg/ml), 
as indicated. Cells were cultured for a further 20 hours, after which a 50μl media 
aliquot was removed and stored at -20
o
C, until ready to be assayed for luciferase 
activity. MTT assay was performed to ensure an equal level of cell viability.  
 
Comparing the effect of INSIG1 isoform mutants on HMGCR protein stability 
On day 1, HeLa-PHGL cells were seeded at 40% confluency in 10 ml FS media in 
10 cm dishes. On day 2, cells were transfected with either pCMV6-AC-HA empty 
vector (Origene), or the indicated INSIG isoform plasmid. A ratio of 8μg of DNA to 
16μl TurboFect transfection reagent was used, as per manufacturer‘s guidelines, in 1 
ml of serum-free media. The total 11ml transfection mixture was removed from cells 
following a six hour incubation and replaced with LDS media with or without 25-
OHC; (concentration of 300 ng/ml, 600 ng/ml or 900 ng/ml, as indicated). Cells 
were cultured for a further 20 hours. Prior to harvesting the cells the media was 
aspirated and the cell monolayer was washed once with ice-cold PBS. Cells were 
scraped into 500 μl of ice-cold PBS and centrifuged at 1500 rpm for 5 minutes in a 
tabletop centrifuge at 4
o
C. The PBS was aspirated and the cell pellets were stored at -
20
o





Preparation of Sterol Compounds  
Cholesterol, 25-hydroxycholesterol (25-OHC (Avanti Polar Lipids) ) and 19-
hydroxycholesterol (19-OHC (Santa Cruz) ) were all prepared as 1 mg/ml stocks in 
EtOH, and stored at -20
o
C. Betulin was prepared as a 1 mg/ml stock in cell culture 
grade dimethyl-sulfoxide (DMSO). 
Methyl-β-cyclodextrin (MβCD)-sterol complexes were prepared as described 
previously (Brown et al. 2002a; Radhakrishnan et al. 2007a). Briefly, cholesterol and 
25-OHC were prepared as 10 mg/ml (25 mM) stocks in EtOH. An aliquot of 100 μl 
of sterol stock solution was added drop-wise to a stirred 1 ml solution of 5% w/v 
MβCD at 80
o
C, until the solution became clear. This solution then contained sterols 
at a final concentration of 2.5 mM. The MβCD-sterol complexes were then 
lyophilised using a vacuum-centrifuge at 45
o
C on high pressure (Thermo Scientific) 
to remove the ethanol from the solution, then resuspended in 1 ml millipore water 
(sterol stock concentration remains at 2.5 mM). A no-sterol MβCD solution was also 
prepared in the same manner to be used as vehicle only control.  
 
Transient transfection of cell lines with pGLuc-promHMGCR 
Cell transfection was optimised for each cell line using pCMV-GLuc (NEB), for 
cells seeded at 40% confluency in a 24-well plate. For all cell lines a ratio of 0.5 μg 
plasmid DNA to 1 μl transfection reagent was determined to be optimal per well. 
Maximal transfection efficiency was achieved for A-498, KYSE-70 and MeWo 
using Lipofectamine 2000 (Invitrogen), for DU-145, HT-29, and MCF-7 using 




Scientific). All transfections were performed according to manufacturer‘s guidelines, 
with cells at approximately 80% confluency at the time of transfection. Transfection 
mixtures were added to 500 μl per well (Optimem or existing FS media) and were 
removed following 6 hour incubation in all cases. Media replaced was either FS or 
LDS media, as per the indicated experiment. 
 
Dose-Response Curves 
On day 1 cells were seeded at 40% confluency in 24-well plate in 500 μl under FS 
conditions. On day 2, cells (except HeLa-PHGL) were transfected with pGLuc-
promHMGCR, as described above. Following six hours incubation, the transfection 
mixture was removed replaced with either 500 μl FS or LDS media only. Cells were 
incubated for a further six hours, at which point a 50 μl aliquot of media was 
removed for normalisation purposes (T6). The treatments of statin and/or oxysterols 
were made up in concentrated amounts in either FS or LDS media, such that 50μl 
volumes could be added back to the remaining 450μL per well, to return the total 
culture volume per well to 500μl that then contained the indicated final 
concentrations of statin and/or oxysterols for each cell line (as described in the 
associated figure legends). Cells were incubated with treatments for a period of 48 
hours, after which a 50μl aliquot of media was removed for end point luciferase 
analysis (T48). Media samples were stored at -20
o
C until ready for luciferase 
analysis. MTT assay was then performed immediately to determine cell viability. An 
Excel add-in ED50V10-2 was used for calculating half maximal effective 







Luciferase Assay of SREBP Reporter Activity 
Media samples were thawed and 10μl was transferred to a polystyrene, solid white 
96-well microplate, which is suitable for luciferase analysis (Nunc, Thermo Fisher 
Scientific). Samples were assayed for Guassia luciferase activity using a microplate 
luminometer (Veritas) which auto-injects 50μl of 1X PBS containing coelenterazine 
(Nanolight Technologies) at a concentration of 1.43 µM. Coelenterazine was added 
fresh to the 1X PBS prior to use from a 1.43 mM stock in methanol which was 




MTT Assay of Cell Viability 
The 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay 
was optimised for use as an end-point analysis for experiments described above. 
Stocks were prepared by dissolving MTT powder in phenol-red-free RPMI-1640 
media at a concentration of 5mg/ml, and stored at -20
o
C (protected from over-
exposure to light). MTT was added to cells at a final concentration of 0.5mg/ml and 
incubated for 90minutes at 37
 o
C, 5% CO2 (ie. 50μl of MTT stock solution was 
added to 450μl remaining media, per well). All media was the aspirated carefully 
and purple formazan crystals were dissolved instantly upon addition of 150μl DMSO 
per well. Aliquots of MTT samples were transferred to a 96-well microtest plate 








Immunoblot Analysis of SREBP and HMGCR in response to statin and oxysterols 
For immunoblot analysis, experiments were performed in 10 cm tissue culture 
dishes. Cells were seeded at 40% confluency on day 1 in FS conditions. On day 2, 
media was aspirated and replaced with either FS or LDS media, containing the 
indicated concentrations of statin and/or oxysterols for each cell line (as described in 
the associated figure legends). All treatments contained mevalonate at 100 μM to 
maintain cell viability. Cells were incubated with treatments for a period of 48 hours. 
Prior to harvesting the cells, media was aspirated and the cell monolayer was washed 
once with ice-cold PBS. Cells were transferred to eppendorf tubes in 500 μl of ice-
cold PBS using sterile cell scrapers (Sarstedt) and centrifuged at 1500 rpm for 5 
minutes in a tabletop centrifuge at 4
o
C. The PBS was aspirated and the cell pellets 
were stored at -20
o
C until ready for analysis. 
 
Immunoblot Analysis (mammalian samples) 
For regular cell lysis, cell pellets were resuspended in ice-cold Radio Immuno 
Precipitation Assay (RIPA) buffer (150 mM sodium chloride, 1.0% NP-40, 0.5% 
sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0) containing 1X Halt protease 
inhibitor cocktail (Thermo Fisher Scientific) and 1mM PMSF. For regular cell lysis, 
cells were incubated for 1 hour with end-over-end rotation at 4
o
C. Cell debris was 
removed by centrifugation for 10 minutes at max on tabletop centrifuge at 4
o
C. The 
soluble fraction was mixed in a 1:1 ratio with the 2X Laemmli buffer for analysis 
(4% SDS, 10% 2-mercaptoehtanol, 20% glycerol, 0.004% bromophenol blue, 0.125 
M Tris-HCl, pH to 6.8) and boiled for 5 minutes in a waterbath. For detection of 
membrane proteins a homemade whole cell lysis buffer was used (1X Buffer: 10% 




mercaptoethanol, 0.02% Bromophenol blue) which is based on a combination of 
buffers used by the Brown and Goldstein lab (ref). Samples were not boiled. Instead, 
resuspended whole cell pellets (300 μl per 10 cm dish) were vortexed briefly, 
incubated in a water bath at 37
o
C for 30 minutes, sonicated at 20% power for 6 x 10 
second bursts until the DNA has been sheared. This was followed by another 
incubation at 37
o
C for 30 minutes. Sample volumes of 15 μl were loaded onto a 0.75 
mm SDS-PAGE gel in all cases. Samples were run through the stacking gel (5% 
acrylamide) at 75V and through the resolving gel (10% acrylamide) at 120V. The 1X 
SDS-PAGE running buffer (25 mM Tris, 250 mM Glycine (pH 8.3), 0.1% SDS) was 
ice-cold prior to use. Separated protein samples were transferred to Whatman Protran 
nitrocellulose membrane using wet transfer conditions (1X Transfer Buffer: 25 mM 
Tris, 192 mM Glycine, 20% methanol, 0.1% SDS) and running at 100V for 1 hour. 
Sponges, filter paper and membranes were all equilibrated in transfer buffer for 10 
minutes prior to cassette assembly and transfer. An ice pack was included during 
transfer and the buffer was ice-cold prior to use. Successful transfer was confirmed 
by Ponceau S staining of the nitrocellulose membrane prior to antibody detection. 
Membranes were then gently washed in 1X TBS-T (50 mM Tris-Cl, pH 7.6; 150 
mM NaCl, 0.1% Tween) to remove the Ponceau S stain, followed by incubation with 
blocking buffer (5% dry skimmed milk (Marvel) dissolved in 1X TBS-T) for 1 hour 
gently rocking at RT. Blocking buffer was removed and membranes were probed 
with the indicated primary antibodies overnight (16 hours) gently rocking at 4
o
C. 
Primary antibodies were removed and not saved for reuse (except actin). Membranes 
were washed 3 x 10 minutes with 1X TBS-T, gently rocking at RT. This was 
followed by incubation with the appropriate horseradish peroxidise (HRP)-




washed 3 x 10 minutes with 1X TBS-T, gently rocking at RT, followed by enhanced 
chemiluminescent (ECL) detection. Primary antibodies used were anti-SREBP2 1C6 
(sc-13552, Santa Cruz (1:200 dilution)), Santa Cruz), anti-HMGCR (sc-271595, 
Santa Cruz (1:500 dilution)), anti-FLAG (F1804, Sigma (1:1000 dilution)), anti-HA 
(MMS-1001R, Covance (1:1000 dilution)), anti-β-Actin (A5441, Sigma (1:1000 
dilution)). (HRP)-conjugated secondary antibodies used were Anti-mouse IgG 
(NXA931, GE Healthcare (1:1000 dilution)), Anti-rabbit IgG (NA934V, GE 
Healthcare (1:1000 dilution)). 
 
ECL Detection 
Excess moisture was removed from the membrane by touching a corner (ie. not a 
region with transferred protein) against tissue. ECL substrate (Pico, Thermo 
Scientific) was mixed fresh prior to use, the membrane was covered with a thin layer 
and incubated for 5 minutes at RT. Excess substrate was removed from the 
membrane, again by touching a corner against tissue and the membrane was placed 
between plastic. Membranes were brought to the dark room where several exposures 
to CL-XPosure film (Medical Supply Company) using a x-ray film cassette were 
taken and developed using a laboratory scale-developer (Kodak).  
 
Measurement of Apoptosis/Cell Cycle Analysis by DNA Content  
On Day1, HeLa-PHGL cells were seeded at 40% confluency (1.66 x 10
6
 cells) in 
10cm dishes (Sarstedt) in 10ml FS media. On Day2, media was replaced to contain 
simvastatin, with or without 25-OHC at the concentrations indicated in the figure 
legends. Cells were incubated with treatments for a period of 24 hours. Cells were 




once in ice-cold 1X PBS. Cells were centrifuged at 1500 rpm  and the pelleted cells 
were resuspended by adding 1ml of ice-cold 70% EtOH drop-wise, while vortexing 
the sample. Samples were incubated for 30 minutes at RT. Cells were then stored at -
20
o
C for at least 24-hours. Cells were then removed from the EtOH solution by 
centrifugation at 200xg for 10 minutes at 4
o
C. The cell pellet was resuspended in 1 
ml 1X PBS/0.2%Triton X-100 and incubated at RT for 10 minutes. Cells were 
removed from suspension by centrifugation at 200 x g for 10 minutes at 4
o
C, and 
then washed once with 1X PBS. Cells were centrifuged at 200 x g for 10 minutes at 
4
o
C, then resuspended in 250 μl of DNA staining solution (100μg/ml propidium 
iodide (PI), 0.2mg/ml RNAse A (DNAse-free) in PBS). An untreated, no PI control 
was also included. Samples were transferred to FACS analysis tubes, the open tops 
covered with parafilm to prevent evaporation, and incubated in a water bath for 30 
minutes at 37
o
C. Sample were then analysed on flow cytometer (Accuri) using the 
recommended parameters for PI fluorescence detection. (excitation-488nm, red 




Statistical analysis was performed using Student‘s t-test, two-way ANOVA or mixed 
model ANOVA (as indicated) to evaluate the difference between experimental and 





































The sterol response element binding proteins (SREBPs) are a family of transcription 
factors which are central to regulating de novo lipid biosynthesis. The activity of the 
SREBPs is regulated by the requirement to cleave the amino-terminal transcription 
factor domain from the inactive precursor protein. This cleavage event occurs in 
response to the sterol requirements of the cell and requires interaction of the SREBPs 
with the SREBP cleavage activating protein (SCAP). SCAP acts as a sensor for 
cellular sterol levels and has an essential role in chaperoning the SREBPs from their 
location in the ER to the Golgi where the cleavage takes place.  
The interaction between SCAP and the SREBPs is mediated by their respective 
carboxy-terminal regulatory domains (CTDs). These CTDs each consist of over 500 
amino acids. Mapping the exact SREBP binding site on SCAP would contribute to 
the knowledge base surrounding SREBP transcription factor regulation. In addition, 
mapping the precise site on SCAP which binds SREBP would be the first step in 
allowing for development of a small molecule inhibitor of the SCAP-SREBP 
interaction which could have potential use for treatment of a number of conditions 
including atherosclerosis, obesity and cancer. This chapter describes the steps taken 
towards identifying the residues within SCAP which bind each SREBP isoform 
using a peptide array approach. Numerous obstacles were encountered in the 
purification of the SREBP proteins required to probe the peptide array of SCAP. In 
this chapter the measures taken to overcome these obstacles to obtain purified 
SREBP protein are described. The results of the peptide array analysis have 
highlighted peptide regions within SCAP which may be key to mediating its 





The Sterol Response Element Binding Proteins (SREBPs) are a family of 
transcription factors involved in the regulation of lipogenic gene expression. The 
SREBPs are distinct from most other transcription factors in that they are translated 
as inactive precursor proteins where the amino terminus transcription factor domain 
(NTD) is tethered to the endoplasmic reticulum (ER) via two transmembrane helices 
followed by a large regulatory domain at the carboxy terminus (CTD) (Hua et al. 
1993b; Hoppe et al. 2001). Immediately following their translation and insertion into 
the ER membrane, the SREBPS are bound by the SREBP cleavage activating protein 
(SCAP) (Sakai et al. 1997). SCAP is essential for facilitating the proteolytic release 
of the active SREBP NTD. All three isoforms of SREBP (1a, 1c, 2) appear to bind 
the one isoform of SCAP, as evidenced by the amounts of the active form of all three 
SREBP isoforms increasing in transgenic mice expressing a constitutively active 
form of SCAP (Korn et al. 1998). This interaction with SCAP is essential for SREBP 
protein stability and in the absence of SCAP, SREBP proteins are rapidly degraded 
(Rawson et al. 1999). Liver-specific knockout of SCAP results in a decrease in the 
amount of all SREBP proteins and a decrease in expression of SREBP target genes 
(Matsuda et al. 2001). Germline deletion of SREBP2 in a mouse model is 
embryonically lethal, thus a germline deletion model of SCAP has not been 
attempted (Shimano, Shimomura, et al. 1997).  
Activation of SREBPs is a tightly regulated process and is regulated in response to 
fluctuations in cellular sterol levels in a negative feed-back manner (Brown & 
Goldstein 2009). This feedback regulation is necessary as excessive levels of 




(Simons & Ikonen 2000; Aye et al. 2010). Aberrant SREBP activation also leads to 
high circulating cholesterol and fatty acid levels which can lead to disease such as 
atherosclerosis and obesity, respectively (Eberlé et al. 2004). Radhakrishnan et al 
previously showed that ER membrane cholesterol levels are maintained at 5% 
through a combination of cholesterol biosynthesis and uptake mediated by SREBP 
activity, and that an increase of just 0.5% above this threshold is sufficient to trigger 
feedback inhibition of SREBP (Radhakrishnan et al. 2008). ER membrane 
cholesterol levels are communicated to SREBP through the sterol-sensing domain of 
SCAP(Motamed et al. 2011). Competitive binding studies using unlabelled and [
3
H]-
labelled cholesterol revealed that cholesterol binds SCAP within this sterol sensing 
domain (Radhakrishnan et al. 2007b). SREBP activation is also regulated by other 
sterol-based compounds such as oxysterols, although threshold levels for these are 
less clear (Radhakrishnan et al. 2007b). It is clear, however, that certain oxysterols 
are more potent inhibitors of cholesterol biosynthesis and uptake in vitro than 
cholesterol itself.  
Briefly, when cellular sterol levels are low, the SCAP-SREBP complex is 
transported from the ER to the Golgi where Golgi-resident proteases cleave SREBP 
at two sites to release the soluble transcription factor domain into the cytosol 
(Duncan et al. 1997a; Duncan et al. 1998; Sakai et al. 1996). This is then bound by 
the nuclear import protein, importin-β, which transports the transcription factor into 
the nucleus where is serves as an activator for a large number of target genes 
(Nagoshi et al. 1999; Nagoshi & Yoneda 2001). SCAP serves as the chaperone in 
this process as the COPII vesicle required for ER to Golgi transport assembles 
around Sec24 binding to a hexapeptide ‗MALADL‘ sequence located near the 




when sterols reach sufficient levels, the SCAP-SREBP complex is retained in the ER 
through the combined action of SCAP undergoing a conformational change which 
prevents Sec 24binding, and SCAP interacting with the ER-retention protein INSIG 
(Adams et al. 2003; Brown et al. 2002a). Transport of the SCAP-SREBP complex to 
the Golgi is a central event for regulation of SREBP activation. Experiments in 
which the protease responsible for release of the NTD was relocated to the ER 
removed the requirement of ER to Golgi transport for SREBP target gene 
upregulation (DeBose-Boyd et al. 1999). SCAP is a key limiting factor in SREBP 
activation. SCAP expression is under the control of SREBP so levels of both 
increases in parallel (Nakajima et al. 1999b). Over expression of the membrane 
domain of SCAP alone has been shown to remove the sterol mediated feedback 
inhibition of SREBP activity through saturation of INSIG proteins and facilitate free 
delivery of the SCAP-SREBP complex to the Golgi for processing (Yang et al. 
2000).  
In 1997, Sakai et al demonstrated that the CTD of SCAP was sufficient to pull down 
the full length SREBP precursor protein (Sakai et al. 1997). Similarly the CTD of 
SREBP was found to be sufficient to pull down the full length SCAP protein. Thus 
the SCAP-SREBP interaction site has been localised to these two approximately 550 
amino acid CTD regions. Although it plays a key role SCAP-SREBP interaction the 
CTD of SCAP is much less studied than its transmembrane region. Analysis of the 
SCAP amino acid sequence in 1996/8 showed that the SCAPCTD contained four/five 
Trp-Asp 40 (WD40) motifs (Hua et al. 1996; Nohturfft et al. 1998).  
WD40 motifs are found in repeats of four to eight, and were originally defined as 










number of repeats) (Neer et al. 1994). The motifs also have defined strand regions A-
D, which refer to folds formed by the motif (Figure 3.1A). Each motif folds in a β-
sheet conformation such that the repeats come together to form a propeller-like 
structure, with each blade of the propeller comprising of strand A-C of one repeat, 
and strand D of the next repeat (Smith et al. 1999; Garcia-Higuera et al. 1996). 
Strand D is believed to be the most accessible region of each WD40 repeat. This 
propeller-like structure then acts as a platform in mediating protein-protein 
interactions.  To date, all proteins containing WD40 repeats which have had their 
crystal structures solved indeed show this to be the case. However, although the 
consensus sequence indicates that four to eight repeats can be present in the SCAP 
CTD, all WD40 proteins that have crystal structures solved have seven to eight 
repeats forming the propeller, with the optimal beta propeller fold described as a 
seven bladed structure (Adams, Ron & P. a Kiely 2011; Cheng et al. 2004; Renault 
et al. 1998; Garcia-Higuera et al. 1996; Voegtli et al. 2003). Despite knowledge of 
the tertiary structure that these repeats tend to form, the loose nature of the consensus 
sequence which defines a WD40 repeat limits molecular homology modelling for 
proteins whose crystal structure is not yet formed. WD40 domain proteins are known 
to facilitate binding of multiple interacting proteins. For example, RACK1 contains 7 
WD40 repeats, forms a beta-propeller structure and acts as a scaffold for multiple 
interacting protein partners (Chen et al. 2004; Adams, Ron & P. a Kiely 2011).  
Since the discovery that the CTD region of SCAP binds SREBP, these WD40 
domains have been predicted to mediate the interaction. Based on the literature 
available on other WD40 domain proteins, it is plausible that these domains are 
involved however WD40 repeats comprise just less than half of the entire CTD, and 




that in other instances where the entire protein does not form the β-propeller 
structure that proteins may also interact with this non-WD40 region.  Also, as 
mentioned, most other WD40 domain proteins interact with multiple other proteins. 
The only protein currently known to interact with the CTD of SCAP is SREBP. Thus 
the presence of WD repeats in this region offers the possibility of SCAP interacting 
with more proteins, and this may add additional layers of complexity to the already 
tightly regulated SREBP feedback process. It could also potentially reveal new roles 
for SCAP outside of SREBP regulation.  
Our hypothesis is that SREBP1 and SREBP2 may bind to distinct regions within 
SCAPCTD, possibly within different WD40 repeats. In this chapter the steps taken 
towards identifying the residues within SCAP which bind each SREBP isoform are 
described. Mapping the SREBP binding site on SCAP would provide valuable 
information on how SCAP differentially regulates activation of the different SREBP 
isoforms and would further contribute to the knowledge base surrounding SREBP 
transcription factor regulation. In addition, mapping the precise site on SCAP which 
binds SREBP would be the first step in allowing for development of a small 
molecule inhibitor of the SCAP-SREBP interaction which could have potential use 
for treatment of a number of conditions including atherosclerosis, obesity and 
cancer. The experimental design to investigate this hypothesis involved the cloning, 
over-expression and purification of both SREBP1 and SREBP2 CTDs. Purified 
protein was then used to probe a peptide array of SCAPCTD to identify residues of 
importance. However, numerous obstacles were encountered in the purification of 
the SREBP proteins. In this chapter the measures taken to overcome these obstacles 
to obtain purified SREBP protein are described. A bioinformatic approach was also 




peptide array approach to possibly rule out false positives, since the crystal structure 






















Bioinformatic Analysis of SCAP Carboxy Terminal Domain  
The human SCAP protein sequence contains two main domains, a sterol-sensing 
transmembrane domain and a large cytosolic CTD tethered to the ER membrane by 
the transmembrane region of the protein.  The CTD of SCAP is known to contain 5 
WD repeat motifs. Further analysis of human SCAPCTD protein sequence using 
Simple Modular Architecture Research Tool (SMART) identified the presence of a 
sixth WD repeat, now designated WD2 (Figure 3.1B). To investigate the 
conservation of these WD40 repeats, a multiple sequence alignment of SCAP protein 
sequences ranging from human to zebrafish was performed. This analysis revealed  
46% sequence identity over the entire CTD region and an average of 70% identity 
within each WD40 repeat outside of WD2 (Figure 3.2). While this level of sequence 
conservation within the WD40 repeats is indicative of their importance, this makes it 
difficult to identify any critical residues of importance within the WD repeats which 
could be essential to the interaction. Also, since the crystal structure of SCAP is not 
solved, this makes it difficult to focus in on residues that may be available on the 
protein surface. However, while the crystal structure is not known, the folding of a 
WD repeat is quite well characterised. Based on the consensus sequence for a WD40 
repeat, the region of each repeat predicted to be at the protein surface, strand d, is 
highlighted in Figure 3.1A. However, the distance of WD1 from WD2-6 suggests 
that it is too far to be a part of a beta propeller structure, and unless there is another 
unidentified WD40 repeat located between WD1 and WD2, then predicting the 




SMART analysis of SCAP homolog sequences from Drosophila (dSCAP) and 
Caenorrhabditis species (scp-1) reveal conservation of the presence of WD40 
repeats within the CTD, although the number of repeats are five and four, 
respectively (Figure 3.1B). The reduced number of repeats in these less complex 
organisms may be related to the fact that they have only one SREBP isoform. The 
conservation of WD40 repeats in such divergent species highlights their importance 
and suggests that they have a role in mediating the only known function of 
SCAPCTD, which is interacting with SREBP.  
A phylogenetic tree was constructed based on the multiple sequence alignment of 
SCAP from vertebrate species (Figure 3.1C). The reliability of this tree was assessed 
using the bootstrap test of phylogeny. The high bootstrap values illustrate the overall 
sequence conservation in SCAP vertebrate homologs. 
Knowing the crystal structure of a protein assists in confirming true positive residues 
of importance identified by peptide array by informing as to which residues are 
accessible for binding. However the crystal structure of SCAP has not been solved. 
Thus, homology modelling was performed using SWISS-MODEL to generate a 
hypothetical 3D protein structure of the CTD of SCAP based on sequence similarity 
with other WD domain proteins which have crystal structures available. The best fit 
homology model for SCAP CTD was modelled based on RACK1 (Figure 3.3A). 
RACK1 is also a WD domain protein whose crystal structure is a seven-bladed 
propeller, which is characteristic of WD domain proteins. However half of the SCAP 
CTD is excluded from this model, which includes WD1. In the structure shown, 
WD2-WD6 are forced into the seven-bladed structure of RACK1 (Figure 3.3B).  
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Figure 3.1. Conservation of WD40 repeat motifs within the carboxy terminal domain of 
SCAP.  A) Consensus sequence for a WD40 repeat (taken from Neer et al, 1994). B) 
Schematic representation of WD40 repeat distribution within the carboxy-terminal domains 
of SCAP homologs from human, fruitfly and worm (* indicates the novel WD repeat 
identified using SMART motif analysis tool). C) Phylogenetic tree based on multiple 
sequence alignment of SCAP from vertebrates. Alignments were performed using Clustal 
W. The tree was constructed using the neighbourhood-joining method, and reliability was 





























H.sapiens  : EIVPLVLRGHLMDIECLASDGMLLVS.CCLAGHVCVWD : 37 
P.abelii   : EIVPLVLRGHLMDIECLASDGMLLVS.CCLAGHVCVWD : 37 
C.jacchus  : EIVPLVLRGHLMDIECLASDGMLLVS.CCLAGHVCVWD : 37 
E.caballus : EIVPLVLRGHLMDIECLASDGMLLVS.CCLAGHVCVWD : 37 
C.griseus  : EIVPLVLRGHLMDIECLASDGMLLVS.CCLAGQVCVWD : 37 
O.cuniculu : EIVPLVLRGHLMDIECLASDGMLLVS.CCLAGRVCVWD : 37 
S.scrofa   : EIVPLVLRGHLMDIECLASDGMLLVS.CCLAGHVCVWD : 37 
L.africana : EIVPLVLRGHLMDIECLASDGMLLVS.CCLAGHVCVWD : 37 
R.norvegic : EIVPLVLRGHLMDIECLASDGMLLVS.CCLAGQVCVWD : 37 
M.musculus : EIVPLVLRGHLMDIECLASDGMLLVS.CCLAGQVCVWD : 37 
B.taurus   : EIVPLVLRGHLMDIECLASDGMLLVS.CCLAGHVCVWD : 37 
C.lupusfam : EIVPLVLRGHLMDIECLASDGMLLVS.CCLAGHVCVWD : 37 
M.gallopav : EIVPLVLRGHLMDIECLASDGMLLVS.CCLVGQIRVWD : 37 
M.domestic : EIIPLVLRGHLMDIECLASDGMLLVS.CCLVGQIRVWD : 37 
X.Silurana : EIVPLVLRGHHMDIECLASDGMLLVS.CCLAGQIRVWD : 37 
D.rerio    : EISPLLLRGHSMDIECLASDGMLL-ASCCLAGQIRVWD : 37 
X.laevis   : EIVPLVLRGHHMDIECLASDKMLLV-SCCLAGQIRVWD : 37 
WD 2 
H.sapiens  : KGSPSLAWAPSAEGSIWSLELQGNLIVVGRSSGRLEVWD : 39 
P.abelii   : KGSPSLAWAPSAEGSIWSLELQGNLIVVGRSSGRLEVWD : 39 
C.jacchus  : KGSPSLAWAPSAEGSIWSLELQGGLIVVGRSSGRLEVWD : 39 
E.caballus : KGSPCLAWAPSADGSIWSLELQGNLIVVGRSSGRLEVWD : 39 
C.griseus  : KGSPPLAWAPSTAGSIWSLELQGNLIVVGRSSGRLEVWD : 39 
O.cuniculu : KGSPSLAWAPSADGSIWSLELQGSLIVVGRSSGRLEVWD : 39 
S.scrofa   : KGSPSFTWAPSADGSIWSLELQGNLIVVGRSSGRLEVWD : 39 
L.africana : KGSPSLIWAPSADGSIWSLELQGSLIVVGRSSGRLEVWD : 39 
R.norvegic : KGSPPLAWAPSTAGSIWSLELQGSLIVVGRSSGRLEVWD : 39 
M.musculus : KGSPPLAWTPSTAGSIWSLELQGNLIVVGRSSGRLEVWD : 39 
B.taurus   : KSCPSLAWAPSADGSIWSLELQGSLIVVGRSSGRLEVWD : 39 
C.lupusfam : KGSPCLAWAPSADGSIWSLELQGSLIVVGRSSGRLEVWD : 39 
M.gallopav : KSSPLPSWGGDFESSVWSLDLQGNLIVAGRSNGKLEVWD : 39 
M.domestic : KGSPIPTWTPDTESSVWSLDLQGNLIVAGRSNGRLEVWD : 39 
X.Silurana : TSSPVLSWTESFESSVWSLGLQGNLIVVGRSNGNLEVWD : 39 
D.rerio    : LPP---QSSADWDSSVWAMELRGNLIATGRSTGKLELWD : 36 
X.laevis   : SSSPAPSWTDSFESSVWSLGLQGNLIVVGRSNGNLEVWD : 39 
WD 3 
H.sapiens  : ACHLTHTVPCAHQKPITALKAAAGRLVTGSQDHTLRVFR : 39 
P.abelii   : ACRLTHTVPCAHQKPITALKAAAGRLVTGSQDHTLRVFR : 39 
C.jacchus  : ACHLTHTVPCAHQKPITALKAAAGRLVTGSQDHTLRVFR : 39 
E.caballus : ACRLTHTVPCAHQKPITALKAAAGRLVTGSQDHTLRVFR : 39 
C.griseus  : ACHLTHTVPCAHQKPITALRAAAGRLVTGSQDHTLRVFR : 39 
O.cuniculu : ACHLTHTVPCAHQKPITALKAAAGRLVTGSQDHTLRVFR : 39 
S.scrofa   : VCHLTHTVPCAHQKPITALKAAAGRLVTGSQDHTLRVFR : 39 
L.africana : ACHLTHTVPCAHQKPITALKAAAGRLVTGSQDHTLRVFR : 39 
R.norvegic : ACHLTHTVPCAHQKPITALRAAAGRLVTGSQDHTLRVFR : 39 
M.musculus : TCHRTHTVPCAHQKPITALRAAAGRLVTGSQDHTLRVFR : 39 
B.taurus   : ACHLTHTVPCAHQKPITALKAAAGRLVTGSQDHTLRVFR : 39 
C.lupusfam : SCRLTHTVPCAHQKPITALKAAAGRLVTGSQDHTLRVFR : 39 
M.gallopav : VCQLTHTVSCAHQKPITALKAAAGRLVTGSQDHTLRVFR : 39 
M.domestic : ICHLTHTVSCAHQKPITALKAAAGRVVTGSQDHTLRVYR : 39 
X.Silurana : GCQRSHTVACAHQKPITALKAAAGRLVTGSQDHTVRVYR : 39 
D.rerio    : SCHLTRSVQCAHQKPITVLKAAAGRVVTGSQDHTVRVYR : 39 




WD 4  
H.sapiens  : DSCCLFTLQGHSGAITTVYIDQTMVLASGGQDGAICLWD : 39 
P.abelii   : DSCCLFTLQGHSGAITTVYIDQTMVLASGGQDGAICLWD : 39 
C.jacchus  : DSCCLFTLQGHSGAITTVYIDQTMVLASGGQDGAICLWD : 39 
E.caballus : DSCCLFTLQGHSGAITTVYIDQTMVLASGGQDGAICLWD : 39 
C.griseus  : DSCCLFTLQGHSGAITTVYIDQTMVLASGGQDGAICLWD : 39 
O.cuniculu : DSCCLFTLQGHSGAITTVYIDQTMVLASGGQDGAICLWD : 39 
S.scrofa   : DSCCLFTLQGHSGAITTVYIDQTMVLASGGQDGAICLWD : 39 
L.africana : DSCCLFTLQGHSGAITTVYIDQTMVLASGGQDGAICLWD : 39 
R.norvegic : DSCCLFTLQGHSGAITTVYIDQTMVLASGGQDGAICLWD : 39 
M.musculus : DSCCLFTLKGHSGAITAVYIDQTMVLASGGQDGAICLWD : 39 
B.taurus   : DSCCLFTLQGHSGAITTVYIDQTMVLASGGQDGAICLWD : 39 
C.lupusfam : DSCCLFTLQGHSGAITTVYIDQTMVLASGGQDGAICLWD : 39 
M.gallopav : DSCCLFTLQGHSGAITAVYIDQTMVLASGGQDGAICLWD : 39 
M.domestic : DSCCLFTLQGHSGAITAVYIDQTMVLASGGQDGAICLWD : 39 
X.Silurana : DACCLFTLQGHSGGITAIYIDETMVLASGGQDGAICLWD : 39 
D.rerio    : DSCCLFTLQGHSGGITAIYIDQTMVLASGGQDGAICVWD : 39 
X.laevis   : DACCLFTLQGHSGGITAIYIDETMVLASGGQDGAICLWD : 39              
WD 5 
H.sapiens  : TGSRVS.HVFAHRGDVTSLTCTTSCVISSGLDDLISIWD : 38 
P.abelii   : TGSRVS.HVFAHRGDVTSLTCTTSCVISSGLDDLISIWD : 38 
C.jacchus  : TGSRVS.HMFAHRGDVTSLTCTTSCVISSGLDDLISIWD : 38 
E.caballus : TGSRVS.HMFAHRGDVTSLTCTTSCVISSGLDDLISIWD : 38 
C.griseus  : TGSRVS.HTFAHRGDVTSLTCTTSCVISSGLDDLINIWD : 38 
O.cuniculu : TGSRVS.HMFAHRGDVTSLTCTASCVISSGLDDLISIWD : 38 
S.scrofa   : TGSRVS.HMFAHRGDVTSLTCTTSCVISSGLDDLISIWD : 38 
L.africana : TGSRVS.HMFAHRGDVTSLTCTTSCVISSGLDDLISIWD : 38 
R.norvegic : TGSRVS.HTFAHRGDVTSLTCTTSCVISSGLDDFINIWD : 38 
M.musculus : TGSRVS.QTFAHRGDVTSLTCTASCVISSGLDDFISIWD : 38 
B.taurus   : TGSRVS.HMFAHRGDVTSLTCTTSCVISSGLDDLISIWD : 38 
C.lupusfam : TGSRVS.HMFAHRGDVTSLTCTTSCVISSGLDDLISIWD : 38 
M.gallopav : TGSKVS.HMYAHRGDVTSLTCTTSCVISSGLDDVISIWD : 38 
M.domestic : TGSRVS.HMFAHRGDVTSLTCTTSCIISSGLDDLISIWD : 38 
X.Silurana : TGSRVS.HMFGHRGDVTSLLCTTSCVISSGLDDVICIWD : 38 
D.rerio    : TGSRVS.HVYGHRGDVTSLVCTTSCIISSGLDDLICIWD : 38 
X.laevis   : TGSRVS.HMFGHRGDVTSLLCTASCVISSGLDDVISIWD : 38 
 
WD 6                
H.sapiens  : TGIKFYSIQQDLGCGASLGVISDNLLVTGGQGCVS.FWD : 38 
P.abelii   : TGIKFYSIQQDLGCGASLGVISDNLLVTGGQGCVS.FWD : 38 
C.jacchus  : TGIKFYSIQQDLGCGASLGVISDNLLVTGGQGCVS.FWD : 38 
E.caballus : TGIKLYSIQQDLGCGASLGVISDNLLVTGGQGCVS.FWD : 38 
C.griseus  : TGIKLYSIQQDLGCGASLGVISDNLLVTGGQGCVS.FWD : 38 
O.cuniculu : TGIKLYSIQQDLGCGASLGVISDNLLVTGGQGCVS.FWD : 38 
S.scrofa   : TGIKLYSIQQDLGCGASLGVISDNLLVTGGQGCVS.FWD : 38 
L.africana : TGIKLYSIQQDLGCGASLGVISDNLLVTGGQGCVS.FWD : 38 
R.norvegic : TGIKLYSIQQDLGCGASLGVISDNLLVTGGQGCVS.FWD : 38 
M.musculus : TGIKLYSIQQDLGCGASLGVISDNLLVTGGQGCVS.FWD : 38 
B.taurus   : TGIKLYSIQQDLGCGASLGVISDNLLVTGGQGCVS.FWD : 38 
C.lupusfam : TGIKLYSIQQDLGCGASLGVISDNLLVTGGQGCVS.FWD : 38 
M.gallopav : SGIKLYSIQQEMGCGSSLGVISDNLLVTGGQGCVS.FWD : 38 
M.domestic : TNIKLYSIQQDMGCGSSLGVISDNLLVTGGQGCVS.FWD : 38 
X.Silurana : TAIRLYSIQQDLGCGSSLGLISDNLLVTGGQGCVS.FWD : 38 
D.rerio    : TGIKLYSIQQEVGCGASLGVISENLLVTGGQGCVS.FWD : 38 





Figure 3.2. Multiple sequence alignments of vertebrate SCAP WD40 repeats. Full length 
protein sequences of SCAP from vertebrates were aligned using ClustalW algorithm in 
MEGA 4.0 software. Shown here are WD repeats only, labelled WD1-WD6, in accordance 
with their distribution with SCAPCTD as outlined in Figure 1B. Alignments visualised using 
the multiple sequence alignment analysing tool GeneDoc. Black indicates 100% identity 
between residues (including synonymous substitutions), grey indicates a high level of 


















































Figure 3.3. Homology model of SCAPCTD. SWISS-MODEL was used to predict the 3D 
protein structure of SCAP CTD using proteins containing similar structural domains which 
have their crystal structures solved. (A) SCAP CTD structure modelled on the crystal 
structure of RACK1 (B) SCAP CTD amino acid sequence aligned with the template RACK1 
sequence. SCAP CTD WD1-WD6 repeats are highlighted by red boxes. Red/blue shaded 








Optimising Expression, Solubility and Purification of GST-SREBP1 and GST-
SREBP2 CTDs 
Based on the knowledge that the SCAPCTD is sufficient to pull down full length 
SREBP protein and vice versa, the aim of this work was to further characterise this 
interaction to the amino acid level by mapping the SREBP interaction site on the 
SCAPCTD. The central approach to achieve this aim was to purify the SREBPCTD to 
probe a peptide array of the SCAPCTD.  
In order to over-express and purify the CTD domains of SREBP1 and SREBP2, 
1776bp of the SREBP1 gene and 1761bp of the SREBP2 gene encoding the CTD 
domains were cloned into an inducible bacterial expression vector (pGEX-6p1). The 
CTD domains in this vector are tagged with an amino terminal GST to facilitate 
affinity purification (Figure 3.4). The GST gene in the vector encodes a 26kDa 
protein while the SREBP1 CTD and the SREBP2 CTD both encode approximately 
65kDa proteins. The expression of the GST-SREBP1CTD fusion protein (~91 kDa) 
and GST-SREBP2CTD fusion protein (~91 kDa) in E. coli was analysed under 
different induction times and IPTG concentrations. Both CTD domains were 
strongly induced at 4, 16 and 30 hrs using 0.5 mM or 1 mM IPTG and the 16 hr 
timepoint was chosen for convenience (Figure 3.5A and 3.5B). Induction of GST 
alone was used as a positive control throughout (data not shown).  
Bacterial cell cultures over-expressing the SREBP proteins were grown and the cells 
were harvested by centrifugation for affinity purification of the tagged proteins. 
Soluble cell extracts were prepared from harvested cell pellets using the standard 










Figure 3.4. Schematic representation of pGEX-6p1-SREBP1CTD and pGEX-6p1- 
SREBP2CTD. The lac promoter (lacP) allows regulated induction of gene expression by 
IPTG. Numbers in brackets refer to the amino acid section of the SREBPs inserted into the 
vector. 
 
SREBP fusion proteins were clearly present in whole cells lysed in SDS loading dye 
(Figure 3.5C and 3.5D, Ind lane), they were not visible in the soluble cell extracts 
(Figure 3.5C and 3.5D Sup lanes) and no SREBP protein was recovered following 
glutathione affinity chromatography (Figure 3.5C and 3.5D, E1-E4 lanes).  By 
comparison, a control sample over-expressing GST alone had protein in both the 
whole cell lysate and in the soluble fractions (data not shown). The simplest 
explanation for this result is that the SREBP proteins are sequestered into inclusion 
bodies (IBs) within the bacteria. Inclusion bodies are aggregates of protein that occur 
in bacteria due to mis-folding of endogenous proteins, but also often as a result of 
recombinant protein over-expression. 
A common approach to producing soluble over-expressed protein in bacteria is to 
grow the bacteria at lower temperatures and for longer times. These conditions slow 
down protein production and can often lead to increased chances of producing 
correctly folded proteins with improved solubility. To investigate if this was the case 
for the SREBPCTD, cultures were grown to an OD600 of 0.5, at temperatures of 30
o
C  
pGex-6p1- SREBP2CTD : 
 
lacP GST SREBP2CTD 
(554-1141) 
pGex-6p1- SREBP1CTD : 
 











Figure 3.5. Analysis of GST- SREBPCTD fusion protein expression. SDS-PAGE analysis of 
E. coli bearing (A) pGEX-6p1-SREBP1CTD or (B) pGEX-6p1-SREBP2CTD .Following 
induction with the indicated concentrations of IPTG for different lengths of time samples of 
the E. coli were removed from the culture and pelleted by centrifugation. Whole cell lysis 
was carried out by boiling the pellets in SDS loading dye and samples were then clarified by 
centrifugation and analysed by SDS-PAGE on 10% polyacrylamide gels and visualised by 
staining with coomassie blue. Analysis of affinity purification of GST- SREBP1CTD  (C) and 
GST-SREBP2CTD (D). E. coli bearing pGEX-6p1- SREBP1CTD or pGEX-6p1- SREBP1CTD 
were induced for 16 hrs in the presence of 0.5 mM IPTG. Following induction whole cell 
lysis was carried out by boiling the pellets in SDS loading dye (Ind samples) or cell extracts 
were prepared and incubated with GST beads. Beads were then collected by centrifugation 
and the supernatant was removed. Beads were then washed in PBS and protein was eluted 
from the beads with PBS containing reduced glutathione. Samples analysed: Ctrl, no IPTG 
added; Ind, induced for 16 hrs with 0.5 mM IPTG; Sup, soluble supernatant; W, wash; FT, 
flow through; E1-4, elutions with reduced glutathione. Samples were analysed by SDS-









C, which took approx 7 and 16 hours, respectively, as opposed to the 2.5-
3hours when grown at 37
o
C. They were then induced with IPTG for the indicated 
lengths of time, using GST alone again as positive control. However, these changes 
to growth conditions failed to induce expression of any fusion protein detectable by 
SDS-PAGE (data not shown) and this approach was not pursued any further.  
 It was originally believed that all IBs comprised of misfolded proteins and that their 
formation was an undesired effect. However, more recent studies have demonstrated 
sequestration of functional protein within IBs and some purification approaches now 
use IB formation to separate their target protein from all the soluble protein and then 
proceed to solubilise their target protein from the inclusion body and refold it.  This 
approach was attempt here. 
Bacteria were cultured at 37
o
C, brought to an OD600 of 0.5, and then induced with 
IPTG for 16 hours. Based on the methods described by Rodríguez-Carmona et al., 
IBs were purified from bacterial whole cell pellets. Briefly, bacterial pellets were 
resuspended in buffer and freeze-thawed for 4 cycles in liquid nitrogen. Cell 
suspensions were then incubated for 2 hours at 37
o
C in the presence of lysozyme, 
followed by addition of Triton X-100 and incubation for a further hour at RT. Cell 
suspensions were then sonicated on ice for 5 x 10 second bursts, NP-40 was added 
and lysates were incubated at 4
o
C for 1 hour. MgSO4 and DNAse were then added 
and samples were incubated at 37
o
C for 45 minutes, followed by centrifugation at 
15000 x g for 15 minutes at 4
o
C. The pellet contains inclusion bodies. SDS-PAGE 
analysis of the prepared IBs showed that the GST-SREBP2CTD fusion protein was 
present (Figure 3.6A).  
Frangioni and Neel reported increased solubilisation of functional aggregated over-




in an attempt to solubilise the over-expressed SREBPCTD proteins (Frangioni & Neel 
1993). In this approach IBs were first harvested by centrifugation and sarkosyl was 
then added to these IBs. High concentrations of sarkosyl (10%) increased solubility 
of the SREBPCTD proteins to 90% as assessed by the levels of the 91 KDa proteins 
remaining in the soluble fraction following centrifugation. However, at this 
concentration of sarkosyl the GST alone positive control protein did not bind the 
affinity resin (data not shown) and consequently it was necessary to reduce the 
sarkosyl concentration. 
Purification of the proteins was then attempted in the presence of 1% sarkosyl as 
outlined in materials and methods. GST alone did bind the affinity resin and could be 
purified to a high level in the presence of 1% sarkosyl. However, little GST-
SREBP2CTD fusion protein was recovered in the purification process and the 91 kDa 
protein was barely detectable by coomassie staining (Figure 3.6B).   
Tao et al previously showed that sarkosyl solubilisation of aggregated protein in the 
presence of other non-ionic detergents can improve fusion protein binding to affinity 
resin (Tao et al. 2010). Triton X-100 and CHAPS have both been reported to 
increase binding of sarkosyl-solubilised proteins to affinity resin. Various 
combinations of these detergents were investigated with respect to improving fusion 
protein binding to affinity resin. Combinations ranged from 1-4% Triton X-100 with 
or without 10-40 mM CHAPS, all in the presence of 1% sarkosyl. The combination 
which yielded the best results was inclusion of 2% Triton X-100 with 1% sarkosyl 
prior to incubation of the soluble fraction with the affinity resin, although this was 
only a marginal improvement in yield over sarkosyl alone purified protein (Figure 




proteins recovered by the IB solubilisation approach was low, that the purification 
was only partial and that a considerable amount of protein was likely to be lost 
during the removal of the detergents prior to using the proteins for interaction studies 
it was decided to switch to a different expression system/fusion tag/purification 




























































Figure 3.6. SDS-PAGE analysis of GST- SREBP2CTD fusion protein in IBs before and after 
solubilisation in detergent. E. coli bearing pGEX-6p1- SREBP2CTD were induced for 16 hrs 
in the presence of 0.5 mM IPTG. Following induction IBs were prepared in the presence of 
the indicated detergents followed by incubated with GST beads. Beads were then collected 
by centrifugation and the supernatant was removed. Beads were then washed in PBS and 
protein was eluted from the beads with PBS containing reduced glutathione. Samples 
analysed: Ctrl, no IPTG added; Ind, induced for 16 hrs with 0.5 mM IPTG; IB, Inclusion 
bodies; Sup, soluble supernatant; W, wash; FT, flow through; E1-4, elutions with reduced 
glutathione; B, beads. Samples were analysed by SDS-PAGE on a 10% polyacrylamide gel 






Optimising Expression and Purification of SREBP1CTD-His6 and SREBP2CTD-His6 
Given that the GST-SREBPCTD over-expressed proteins were problematic with 
respect to solubility an alternative over-expression system was attempted. The 
alternative system is based on tagging of the proteins with six histidines residues at 
the carboxy terminus whereas the tag was at the amino terminus in the GST system 
already described. It was hoped that placing a smaller tag at a different location 
might improve solubility. The same protein sequences of SREBP1 and SREBP2 
CTDs as for the GST expression system outlined above were cloned into a 
pBADtopo TA expression vector, such that each SREBP is tagged with six histidines 
(His6) at the carboxy terminus. The molecular weight of the His6 tagged proteins is 
approximately 65 kDa and is close to the native size of the SREBPCTD proteins as the 
tag is small (Figure 3.7). GST-GFP-His6 (~53 kDa) was used as a positive control for 







Figure 3.7. Schematic representation of pBADtopo- SREBP1CTD and pBADtopo- 
SREBP2CTD. The araBAD promoter provides tight, dose-dependent regulation of gene 
expression by L-arabinose. Numbers in brackets refer to the amino acid section of the 
SREBPs inserted into the vector. 















 In order to over-express the His6 tagged SREBPs, bacterial cultures containing these 
constructs were grown to an OD600 of 0.5 and induced with 0.02% of L-arabinose for 
four hours. Unlike the GST fusion proteins, induction of the His fusion proteins 
could not be detected by coomassie staining and were checked instead by 
immunoblot analysis using an anti His tag antibody which confirmed the presence of 
the fusion proteins. Scale up to 500 mL using these induction conditions followed by 
cell lysis and preparation of cell extracts indicated that the majority of the protein 
expressed was in the soluble fraction (Figure 3.8A, Sol vs. Ind lane). Purification of 
the tagged proteins was attempted using nickel affinity chromatography.  Initially, 
affinity purification of the fusion protein from this soluble fraction, as described 
under materials and methods, yielded very small amounts of purified SREBP2 fusion 
protein detectable by immunoblot (Figure 3.8A, E1-E5 lanes) while the positive 
control fusion protein (GST-GFP-His6) was present at higher levels (Figure 3.8B, 
E1-E5 lanes).  
To achieve a higher yield of purified SREBPCTD-His6, the culture volume was scaled 
up to 5L of bacteria over-expressing pBADtopo-SREBP2CTD or pBADtopo-
SREBP1CTD (or pBADtopo-GFP-GST control), induced as outlined above and lysed 
in a 50-fold more concentrated volume of buffer than the recommended volume of 
buffer required for lysis of a 5L culture. Again, following lysis by sonication, the 
majority of the SREBP protein was present in the soluble fraction (Figure 3.8C and 
3.8D, Sol lane). Nickel affinity purification of the fusion protein yielded quantities 
detectable by immunoblot, however compared to the signal obtained for control 
protein, both the expressed and purified fractions for SREBP2CTD-His6 and 




    
   
Figure 3.8. Immunoblot analysis of SREBPCTD and GFP-GST His6-fusion proteins. E. coli 
bearing pBADtopo-SREBP2CTD (A,C),  pBADtopo-SREBP1CTD (D) or pBADtopo-GFP-GST 
(B,E) were induced for 4 hrs in the presence of 0.02% L-arabinose, in either 500mL LB 
(A,B) or 5L LB(C,D). Following induction, bacterial cells were pelleted by centrifugation, 
lysed by sonication in the presence of lysozyme in hypotonic buffer, followed by incubation 
with nickel affinity resin. The resin was then collected by centrifugation and the supernatant 
was removed. The resin was then washed in buffer containing 20mM of imidazole and 
protein was eluted from the resin with buffer containing a 250mM of imidazole. Samples 
analysed: Ind, induced for 4 hrs with 0.02% L-arabinose; Sol, soluble cell extract fraction; 
W, wash; FT, flow through; E1-4, elutions with reduced glutathione; B, beads (resin). 
Samples were analysed by SDS-PAGE on a 10% acrylamide gel. Protein was transferred to 
nitrocellulose membrane by wet transfer and immunoblot analysis was performed using 
mouse anti-His primary antibody incubated overnight at 4
o
C (Genescript, 1:2500) and goat 
anti-mouse IRDye680LT incubated for 1hour at RT (Li-cor, 1:20 000). Blots were visualised 









In addition, the majority of the fusion protein did not bind to the resin and was 
present in the flow through (Figure 3.8C and 3.8D, Sol vs. FT lanes). Attempts to 
purify more fusion protein from the flow through fraction by re-incubation with fresh 
resin, did not result in any extra yield (data not shown) indicating that the bound 
protein has different properties to the protein that did not bind. The basis of this 
difference is unclear.  
The eluted fractions which were positive for SREBP2CTD-His6 protein by 
immunoblot from the 5L preparation were run on an SDS-PAGE gel to assess the 
purity of the eluted fusion protein. The results showed the presence of a large 
amount of contaminating protein in the fractions (Figure 3.9A). Attempts to increase 
purity by re-incubation of the eluted fractions with fresh affinity resin did not 
increase purity (Figure 3.9B). Gel filtration FPLC was then attempted as to increase 
fusion protein purity. BSA was run separately on the column as a protein standard of 
similar molecular weight and apparent size. The SREBP2CTD-His6 tagged fusion 
protein, like BSA, eluted from the column in fraction B1 (Figure 3.10A and 3.10B). 
There was a significant amount of protein in the other peaks on the chromatogram 
but these were negative for the SREBP2CTD-His6 fusion protein by immunoblot 
analysis (Figure 3.10B). The fractions flanking fraction B1 also contained fusion 
protein but at lower levels (Figure 3.10C). However, as indicated by the 
chromatogram, the fractions containing the fusion protein appeared to contain quite a 
small amount of the total protein applied. The low concentration of the SREBP2CTD-
His6 fusion protein was confirmed when the FPLC fusion protein fractions were run 
on an SDS-PAGE gel along with serial dilutions of a BSA protein standard (Figure 
3.10D). The concentration of the SREBP2CTD-His6 fusion protein was maximally 




detectable by coomassie blue staining at this concentration, and neither was the 
SREBP2CTD-His6 tagged fusion protein. In addition, following the FPLC cleanup, 
the fusion protein was still not the primary protein in the fraction, as detected by 
coomassie staining. There was a lower molecular weight band detectable at 
approximately 1 µg/ml concentration, which is likely either a contaminating protein 
or a degradation product of SREBP2CTD-His6. While this method did decrease 
contaminating protein from the SREBPCTD-His6 tagged fusion protein, it failed to 
increase yield sufficiently for peptide array studies. The required amount of fusion 
protein to probe the peptide array is 6 mLs at 100 µg/mL, and this method yielded 
only 1.5 mL of protein at a concentration of less than 1 µg/mL, from a total starting 
culture volume of 5 L.  
The anti-His antibody used was highly sensitive and gave a strong clean signal for 
the SREBPCTD-His6 fusion proteins in the pre FPLC crudely purified fractions. 
Therefore the crudely purified fusion protein was used for probing of SCAPCTD 













    
          
 
Figure 3.9. SDS-PAGE analysis of SREBP2CTD-His6 eluted protein fractions. (A)Eluted 
fractions E1, E2 and E3 containing purified SREBP2CTD-His6 fusion protein were analysed 
by SDS-PAGE on a 10% polyacrylamide gel and staining with coomassie blue. (B) 
Fractions E1, E2 and E3 from (A) were pooled and re-incubated with Nickel affinity resin. 
The resin was then collected by centrifugation and the supernatant was removed. The resin 
was then washed in buffer containing 20mM of imidazole and protein was eluted from the 
resin with buffer containing a 250mM of imidazole. Samples analysed: BSA, 1 and 0.1 
mg/ml; E1-E7, eluted fractions. Samples were analysed by SDS-PAGE on a 10% 












Figure 3.10. Analysis of purity of FPLC Nickel-affinity purified SREBP2CTD-His6. (A) 
Absorbance spectra of protein fractions following separation by gel filtration FPLC.  E. coli 
bearing pBADtopo-SREBP2CTD were induced for 4 hrs in the presence of 0.02% L-
arabinose, in 5L LB. Following induction, bacterial cells were pelleted and lysed, and 
SREBP2CTD-His6 fusion protein was applied to a nickel affinity chromatography column.  The 
eluted fractions were pooled and separated by gel filtration FPLC. (*, peak containing 
SREBP2CTD-His6 fusion protein), (B and C) Analysis of eluted fractions following FPLC for 
presence of SREBP2CTD-His6 fusion protein. Eluted fractions were analysed by SDS-PAGE 
on a 10% polyacrylamide gel. Protein was transferred to nitrocellulose membrane by wet 
transfer and immunoblot analysis was performed using mouse anti-His primary antibody 
incubated overnight at 4
o
C (Genescript, 1:2500) and goat anti-mouse IRDye680LT 
incubated for 1hour at RT (Li-cor, 1:20 000). Blots were visualised on Odyssey Infrared 
Imaging System (Li-cor). D) Estimation of the concentration of SREBP2CTD-His6 fusion 
protein yield following FPLC clean-up using a BSA standard. Samples analysed: BSA, 
1000, 100, 10, 1 and 0.1µg/ml; B1, B2 and B6, FPLC eluted fractions. Samples were 
analysed by SDS-PAGE on a 10% polyacrylamide gel and staining with coomassie blue.* is 
a non-specific band. 
SREBP2CTD-His6 








Peptide array analysis of SCAPCTD probed with SREBP2CTD-His6 fusion protein 
In order to identify residues within SCAPCTD involved in the SCAP-SREBP2 
interaction, the CTD of SCAP was immobilised in a peptide array. The peptide array 
was synthesised by Dr. Emilie Tresse in the laboratory of Prof. Rosemary O‘ 
Connor, Biosciences, UCC and consisted of a series (107 peptides in total) of 18-mer 
peptides attached to a cellulose membrane, with each peptide overlapping by a 5 
amino acid window. The array was incubated with SREBP2CTD-His6 fusion protein 
for 16 hours at 4 
o
C. Following washing, mouse anti-His primary antibody was used 
to detect SREBP2CTD-His6 bound to the array. Two spots (spots 3 and 4) gave 
positive signal (Figure 3.11A) and there was no binding of a non-specific control 
His6 fusion protein (EndoIV-His6) to these spots in a duplicate SCAPCTD peptide 
array (Figure 3.11B). The latter was stripped and reprobed with SREBP2CTD-His6 
fusion protein and also resulted in fusion protein binding to spots 3, 4 and also to 
spot 5 (Figure 3.11C).  
Binding of the SREBP2CTD-His6 fusion protein to spot 3 gave the strongest signal. 
This corresponds to the peptide GGPGRRRRGELPCDDYGY. An alanine scanning 
array based on the parent peptide of spot 3 was generated in which each amino acid 
was sequentially and individually substituted with alanine. Alanine scanning arrays 
are used to identify which residues within a given 18-mer peptide are essential to the 
fusion protein binding to a given spot. This array was probed with SREBP2CTD-His6 
fusion protein and surprisingly there was no fusion protein bound to spot 1 of the 
alanine scanning array (Figure 3.11D). Spot 1 is based on the unmodified parent 
peptide and is the sequence to which the SREBP2CTD-His6 fusion protein originally 




interacting with SREBP2CTD-His6 fusion protein, the presence and absence of other 
spots in the alanine scanning array cannot be interpreted with confidence.  
The batch of SREBP2CTD-His6 fusion protein used to probe the original SCAPCTD 
peptide arrays was different to the batch of SREBP2CTD-His6 fusion protein used to 
probe the alanine scanning array. Both of these batches were purified in the same 
way and both were confirmed as having fusion protein present. In the repeat array, 
the peptide spots which previously came up as positive for binding SREBP2CTD-His6 
fusion protein were now absent, and different peptide spots were positive (Figure 
3.11E). The reasons for this discrepancy are unclear but are likely to be linked to the 
problematic purification of the SREBP-His6 fusion proteins. The initial binding to 
peptide spots 3 and 4 shown in Figure 3.11A and 3.11C was achieved using the same 
















Figure 3.11.  Probing of peptide array analysis of SCAPCTD with SREBP2CTD-His6 . 
Independent peptide arrays of immobilized peptide ‗spots‘ of overlapping 18-mer peptides 
each shifted along by a five amino acid window in the CTD sequence of human SCAP were 
probed with either purified SREBP2CTD-His6 fusion protein (A) or purified non-specific 
control His6 fusion protein (EndoIV-His6) (B). The control protein array from (B) was then 
stripped and re-probed with purified SREBP2CTD-His6 fusion protein (C). A peptide array 
based on 18 amino acids of the parent peptide corresponding to spot 3 in which each amino 
acid was sequentially and individually substituted for alanine was probed with purified 
SREBP2CTD-His6 fusion protein (D). A newly synthesised peptide array of the CTD sequence 
of human SCAP was incubated with a new batch of purified SREBP2CTD-His6 fusion protein 
(E). Spot numbers relate to peptides in the scanned array. Interactions were detected by 
immunoblotting with mouse anti-His6 antibody and visualised by ECL. Positively interacting 



































Peptide array analysis of SCAPCTD probed with SREBP1CTD-His6 fusion protein 
In order to identify residues within SCAPCTD involved in the SCAP-SREBP1 
interaction a peptide array of SCAPCTD was probed with the SREBP1-His6 fusion 
protein. The peptide array again consisted of a series of 18-mer peptides attached to 
a cellulose membrane, with each peptide overlapping with the next by 5 amino acids. 
Protein-peptide interactions were detected by immunoblot using the anti-His 
antibody. Probing of this peptide array with SREBP1CTD-His6 fusion protein resulted 
in the fusion protein binding to spots 3, 17, 25, 49, and 57-60 (Figure 3.12A). Spot 
59 gave the strongest signal spot in a run of four spots and therefore was chosen for 
further investigation.  
Spot 59 corresponds to the peptide ARLNGSLDFFSLETHTAL. An alanine 
scanning array based on the parent peptide of spot 59 was generated in which each 
amino acid was sequentially and individually substituted for alanine. This array was 
probed with SREBP1CTD-His6 fusion protein and surprisingly there was no fusion 
protein bound to spot 1 of the alanine scan array (Figure 3.12B). Spot1 is based on 
the unmodified parent peptide and is the sequence to which the fusion protein 
originally bound strongly. Thus, similar to the situation for the alanine scan using 
SREBP2CTD-His6 described earlier the alanine scanning array cannot be interpreted 
with confidence.   
Also similar to the scenario seen with SREBP2CTD-His6 fusion protein different batch 
of SREBP1CTD-His6 fusion protein was used for probing the original full array than 
was used to probe the alanine scanning array. To investigate the reproducibility of 
specific binding a new batch of SREBP1CTD-His6 fusion protein was used to probe a 








Figure 3.12.  Peptide array analysis of SCAPCTD. Peptide array of immobilized peptide 
‗spots‘ of overlapping 18-mer peptides each shifted along by five amino acids in the CTD 
sequence of human SCAP were probed with purified SREBP1CTD-His6 fusion protein (A). A 
peptide array based on 18 amino acids of the parent peptide corresponding to spot 3 in which 
each amino acid was sequentially and individually substituted for alanine was probed with 
purified SREBP1CTD-His6 fusion protein (B). A new peptide array of the CTD sequence of 
human SCAP was incubated with a new batch of purified SREBP2CTD-His6 fusion protein 
(C). Spot numbers relate to peptides in the scanned array. Interactions were detected by 
immunoblotting. Positively interacting peptides generate dark spots and non interacting 








sequences which were positive for SREBP1CTD-His6 fusion protein binding in the 
first array were positive in the repeat array also (Figure 3.12C)including the peptide 
sequence which was used for the alanine scanning array and to which the 
SREBP1CTD-His6 fusion protein failed to bind. The reasons for SREBP1CTD-His6 
fusion protein not binding the control peptide in the alanine scanning array are 
unclear.  
The distribution of the SCAPCTD peptide sequences which bound SREBP1CTD-His6 
fusion protein are shown in Figure 13. Within these peptide sequences, only some of 
the residues are conserved among vertebrate SCAP homologs. The conserved 
residues are initial candidate residues for mutating by site directed mutagenesis 
(SDM) and investigating the impact of their absence on SCAPs interaction with 
SREBP1.  Interestingly, there is overlap between the peptide sequences bound by 
SREBP1CTD-His6 and the peptide sequences bound by SREBP2CTD-His6 (Figure 
3.13, blue vs. underlined). The significance of this overlap with respect to the sites at 
which SREBP1 and SREBP2 interact with SCAP remains to be determined and 
requires clarification of the peptide array analysis with SREBP2CTD-His6 fusion 













Figure 3.13. SCAPCTD amino acid sequence. WD40 repeats are highlighted in red boxes. 
Peptides of SCAP bound by preparations of SREBP1CTD-His6 are underlined. Amino acids 
present in peptides bound by preparations of SREBP1CTD-His6 and SREBP2CTD-His6 are in 















The SREBP family of transcription factors are central in regulating the expression of 
genes involved in sterol and fatty acid biosynthesis. The interaction of SCAP with 
the SREBPs is essential for maintaining SREBP protein stability (Rawson et al. 
1999). The interaction of SCAP with the SREBPs is also essential for regulating the 
proteolytic processing of the SREBP precursor proteins which yields the active 
transcription factor domain (Korn et al. 1998). The interaction between the SREBP 
and SCAP has been localised to the respective CTDs of these two proteins (Sakai et 
al. 1997). The CTD of SCAP is a large cytosolic portion of the protein which was 
initially reported to contain five WD40 repeat motifs (Nohturfft et al. 1998). 
Analysis of human SCAPCTD protein sequence using EMBL‘s SMART tool 
indicated the presence of a sixth WD40 motif, designated WD2. The loose nature of 
the WD40 consensus sequence may be a reason for this extra motif not being 
recognised when initial sequence analysis was performed by others.  
The WD40 repeats within SCAPCTD are attributed with mediating SCAPs interaction 
with SREBP. Conservation of these repeats in SCAP protein homologs from other 
vertebrate species was investigated at the protein level to gain insight into identifying 
residues of importance within these WD repeat regions. Multiple sequence alignment 
of SCAP amino acid sequences from a wide variety of vertebrates ranging from 
humans to zebrafish revealed 46% sequence identity within the CTD.  It also showed 
conservation of the presence of all six WD repeats. Within the WD40 repeats only 
there is an average of 70% identity, with the exception of WD2 which had 44%. This 
high level of identity within the WD repeats relative to the rest of the CTD is a 




makes identification of residues critical to the SCAP-SREBP interaction more 
difficult. While analysis of SCAP homologs from invertebrates showed that they 
also contain a number of WD repeats, their overall SCAP protein sequences are quite 
divergent from vertebrate SCAP. Similarly their SREBP homolog with also has a 
sequence highly divergent from vertebrate SREBP. Thus for the purpose of 
identifying residues important for vertebrate SCAP-SREBP interaction, comparison 
with invertebrate SCAP was not deemed appropriate. However, the evolutionary 
conservation of WD repeats is a strong indicator of their importance in mediating the 
interaction with SREBPs, which is the only known function of SCAPCTD. 
Identifying a protein interaction site by peptide array analysis involves one protein 
being immobilised as 18-25mer overlapping peptides and being probed with the 
interacting protein in its native state. Although the protein on the array is not in its 
natively folded state, this approach has been successfully used in many other cases to 
identify key interacting sites. SCAP CTD is a WD domain protein but its crystal 
structure is not known. Other WD domain proteins that have crystal structures 
available appear to form a consensus β-propeller structure. Attempts to generate a 
predicted 3D structure of SCAP CTD by homology modelling based on other WD 
domain proteins proved unsuccessful. This is likely limited by the WD domain 
proteins with crystal structures solved as they contain seven or eight WD repeats, 
and no protein structures with six WD repeats are available.  
The above bioinformatic analysis was performed to compliment experimental 
determination of the binding site for each SREBP1 and SREBP2 on SCAP by 




Determining the site on SCAP which interacts with SREBP1 and SREBP2 by 
peptide array analysis required cloning, over-expression and purification of human 
SREBP1 and SREBP2 CTDs fused to an epitope tag to facilitate purification by 
affinity chromatography. However, several issues were encountered in attempts to 
purify this protein. Firstly, GST-SREBPCTD was found to be insoluble by 
conventional bacterial cell lysis using a combination of lysozyme and sonication. 
The fusion protein aggregated in insoluble IBs. IBs are a common occurrence when 
forcing exogenous protein over-expression but are believed to contain correctly 
folded proteins (Frangioni & Neel 1993). Attempts to solubilise these IBs with 
detergents under conditions that would facilitate purification of the GST-SREBPCTD 
fusion proteins were somewhat successful but were not pursued as the downstream 
removal of the detergents combined with the low yield of protein was considered 
problematic. Thus an alternate approach to clone and over-express SREBPCTD fused 
to a carboxy terminalHis6 tag was pursued.  
SREBPCTD-His6 fusion proteins were expressed at much lower concentrations than 
the GST-SREBPCTD fusion proteins. The reason for this difference is unclear but is 
likely to be due to the context of translation in GST being higher than the context for 
translation in SREBPCTD. Fortuitously, the lower expression of SREBPCTD-His6 
resulted in a higher yield of soluble fusion protein. Attempts to purify the 
SREBPCTD-His6 fusion proteins resulted in only a small fraction of the fusion protein 
binding the nickel affinity column and the rest remained in the flow through fraction. 
Re-purification of the flow through fraction did not result in any further SREBPCTD-
His6 fusion protein binding. A likely explanation for this occurring is that there are 
two conformations of fusion protein present in the soluble fraction; one with His6 tag 




conformation which has the tag occluded. We chose to proceed with the fraction that 
was binding the resin, as detection with the His antibody at the peptide array stage 
would only be possible for this fraction. 
Analysis of the fractions containing purified SREBPCTD-His6 by coomassie staining 
indicated there was substantial contaminating protein present. Increasing the amount 
and stringencies of the wash steps prior to elution did not remove this contamination.  
Gel filtration FPLC of the eluted fractions did reduce contaminating protein present 
with the SREBPCTD-His6 fusion protein, but also resulted in lowering the fusion 
protein concentration to less than 0.1µg/ml. This is 100-fold less than the minimum 
concentration of fusion protein required for probing the peptide array. However, the 
anti-His antibody used was highly sensitive and gave a strong clean signal for the 
SREBPCTD-His6 fusion proteins in the pre FPLC crudely purified fractions. Therefore 
the crudely purified fusion protein was used for peptide array experiments.   
A peptide array of SCAPCTD probed with SREBP2CTD-His6 identified one peptide 
region of interest with respect to SREBP2 binding. However SREBP2CTD-His6 failed 
to bind the positive control peptide of an alanine scanning array of this peptide. The 
batch of SREBP2CTD-His6 used to probe the alanine scanning array was different to 
that used in the initial array, and it was suspected that the issues surrounding fusion 
protein purification were causing the differences between the two results. However, 
not only did a new batch of SREBP2CTD-His6 fusion protein fail to bind the initially 
identified peptides but bound to new peptides not recognised by the original batch. 
This variability between batches of purified SREBP2CTD-His6 offers an explanation 




unclear. This issue requires clarification before results from the SCAPCTD peptide 
array probed with SREBP2CTD-His6 can be interpreted correctly.  
A peptide array of SCAPCTD probed with SREBP1CTD-His6 indicated multiple 
peptide spots of interest. The strongest spot in a run of four spots in a row was 
deemed the strongest candidate to follow up first. However similar to what occurred 
with SREBP2CTD-His6, SREBP1CTD-His6 failed to bind the positive control peptide 
of an alanine scanning array of this peptide. The batch of SREBP1CTD-His6 used to 
probe the alanine scanning array was also different to that used in the initial array. 
However, unlike what occurred with SREBP2CTD-His6, probing of the repeat 
SCAPCTD array with the new batch of SREBP1CTD-His6 fusion protein confirmed the 
original peptides of interest. Thus in this instance, the reason for SREBP1CTD-His6 
not binding alanine scanning array is not likely due to differences between the 
batches of purified fusion protein and remains unclear. 
In the absence of a crystal structure to narrow the amino acids of interest down, all of 
the residues in the SCAPCTD peptides detected as binding SREBP1CTD-His6 require 
follow up with SDM and co-immunoprecipitation and/or SREBP bioassay screening 
experiments before any inferences on residues mediating the binding of SCAP to 
SREBP1can be made. However, the residues which are conserved among vertebrate 
SCAP homologs are ideal candidates to investigate first. 
Interestingly, there are several motifs present within the SCAPCTD peptides detected 
as binding SREBP1CTD-His6 when analysed using ‗Motif Scan‘, which is available 
on the ExPASy bioinformatics resource portal. The ‗PGRR‘ motif in the first peptide 
was identified as candidate amidation site. The ‗RRDS‘, ‗GVGSGL‘ and ‗SGLE‘ 




protein kinase phosphorylation, N-myristoylation and casein kinase II 
phosphorylation, respectively. The third peptide ‗PLRHRPRGPPPP‘, together with 
the eight amino acids upstream of this peptide sequence within SCAPCTD 
(PEEPGDSP) was identified as a proline rich region. Finally the ‗GVLCCS‘ motif in 
the fourth peptide was identified as another candidate N-myristoylation site. 
However it is important to note that the match score given for the above post-
translational modification sites (based on their similarity to template motifs in the 
Prosite database) was ‗questionable‘ and would require biological evidence to 
confirm post-translational modification on SCAP within these sites. It would be 
interesting to see if SDM of the residues of these motifs would influence the 
interaction of SCAP with SREBP1. The presence of a proline rich region within the 
SCAPCTD is interesting as other proteins contain domains which are known to bind 
proline rich motifs. Domains which bind proline rich motifs include SH3, WW, 
EVH1, GYF, UEV and profilin domains  (Ball et al. 2005). It would be interesting to 
see if the proline region within SCAP is a binding site for a protein containing one of 
the already characterised proline motif binding domains. SREBPCTD does not appear 
to contain any of the characterised proline motif binding domains when the 
SREBPCTD amino acid sequence was analysed in Motif Scan, although this does not 
rule out SREBPCTD containing a novel proline rich motif binding domain, if this 






































Promoter analysis typically employs a reporter gene fused to a test promoter 
combined with a second reporter fused to a control promoter which is used for 
normalisation purposes. However, this approach is not valid when experimental 
conditions affect the control promoter. We have developed and validated a single 
secreted luciferase reporter assay (SSLR) for promoter analysis that avoids the use of 
a control reporter. The approach uses an early level of expression of a secreted 
luciferase linked to a test promoter as an internal normalisation control for 
subsequent analysis of the same promoter. Comparison of the SSLR assay with the 
dual luciferase reporter (DLR) assay using HMGCR and LDLR promoter constructs, 
which are down regulated by 25-hydroxycholesterol, show that both assays yield 
similar results. Comparison of the response of the HMGCR promoter in SSLR 
transient assays compared very favourably with the response of the same promoter in 
the stable cell line. Overall the SSLR assay proved to be a valid alternative to the 
DLR assay for certain applications and had significant advantages in that only 
measurement of one luciferase is required and monitoring can be continuous as cell 













Gene reporter assays are widely used to study the composition and activity of 
promoters under different experimental conditions. In such assays, the reporter gene 
is placed under the control of a promoter of interest and serves as a quantitative 
readout of promoter activity. These assays have a very high utility and are commonly 
used for mapping promoters and investigating the response of promoters to 
transcription factor activity or upstream signalling pathway activity. Several reporter 
genes encode enzymes whose activity can be readily and easily monitored in a 
quantifiable fashion. Luminescent reporter gene assays utilising luciferases are 
arguably the most prominent for promoter analysis in cell culture models and in 
biomolecular cell screening. The high signal to noise ratio and the wide dynamic 
range of luminescent reporter gene assays make them particularly suited for high 
throughput screening applications and the development of modified, or use of novel 
luciferases has greatly extended the utility of these assays (Miraglia et al. 2001), 
(Fan & Wood 2007). The recent development of secreted luciferases (Nakajima et al. 
2004; Verhaegen & Christopoulos 2002) has removed the requirement for cell lysis 
and has extended the utility of these assays even further enabling continuous 
monitoring of promoter activity in a single sample.  
The employment of luminescent reporter gene assays for investigation of promoters 
is typically performed by transient transfection of a promoter-luciferase construct 
into a host cell and measuring luciferase activity in control and test samples under 
different conditions. As transient transfection efficiencies can vary across samples, 
this approach requires an internal transfection control in each sample for 
normalisation purposes. In addition to normalising for transfection efficiencies, the 




in cell plating and cell lysis efficiencies, toxicity and pipetting inconsistencies 
(Schagat et al. 2007).  
A DLR assay system has been developed for the use of promoter-luciferase 
constructs in transient transfections (Dyer et al. 2000) and is widely used. In this 
dual system one luciferase, whose activity can be determined using a specific 
substrate, is used for reporting on the test promoter while a second luciferase, whose 
activity can be determined using a different substrate, and which is linked to a 
constitutively active promoter (such as that of thymidine kinase (TK), 
cytomegalovirus (CMV) or simian virus 40 (SV 40)) functions as the control. This 
DLR assay system typically employs Firefly (P. Pyralis) luciferase as the reporter 
for the promoter being tested and Renilla (R. Reniformis) luciferase as the reporter 
for the control promoter. Firefly and Renilla luciferases both generate light but 
utilise distinct substrates (D-luciferin and coelenterazine, respectively) which 
enables the activity of each enzyme in a single sample to be measured (Dyer et al. 
2000). More recently, a DLR assay has been developed which utilises secreted 
luciferases from Cypridina and Gaussia species (Wu, Suzuki-ogoh, et al. 2007). The 
sensitivity and ease of measurement of this dual secreted luciferase assay is 
comparable to the original DLR assay, but it has advantages in that cell lysis is not 
required and readings can be taken across multiple time points from the same cell 
population. Like the original DLR assay, this method also requires normalisation to a 
control reporter plasmid (Wu, Suzuki-ogoh, et al. 2007). However, the secreted dual 
assay has not been widely adopted largely due to the instability of the Cypridina 
substrate (Wu, Kawasaki, et al. 2007). One concern with the DLR assay system is 
that an assumption is made that the transfection efficiency of the test plasmid is 




the utility of the DLR assay is limited in some situations where the promoter driving 
the control reporter is affected by experimental conditions (Ibrahim et al. 
2000)(Chatterjee et al. 2009). Thus the use of the control reporter in the DLR assay 
system requires preliminary investigation to ensure that the control promoter is not 
affected by the test conditions. If the control promoter is affected by the test 
conditions, this obstacle may be overcome in some cases through the use of 
alternative control promoters, however, in many cases factors that affect one control 
promoter also affect other control promoters (Ho & Strauss III 2004). During the 
course of this thesis it was realised that progesterone negatively affected readout of 
both CMV and TK promoters of the Renilla control reporter plasmid. This meant 
that the DLR assay system was not suitable for investigation of progesterone. This 
prompted the development of a luciferase reporter system that was independent of a 
control reporter and better suited our needs.  
Here we report and validate a single secreted luciferase (SSLR) assay approach for 
promoter analysis that avoids the use of a control reporter. This assay provides a 
valid alternative to the DLR assay particularly for situations where experimental 
factors affect control promoters. In addition, the assay offers a simpler approach than 
the DLR assay and can be used to replace it in appropriate situations.  
The promoters used in the development of the SSLR are regulated by the 
transcription factor (TF) SREBP2. SREBPs are synthesised as inactive precursor 
proteins and SREBP target gene expression is induced upon proteolytic processing 
and release of the TF domain. A HeLa stable cell line was also generated which 
contained the secreted luciferase reporter used in the development of the SSLR to 





Development and Validation of SSLR Assay 
We have employed a secreted luciferase from Gaussia (GLuc) species for use in this 
assay system. The advantage of a secreted luciferase is that lysing of cells is not 
necessary and production of the luciferase from the cells can be monitored 
continuously. In addition, GLuc is stable and easy to assay and like Renilla 
luciferase oxidises coelenterazine (Wurdinger et al. 2008). The basis of the approach 
reported here is that an early level of expression of luciferase from a promoter-GLuc 
reporter plasmid can be used as an internal normalisation control for experimental 
variables that occur in analysis of the promoter using the same plasmid.  
To validate and demonstrate the use of the SSLR assay we applied it to the sterol 
response element binding protein (SREBP) pathway. Briefly, SREBPs are a family 
of transcription factors that regulate expression of genes involved in lipid and 
cholesterol synthesis, including HMGCR (3-hydroxy-3-methylglutaryl-Coenzyme A 
reductase receptor) and LDLR (low density lipoprotein receptor) (Horton et al. 
2002a). These SREBP proteins are synthesised as endoplasmic reticulum (ER)-
membrane bound inactive transcription factors and following release from the ER, 
they undergo proteolytic processing in the Golgi to yield a large N-terminal product 
which serves as an active transcription factor (nSREBP) (Goldstein and Brown, 
1999). nSREBP activates target gene expression through binding to sterol response 
elements (SREs) within a large number of target promoters including the HMGCR 
and the LDLR promoter. 25-hydroxycholesterol (25-OHC) is a potent inhibitor of 
SREBP activation and functions by preventing SREBP release from the ER. It is 
well established that incubation of cells with this oxysterol results in a decrease in 




HMGCR and LDLR promoter reporter plasmids were constructed by inserting the 
core promoter region of either the HMGCR (-270 to +77) gene or the LDLR gene (-
590 to +93) directly upstream of the GLuc in the plasmid pGLuc-basic and were 







Figure 4.1. Sterol regulatory elements (SRE) within the human LDLR and HMGCR 
promoters cloned into pGL3-basic and pGLuc-basic luciferase reporter plasmids.  
 
To simulate a large difference in transfection efficiency, HeLa cells were transfected 
with two different amounts (250ng or 500ng) of pGLuc-promHMGCR or pGLuc-
promLDLR plasmid DNA. Fresh media was added to the cells following removal of 
the transfection agent and secreted luciferase activity was measured at hourly 
intervals over a 15 hr period (Fig. 4.2A and 4.2C). As expected, the level of 
luciferase secreted was greater in the cells transfected with 500ng vs. 250ng of the 
construct. The fold difference in secreted luciferase activity was calculated across all 
of the time points for the 500ng vs. 250ng of plasmid transfected (data not shown). A 
pGL3-/pGLuc-promLDLR: 
SRE-1 Sp1    FF/GLuc 5’ 3’ Sp1 
pGL3-/GLuc-promHMGCR: 




two-fold difference was expected for a scenario whereby transfection efficiencies 
were identical and experimental variables were absent. The fold differences observed 
varied substantially from two fold and ranged from 2.76 to 3.60 for pGluc-
promHMGCR and 1.34 to 1.84 for pGluc-promLDLR. The variation observed 
presumably reflects experimental variables including transfection and cell plating 
efficiencies. Normalisation of output to input should correct for the experimental 
variables as long as the output and input are from the same transfected cells. 
Normalisation is possible using secreted luciferase since secreted luciferase from the 
same transfected cells can be measured at an early point (input) and measured again 
at a later point (output). The normalised secreted luciferase activity should be the 
same for a given reporter construct and should be independent of reporter plasmid 
concentration since there should be a direct correlation between input and output. 
Normalisation was examined statistically using two different approaches. In the first 
approach, data from each timepoint for the 250ng and 500ng pGLuc-promHMGCR 
or pGLuc-promLDLR transfections was normalised to the data from each time point 
from one to eight hours and statistical analysis using a mixed-model ANOVA was 
performed. P values for normalisation of the pGLuc-promHMGCR readout using 
time points from 1 to 8 hours were 0.0001, 0.233, 0.01, 0.429, 0.081, 0.052, 0.052, 
and 0.796 respectively while P values for normalisation of the pGLuc-promLDLR 
readout using time points from 1 to 8 hours were 0.961, 0.116, 0.070, 0.116, 0.175, 
0.717, 0.781 and 0.359 respectively. Thus significant differences were only observed 
using 1 or 3hr time points for normalisation. Normalisation of the pGLuc-
promHMGCR data using the 5, 6 and 7hr time points were close to being 
significantly different (P= 0.081, 0.052 and 0.052 respectively). However, close 




point for the 250ng pGLuc-promHMGCR transfection is contributing substantially 
to this.  In the second normalisation approach the 15 hour time point was normalised 
to each time point from 1 to 8 hours and statistical analysis was performed using the 
Student t test. P values for normalisation of the data using time points from 1 to 8 
hours were 0.04, 0.385, 0.003, 0.955, 0.367, 0.332, 0.593 and 0.491 respectively for 
pGLuc-promHMGCR and 0.956, 0.099, 0.067, 0.163, 0.260 and 0.671, 0.764 and 
0.399 respectively for pGLuc-promLDLR. Thus, both statistical approaches are in 
agreement with statistically significant differences only observed using 1 hour and 3 
hour points for normalisation for the pGLuc-promHMGCR data across all the data 
sets. We assume that the differences observed using early time points for 
normalisation reflect a) variation in cell recovery time following removal of the 
transfection agent and b) variation in time required to achieve full establishment of 
expression of luciferase post transfection.  Informed by this analysis, we chose the 
six hour time point for normalisation in further experiments as we deemed three 
additional recovery hours after the latest point where statistical differences were 
observed (3 hours) a sufficient margin to ensure for full recovery post transfection 
and achievement of steady state expression in the protocol outlined here. Plotting of 
the data normalised to the 6hr timepoint shows that the approach did indeed correct 
for transfection efficiencies and experimental variables as little appreciable 
difference was observed between the 500ng and 250ng samples at each timepoint 
(Fig. 4.2B, 4.2D) and fold variation only ranged from 0.85 to 1 for pGLuc-
promHMGCR and 0.92 to 1.09 for pGLuc-promLDLR. In the DLR assay, data 
points are typically generated for a single time point and compared using the 
Student‘s t test. In essence, comparison of the final 15hr time point normalised to the 







Figure 4.2. Normalising secreted GLuc data to an initial secretion time point corrects for 
differences in plasmid transfection efficiencies. HeLa cells were transfected for 6- 9 hours 
with 250ng or 500ng of luciferase reporter construct. Following removal of the transfection 
agent, secreted luciferase activity was measured at hourly intervals. A) Luciferase activity 
after transfection with 250 ng or 500 ng pGluc-promHMGCR, B) pGluc-promHMGCR  
luciferase activtity normalised to the 6 hour time point, C) Luciferase activity after 
transfection with 250 ng or 500 ng pGluc-promLDLR, D) pGluc-promLDLR  luciferase 
activtity normalised to the 6 hour time point. The values shown represent the average from 








As outlined above no significant difference was observed between the HMGCR 
samples (P=0.332) or between the LDLR samples (P=0.671) normalised in this 
manner. These data show that normalisation using this SSLR assay approach 
essentially corrects for experimental variables and this method should be a viable 
alternative for the DLR assay.  
As 25-OHC is a potent inhibitor of SREBP activation and down regulates both the 
HMGCR and LDLR promoters we compared the results of the effect of 25-OHC on 
the activity of these two promoters using the SSLR and the DLR assay. The 
concentration of 25-OHC chosen was checked to determine if it had any inhibitory 
or stimulatory effect on HeLa cell proliferation using a MTT assay. No significant 
change in cell proliferation was observed with the addition of the 25-OHC to the 
media over the treatment period (data not shown). For the DLR assay, the core 
promoter regions of HMGCR and LDLR in pGLuc-promHMGCR and pGLuc-
promLDLR were cloned directly upstream of Firefly luciferase in the plasmid pGL3-
basic, and designated pGL3-promHMGCR and pGL3-promLDLR, respectively. 
HeLa cells were transfected with a) pGLuc-promHMGCR or pGLuc-promLDLR, or 
b) pGL3-promHMGCR or pGL3-promLDLR with a reporter control plasmid (pRL-
TK) comprising the Renilla luciferase fused to the TK promoter. Fresh media was 
added following removal of the transfection mixture and cells were allowed to 
recover for 6 hours, at which point a small aliquot of media was removed from the 
SSLR samples for normalisation purposes and 25-OHC was added at a final 
concentration of 1.25 µM. After a 16 hour incubation period in the presence of the 
oxysterol, samples were collected and analysed (Fig. 4.3A). Analysis of the raw data 
showed that the 25-OHC down regulated luciferase readout from all the constructs. 




promHMGCR and a 2.92 fold decrease in pGL3-promHMGCR (Fig. 4.2A and Table 
4.1). Normalisation of the data showed that both assays had generated similar results 
with a 2.03 fold and a 2.8 fold decrease recorded using the SSLR and DLR assays 
respectively (Fig. 4.3B and Table 4.1). For the LDLR promoter without 
normalisation, 25-OHC treatment registered a 3.71 fold decrease in pGLuc-
promLDLR and a 1.87 fold decrease in pGL3-promLDLR, while normalisation of 
the data showed a 4.28 fold and 1.95 fold decrease using the SSLR and DLR assays 
respectively (Table 4.1). For comparison purposes, we removed the experimental 
variables associated with the transfection by generating stable HeLa cell lines (A6, 
B2 and B3) using the pGLuc-promHMGCR construct. Treatment of the A6, B2 and 
B3 stable cell lines with 25-OHC in a similar manner to the transfected cells resulted 
in a 2.23, 2.81 and 2.20 fold decrease in HMGCR promoter activity respectively. 
The decrease recorded was similar to that observed in the transfected HeLa cells 
using the SSLR assay and the DLR assay. 
 
 








Figure 4.3. Comparison of the SSLR Assay and DLR Assay. HeLa cells, transfected with 
pGLuc-promHMGCR, pGLuc-promLDLR, pGL3-promHMGCR/ pRL-TK or pGL3-
promLDLR/ pRL-TK or stable pGLuc-promHMGCR Hela cell lines were incubated in the 
absence or presence of 25-OHC. For SSLR assay samples, luciferase activity was measured 
6 hours after transfection agent removal prior to 25-OHC treatment and after 16 hours 
incubation with 25-OHC. (A)  HMGCR and LDLR promoter activity ±25-OHC, not 
normalised. (B) HMGCR and LDLR promoter activity ± 25-OHC, normalised to secreted 
luciferase at 6hours for the SSLR Assay and normalised to Renilla for the DLR Assay The 
values shown represent the average from three independent transfection experiments 
(±S.D.). (C) HMGCR promoter activity ± 25-OHC in the stable pGLuc-promHMGCR Hela 





Table 4.1: Comparison of the levels of repression of the HMGCR promoter and the 
LDLR promoter by 25-OHC in HeLa cells as measured by the SSLR and the DLR 
assay.  
 
 Fold repression of 
HMGCR promoter by 
25-hydroxycholesterol*  
 
Fold repression of 
LDLR promoter by 25-
hydroxycholesterol*  
 
SSLR assay  
- not normalised 
3.83 (± 0.356) 3.71 (± 0.122) 
SSLR assay  
- normalised 
2.03 (± 0.536) 4.28 (± 0.657) 
DLR assay  
- not normalised   
2.92 (± 0.428) 1.87 (± 0.141) 
DLR assay  
- normalised 





(A6, B2, B3) 
(A6) 2.23 (± 0.266) 
(B2) 2.81 (± 0.523) 
(B3) 2.20 (± 0.186) 
 
 
The values shown represent the average from three independent transfection 
experiments. 




Generation of HeLa-PHGL Stable Cell Line 
In order to conveniently and routinely monitor SREBP activity in response to 
various treatments or culture conditions, a HeLa cell line was generated which stably 
expresses the pGLuc-promHMGCR secreted luciferase reporter plasmid. Activation 
of SREBP target genes, including HMGCR, serves as an accurate readout for 
SREBP processing. Briefly, HeLa cells were transfected at 80-90% confluency with 
pGLuc-promHMGCR using TurboFect transfection reagent (as described under 
methods). Following six hour incubation, the transfection mixture was removed and 
replaced with FS media. Cells were cultured for a further 48 hours, at which point 
they were trypsinized and re-seeded in selection media (FS media containing 400 
µg/ml G-418). The selection media was replenished every 3-4 days to identify 
individual clones expressing the luciferase reporter construct, which were then 
isolated using cloning discs. Eight single stable integrants were grown up and 
assayed for SREBP feedback response in the presence of 25-OHC under LDS 
conditions (Figure 4.4A). The three best responding colonies; A6, B2 and B3, were 
grown up and again assayed assayed for SREBP feedback response in the presence 
of 25-OHC under LDS conditions (Figure 4.4B). Colony B2 displayed the maximum 
fold repression of the HMGCR reporter plasmid (4.03-fold, p=0.0189) and thus was 











Figure 4.4. Assessment of HeLa pGLuc-promHMGCR stable cell lines for secreted 
luciferase activity and cholesterol feedback response. (A) Eight HeLa cell lines selected for 
stable pGLuc-promHMGCR integration were grown to 80% confluency and assayed for 
SREBP feedback response in the presence of  1µg/ml 25-OHC in LDS conditions. (B) The 
three best responding colonies (A6, B2, B3) were sub-cultured, grown to 80% confluency 
and  assayed for SREBP feedback response in the presence of 25-OHC in LDS conditions. 
Experiments were performed in triplicate and error bars represent ± SD. Significance of 














These results show that the SSLR assay is a valid substitute for the DLR assay and 
offers an alternative approach to overcome circumstances where the control reporter 
is affected in the DLR assay. In addition, we find this assay to have a number of 
advantages over the widely used DLR assay. Firstly, the assay has a lower number of 
experimental variables as a co-transfection of a control reporter plasmid is not 
required. Secondly, unlike the DLR assay, normalisation does not assume correlation 
of transfection efficiency between the test and control reporters. Finally, the DLR 
assay requires two different substrates whereas the SSLR assay system only requires 
a single substrate and consequently requires less time and is more cost-effective. In 
addition, it has been reported that GLuc works efficiently in simple buffers 
(Verhaegen & Christopoulos 2002), and worked well in phosphate buffered saline 
(PBS) in our hands.  The secreted aspect of the luciferase provides an additional 
significant advantage over the standard DLR as measurements can be made 
continuously from a single transfection and cell lysis is not required. The results 
suggest that the SSLR assay has a similar accuracy level to the DLR assay since the 
down regulation of the HMGCR promoter by 25-OHC recorded using the SSLR and 
DLR assays were in the same range as the down regulation observed in the cell lines. 
The robust nature of the GLuc, the simplicity of the SSLR assay and the lack of a 
requirement for cell lysis makes the SSLR an attractive platform for promoter 
analysis particularly in the area of analysing of the effect of small molecules on 
promoter activity in transient assay systems.  
This SSLR assay and the HeLa-PHGL stable cell line proved to be valuable tools in 
monitoring SREBP processing and were subsequently used throughout the course of 

































Investigation of the Regulation of SREBP 






















The activity of the sterol response element binding protein (SREBP) family of 
transcription factors is regulated by a proteolytic processing event which requires 
translocation of inactive SREBP precursor proteins from the endoplasmic reticulum 
(ER) to the Golgi. The SREBP cleavage activating protein (SCAP) is essential for 
regulating this translocation in response to cellular sterol levels. A direct interaction 
between SCAP and progesterone receptor membrane component 1 (PGRMC1) was 
recently identified. In this chapter, PGRMC1 was investigated with respect to 
regulation of SREBP processing. The results indicate that over-expression of 
PGRMC1 does not affect SREBP processing, as measured by SREBP/HMGCR 
luciferase reporter readout. Co-expression of SCAP with PGRMC1 caused a minor, 
yet significant, increase in SREBP processing under lipid depleted conditions only. 
PGRMC1 is a putative progesterone (P4) binding protein. The presence of P4 did not 
change the lack of effect of PGRMC1 on regulating SREBP processing. 
Interestingly, P4 decreased cell viability under FS conditions but not under LDS 
conditions. Over-expression of PGRMC1 was found to abolish the protective effect 
against P4 observed in LDS and decreased cell viability. Over-expression of SCAP 
was found to have the same effect, but to a lesser extent. While PGRMC1 appears to 
not regulate SREBP processing, the significance of PGRMC1 interacting with SCAP 
is unclear, but may be linked to mediating the cytotoxic effects of P4 in lipid 







Introduction             
The human progesterone receptor membrane component-1 (PGRMC1) gene maps to 
chromosome Xq22-24 (Mansouri et al. 2008). This gene encodes a protein 
comprising an amino-terminal membrane spanning domain which anchors a larger 
cytoplasmic domain (Mifsud & Bateman 2002). Literature surrounding PGRMC1 is 
documented under a number of names owing to its discovery in distinct scientific 
areas. The history surrounding this and distant PGRMC1 homologs is found in a 
comprehensive review by Cahill (Cahill 2007). Expression of human PGRMC1 was 
first reported in 2002, although this was not the original work on this protein. 
Vertebrate non-genomic progesterone receptors were identified in 1996 and this was 
closely followed by cloning of the human gene in 1998 under the name heme 
progesterone receptor 6.6 (Hpr 6.6).   
The PGRMC1 protein is localised to the ER membrane, however evidence also 
exists for its translocation to both the plasma membrane surface and the nucleus, 
although regulation surrounding such translocation is unclear (Nölte et al. 2000; 
Peluso et al. 2010; Peluso et al. 2005). Homology sequence analysis revealed that the 
cytosolic domain of PGRMC1 is highly similar to the heme-binding domain of 
Cytochrome b5 (Song et al. 2004). PGRMC1 is broadly expressed and has elevated 
levels in the liver and adrenal glands, which are sites of high P450 activity (Meyer et 
al. 1996; Raza et al. 2001). Subsequently, evidence emerged that PGRMC1 was in 
fact a heme-binding protein, and elicits similar effects to Cytochrome b5 in 
regulating the activity of Cytochrome P450 proteins (Min et al. 2005). Cytochrome 
P450 proteins are a large family of proteins that are involved in the oxidation of a 
wide variety of substrates. P450 proteins have a variety of roles within the cell, 




acid synthesis (Bistolas et al. 2005). PGRMC1 is reported to interact with multiple 
P450 enzymes in humans, one of which is CYP51A (Hughes et al. 2007). CYP51A 
is also known as lanosterol 14-α demethylase, which is the only P450 enzyme 
involved in cholesterol biosynthesis, and regulates the conversion of lanosterol to 
4,4-dimethyl-5α-cholest-8,14,24-triene-3β-ol, which is an essential step in the 
cholesterol biosynthetic/mevalonate pathway (Strömstedt et al. 1996). PGRMC1 
binding to Cyp51A has a similar effect to that of Cytochrome b5, and it acts as the 
electron donor to facilitate P450 oxidation of substrates.  Loss of PGRMC1 has also 
been shown to reduce the activity of CYP51A and negatively impact on cholesterol 
biosynthesis (Hughes et al. 2007). PGRMC1 also has been shown to alter proteins 
involved in cell proliferation and cell survival (Peluso, Liu, et al. 2008; Peluso 2011; 
Ahmed et al. 2010). PGRMC1 has also been shown to be up-regulated in a variety of 
cancers (Craven 2008; Mir et al. 2012; Difilippantonio et al. 2003; Nie et al. 2006).  
In addition to its regulatory effect on CYP51A activity, PGRMC1 also has other 
links to the cholesterol biosynthesis pathway. CYP51A is an SREBP regulated gene 
whose expression is induced under sterol limited conditions (Rozman et al. 1996). 
SREBP regulation of PGRMC1 expression has not yet been conclusively shown, 
although the promoter region does contain an SRE-element (Lösel et al. 2008). The 
yeast homolog of PGRMC1 (Dap1), however, is under regulation by SREBP 
homolog (SRE-1) (Hughes et al. 2007). Further to this, PGRMC1 was recently 
identified as interacting directly with both SCAP and INSIG1 (Suchanek et al. 
2005). A novel method for photo-cross-linking proteins in living cells to identify 
protein-protein interactions was used to investigate if PGRMC1 interacted with 
members of the INSIG1-SCAP-SREBP complex, as all of these proteins reside in the 




INSIG1 and between PGRMC1 and SCAP was identified, while an unrelated ER 
membrane protein failed to bind PGRMC1 (Suchanek et al. 2005). Both SCAP and 
INSIG1 are key proteins involved in regulating the localisation, and thus activation, 
of the SREBP family of transcriptions factors in response to cellular fluctuations in 
sterols (Goldstein et al. 2006; Radhakrishnan et al. 2007b). SCAP contains a WD 
domain within its carboxy-terminal regulatory region (Hua et al. 1996). This region 
mediates its binding to SREBP, but no other function/interaction is reported for this 
CTD region of SCAP (Sakai et al. 1997). Other WD domain proteins have been 
shown to have multiple interaction partners (Adams, Ron & P. A. Kiely 2011; Chen 
et al. 2004). Thus identification of PGRMC1 as a SCAP interacting is consistent 
with the presence of WD domains on SCAP. This interaction, together with its 
regulatory effect on CYP51A, suggested a possible role for PGRMC1 in the 
regulation of SREBP processing.  
A role for PGRMC1 in regulating SREBP processing may be linked to progesterone 
(P4). SREBP processing is regulated by end product feedback inhibition. Outside of 
cholesterol, other known regulators include oxysterols (24,25-, 25, 27 and 7beta 
hydroxycholesterol)(Radhakrishnan et al. 2007b). Regulation by these compounds 
has been demonstrated through their binding to either SCAP or INSIG1 
(Radhakrishnan et al. 2007b). P4 is a steroid hormone involved in the regulation of 
the female menstrual cycle, embryogenesis and maintaining pregnancy (Stormshak 
& Bishop 2008). It also has roles in the body outside of reproduction, including a 
positive effect on axonal myelin sheath formation in the brain (Baulieu & 
Schumacher 2000). P4 is synthesised from cholesterol in a 5-step enzymatic process, 
the rate limiting step of which is delivery of cholesterol to the inner mitochondrial 




SREBP regulated gene (Christenson et al. 1998; Shea-eaton et al. 2014). Given that 
SREBPs are involved in the regulated availability of cholesterol both by de novo 
synthesis and uptake, and in the expression of the rate limiting step of P4 
biosynthesis, it seems possible that P4 levels may elicit a regulatory effect on 
SREBP cleavage (Horton et al. 2002b; Shea-eaton et al. 2014). This is consistent 
with the current regulatory model of sterol based products‘ feedback inhibition of 
SREBP cleavage (Brown & Goldstein 2009). Also, despite the lack of a link to the 
SREBP pathway, P4 has demonstrated an inhibitory effect on cholesterol 
biosynthesis in a variety of human cell lines, although this regulation was at higher 
P4 concentrations than physiological levels (Metherall et al. 1996).  
Whether or not PGRMC1 binds P4 appears to be a bone of contention in the 
literature. PGRMC1 shares no sequence homology and has a completely different 
protein structure to the classical P4-binding receptor (PR) (Mifsud & Bateman 
2002). There exists evidence both for and against this issue. Most notably, 
recombinant PGRMC1 purified from a bacterial expression system was shown not to 
bind [
3
H]-P4 (Min et al. 2005). It appears that the most accepted view to date is that 
PGRMC1 is part of a multi-protein complex, which requires another protein; 
plasminogen activator inhibitor 1 RNA binding protein (PAIR-BP), to mediate its P4 
action, but that PGRMC1 itself is not capable of binding P4 (Cahill 2007; Peluso et 
al. 2013).  However, Peluso et al demonstrated in partially purified preparations from 
rat SIGCs that recombinant PGMRC1 bound [
3
H]-P4, although the exact P4-binding 
site has not yet been elucidated, and that this binding enhances PGRMC1 association 
with another protein; PAIR-BP1 (Peluso et al. 2013). Peluso et al. acknowledge the 
requirement of PAIR-BP to mediate P4 actions in SICGs, but maintain the direct 




BP does not limit the ability of PGRMC1 to bind P4 (Peluso et al. 2013). This group 
also suggest P4-mediated regulation of gene expression. This is evidenced by their 
detection of PGRMC1 dimers exclusively in the nucleus, and they have 
demonstrated that P4 decreases Tcf/Lef transcription factor activity in a PGRMC1 
dependent manner (Peluso et al. 2010; Peluso et al. 2012). PGRMC1 is also up-
regulated in a number of cancer cell lines and in tumours (Craven 2008; Mir et al. 
2012; Difilippantonio et al. 2003). PGRMC1 was also reported to be one of six 
genes consistently up-regulated in response to carcinogens in rats (Nie et al. 2006). 
PGRMC1-depleted tumours are reportedly more sensitive to DNA damage (Crudden 
et al. 2006). PGRMC1 has also been shown to be essential for mediating the anti-
apoptotic action of P4 in spontaneously immortalised granulosa cells (SIGCs), which 
lack classic nuclear P4 receptors (Peluso, Romak, et al. 2008).  
Activation of the SREBPs is primarily regulated by end product feedback inhibition 
(Goldstein et al. 2006). The evidence that exists for the idea that PGRMC1 binds P4, 
together with this receptor being ER membrane localised and its association with 
cholesterol biosynthesis supports the merit of further investigation of the SREBP-
regulatory potential of PGRMC1. While P4 has previously been characterised as not 
regulating SREBP cleavage levels, it has some links to the cholesterol 
biosynthesis/SREBP pathways (Wang et al. 1994). Our hypothesis is based on its 
regulatory capacity potentially being dependant on PGRMC1 availability.  
For the purpose of the experiments reported here, a luciferase-based gene reporter 
system responsive to SREBP activation was used. By cloning the promoter region of 
an SREBP target gene upstream of a gene encoding a luciferase enzyme, this serves 




SREBP target gene promoter; HMGCR, was utilised for this gene reporter assay. 
Initial experiments indicated that the commonly used dual luciferase reporter assay 
system (DLR) was not suitable for our investigation. This assay system requires co-
transfection of a constitutively active control luciferase reporter plasmid along with 
the test reporter plasmid for internal normalisation purposes (Sherf et al. 1996). 
Expression of this control reporter plasmid is regulated by a constitutive TK, CMV 
or SV-40 promoter. The results indicate that progesterone (P4) down regulated 
expression of luciferase from TK and CMV Renilla reporters which is problematic 
for analysis. Regulation of control luciferase reporter plasmids by compounds and 
cDNAs has been reported previously (Ho & Strauss III 2004; Ibrahim et al. 2000). 
Normalisation in this case would mask test reporter results and thus is not suitable. 
This prompted us to develop the novel luciferase-based SSLR assay (Chapter 4).  In 
the process of developing this assay, a HeLa cell line stably expressing the secreted 
Gaussia luciferase driven by the HMGCR promoter was also generated and 
designated HeLa-PHGL (Chapter 4). This SREBP/HMGCR luciferase reporter 
system is an accurate means of assessing processing of the active nSREBP 
transcription factor domain from the full length precursor protein. SCAP and 
INSIG1 are central proteins involved in the regulation of SREBP processing in 
response to cellular sterol levels (Radhakrishnan et al. 2007b). In this chapter, the 
effect of PGRMC1 binding to SCAP and/or INSIG was investigated with respect to 
regulation of SREBP processing. The requirement of P4 in this potential regulatory 







P4 decreases Renilla luciferase expression from constitutive promoters 
The DLR assay system was initially investigated for use as a gene reporter system to 
measure SREBP activity in response to PGRMC1 over-expression in the absence 
and presence of P4. Transient transfection of luciferase gene reporter plasmids 
requires co-transfection of a constitutively active luciferase control reporter which 
serves as an internal control to which the test reporter is normalised. Based on 
previously published literature, certain compounds and some cDNA over-expression 
clones have been known to affect expression of constitutive control reporter 
plasmids. Therefore, the control reporter assay requires initial characterisation in the 
context of your experimental parameters. HeLa cells were transfected with the 
control reporter, pRL-TK. This construct has   Renilla luciferase under the control of 
the constitutive promoter thymidine kinase (TK). A decrease in control reporter 
readout was observed in response to increasing concentrations of P4 (Figure 5.1A). 
Analysis of cell viability revealed that the decrease in promoter activity was greater 
than the decrease in cell viability induced by P4 (Figure 5.1C). At 100 nM P4, there 
was a 2.48-fold decrease in luciferase reporter readout while there was only 1.13-
fold decrease in cell viability at the same concentration. The same effect in response 
to P4 was observed with another commonly used constitutively active luciferase 
control reporter where is the Renilla luciferase is under the control of the constitutive 
promoter cytomegalovirus (CMV) promoter (Figure 5.1B). At 100 nM P4, there was 
a 1.38-fold decrease in luciferase reporter readout. Thus, the use of control promoter 
proved problematic for P4 treatments and this prompted development of the 
alternative SSLR system, described in Chapter 4. Following development of the 




HeLa cell line (HeLa-PHGL) with a SREBP target promoter (the HMGCR promoter 









Figure 5.1. Analysis of P4 effect on Renilla luciferase control reporter plasmid expression. 
(A and B) HeLa cells were transfected at approximately 80% confluency with the either 
pRL-TK or pRL-CMV Renilla luciferase plasmid. Following a 6 hour transfection period, 
cells were treated with increasing concentrations of P4 in EtOH for 24 hours. Cells were 
then harvested and luciferase analysis performed. (C) HeLa cell viability in response to 
increasing concentrations of P4, as measured by the MTT assay. All experiments were 
performed in triplicate. Error bars represent ±SD. Statistical significance was measured 



















PGRMC1 regulation of SREBP processing 
To investigate if PGRMC1 has an effect on SREBP processing, HeLa-PHGL cells 
were transfected with plasmid DNA over-expressing human PGRMC1. Over-
expression of PGRMC1 failed to change SREBP luciferase reporter readout 
significantly compared to the empty vector control, under FS (p=0.96) or LDS 
(p=0.26) culture conditions (Figure 5.2A; Control vs. PGRMC1). PGRMC1 was 
recently identified as interacting with SCAP. To investigate if SCAP was required 
for a regulatory effect of PGRMC1 on SREBP processing, HeLa-PHGL cells were 
transfected with SCAP in the absence and presence of PGRMC1. Over-expression of 
SCAP alone caused a significant increase in luciferase reporter readout in both FS 
and LDS (p=0.02 and p=4.3E-03, respectively) compared to empty vector control 
(Figure 5.2A; Control vs. SCAP). This is as expected as SCAP is a limiting factor in 
SREBP processing and its over-expression has been shown to increase SREBP 
processing. Co-expression of PGRMC1 with SCAP did not significantly alter this 
SCAP-mediated increase in luciferase reporter readout in FS (p=0.88) (Figure 5.2A; 
SCAP vs. PGRMC1+SCAP). However, co-expression of PGRMC1 with SCAP in 
LDS significantly increased luciferase reporter readout beyond that achieved with 
over-expression of SCAP alone (p=0.03) (Figure 5.2A; SCAP vs. PGRMC1+SCAP). 
Over-expression of PGRMC1 or SCAP, individually or together had no significant 
effect on HeLa-PHGL cell viability compared to cells transfected with empty vector 










Figure 5.2. Effect of PGRMC1 expression on SREBP luciferase reporter activity. (A) HeLa-
PHGL cells were transfected at approximately 80% confluency with the indicated over-
expression plasmids, or empty vector control, under FS culture conditions. Following a six 
hour transfection period, cells media was replaced with either FS or LDS media, as 
indicated. Cells were incubated for a further 24 hours, followed by analysis of luciferase 
levels. (B) HeLa cell viability in response to protein over-expression, as measured by the 
MTT assay. All experiments were performed in triplicate. Error bars represent ±SD. 












PGRMC1 effects on SREBP in the presence of P4 
PGRMC1 is a potential P4 binding protein. To investigate if P4 is required for 
PGRMC1 regulation of SREBP processing, HeLa-PHGL cells transfected with 
PGRMC1 in the absence or presence of SCAP were treated with increasing 
concentrations of P4. Under FS conditions, treatment of cells with 10 nM and 100 
nM concentrations of P4 alone did not result in any significant decrease in SREBP 
luciferase reporter readout (p=0.27 and p=0.06, respectively) (Figure 5.3A; Control). 
Treatment with 500 nM P4 reduced reporter readout 4.1 fold compared to vehicle 
treated control (p=1.23E-04) (Figure 5.3A; Control). However analysis of cell 
viability for the same experiment indicates that this reduction is linked to the 2.6-fold 
decrease in cell viability induced with 500 nM P4 (p=9.85E-06) (Figure 5.3B; 
Control). P4 at 10 nM and 100 nM also significantly affected cell viability (p=0.02 
and p=5.32E-04, respectively) (Figure 5.3B; Control). Over-expression of PGRMC1 
under FS conditions did not significantly alter the luciferase readout or cell viability 
in response to increasing P4 compared to empty vector control, as measured by 
student‘s t-test (p>0.05 for all) (Figure 5.3A and 5.3B, Control vs. PGRMC1). Over-
expression of SCAP increased luciferase reporter readout 1.44-fold in the presence 
of 10 nM (p=0.006) and 1.43-fold in the presence of 100 nM P4 (p=0.003) compared 
to empty vector transfected cells, but failed to impact on the P4-induced decrease in 
cell viability (Figure 5.3A and 5.3B, Control vs. SCAP). Co-expression of PGRMC1 
with SCAP had no significant effect on the SCAP induced increase on luciferase 
reporter readout for 10 nM and 100 nM P4 (p=0.67 and p=0.17, respectively), and 
also did not impact on the P4 induced decrease in cell viability (Figure 5.3A and 





Figure 5.3. Effect of P4 on SREBP luciferase reporter activity in the presence and absence of 
PGRMC1 under FS conditions. (A) HeLa-PHGL cells were transfected at approximately 
80% confluency with the indicated over-expression plasmids, or empty vector control, under 
FS culture conditions. Following a six hour transfection period, media was replaced with FS 
media, containing P4 at the indicated concentrations. Cells were incubated for a further 24 
hours, followed by analysis of luciferase levels. (B) HeLa cell viability in response to 
protein over-expression in the presence of P4, as measured by the MTT assay. All 
experiments were performed in triplicate. Error bars represent ±SD. Statistical significance 


















At 500 nM P4, co-expression of PGRMC1 with SCAP did significantly increase 
luciferase reporter readout 1.16-fold beyond that achieved with SCAP alone 
(p=0.02) (Figure 5.3A; PGRMC1+SCAP vs. SCAP). Cell viability was also 
significantly increased in the presence of 500 nM P4 by co-expression of PGRMC1 
with SCAP (p=0.02) (Figure 5.3B; PGRMC1+SCAP vs. SCAP). Changes in 
luciferase reporter expression levels are linked to changes in cell viability. Whether 
this small increase observed here in SREBP luciferase reporter readout for 500 nM 
P4 with PGRMC1+SCAP is a consequence of an impact on cell viability, or 
specifically linked to SREBP pathway remains to be determined.  
When the same experiment was performed under LDS culture conditions, similar 
results were obtained. Treatment with 10 nM and 100 nM P4 alone did not 
significantly affect luciferase reporter readout (p=0.15 and p=0.61) or cell viability 
(p=0.34 and p=0.16) (Figure 5.4A and 5.4B; control). However, treatment with 500 
nM P4 under LDS conditions only resulted in a 1.17-fold decrease in luciferase 
reporter readout (p=0.18) and a 1.15-fold decrease in cell viability (p=0.007). While 
the decrease in cell viability is statistically significant, it differs from the effects of 
500 nM P4 on cell viability under FS conditions which caused a decrease of 2.56-
fold compared to vehicle treated cells (p=9.85E-06). Over-expression of PGRMC1 
did not significantly alter luciferase reporter readout at 10 nM and 100 nM P4 
(p=0.08 and p=0.17, respectively) (Figure 5.4A; control vs. PGRMC1). Cell viability 
in the presence of 10 nM and 100 nM P4 was also unaffected by over-expression of 
PGRMC1 compared to empty vector transfected cells (p=0.72 and p=0.17, 
respectively) (Figure 5.4B; control vs. PGRMC1). However, over-expression of 
PGRMC1 in the presence of 500 nM P4 caused a 1.76-fold decrease in luciferase 




(p=0.007) compared to the corresponding 500nM P4 control (Figure 5.4A and 5.4B; 
PGRMC1). Thus the presence of PGRMC1 counteracts the anti-cytotoxic effect that 
LDS has on 500 nM P4 and returns it to the cytotoxic effect that 500 nM P4 alone 
has under FS conditions. Under LDS conditions, over-expression of SCAP alone 
causes a 1.48-fold increase in luciferase reporter readout (p=0.004), and this increase 
is not affected by 10 nM or 100 nM P4 (p=0.76 and p=0.43, respectively) (Figure 
5.4A; SCAP). Over-expression of SCAP does not affect cell viability for 10 nM or 
100 nM P4 compared to that seen for empty vector treated cells (p=0.72 and p=0.60, 
respectively) (Figure 5.4B; control vs. SCAP). However, over-expression of SCAP 
alone decreases cell viability 1.31-fold (p=0.03) in the presence of 500 nM P4 under 
LDS conditions (Figure 5.4B; SCAP vs. Control), although this is not to the same 
extent as the 1.66-fold decrease seen with PGRMC1 alone in the presence of 500 nM 
P4 (Figure 5.4B; PGRMC1 vs. Control). Over-expression of SCAP in the presence 
of 500 nM P4 results in a decrease of 1.09-fold in luciferase reporter readout 
compared to empty vector transfected cells (p=0.42) (Figure 5.4A; SCAP vs. 
Control). While the effects on luciferase reporter readout are not statistically 
significant, this data suggests that over-expression of SCAP contributes to the 
cytotoxic effects of 500 nM P4 under LDS conditions, but to a lesser extent than 
PGRMC1.  Co-expression of PGRMC1 with SCAP did not affect the SCAP-
mediated increase in luciferase reporter activity in the presence of 10 nM or 100 nM 
P4 (p=0.45 and p=0.45, respectively) (Figure 5.4A; PGRMC1+SCAP vs. SCAP).  
PGRMC1 with SCAP also had no significant effect on cell viability in the presence 
of 10 nM or 100 nM P4 compared to cells transfected with SCAP alone (p=0.35 and 
p=0.28, respectively) (Figure 5.4B; PGRMC1+SCAP vs. SCAP). In the presence of 




decrease in cell viability compared to cells transfected with empty vector only 
(p=2.41E-05) (Figure 5.4B; PGRMC1+SCAP vs. Control). This is compared to the 
1.66-fold and 1.31-fold decrease seen with PGRMC1 and SCAP alone, respectively. 
The 1.6-fold decrease luciferase reporter readout (p=0.01) for PGRMC1 with SCAP 
in the presence of 500 nM P4 compared to empty vector transfected cells treated 
with 500 nM P4 reflects this decrease in cell viability (Figure 5.4A; 
PGRMC1+SCAP vs. Control). This data would indicate an additive effect of 












Figure 5.4. Effect of P4 on SREBP luciferase reporter activity in the presence and absence of 
PGRMC1 under LDS conditions. (A) HeLa-PHGL cells were transfected at approximately 
80% confluency with the indicated over-expression plasmids, or empty vector control, under 
FS culture conditions. Following a six hour transfection period, media was replaced with 
LDS media, containing P4 at the indicated concentrations. Cells were incubated for a further 
24 hours, followed by analysis of luciferase levels. (B) HeLa cell viability in response to 
protein over-expression in the presence of P4, as measured by the MTT assay. All 
experiments were performed in triplicate. Error bars represent ±SD. Statistical significance 

















PGRMC1 was identified as interacting with the SREBP regulatory proteins SCAP 
and INSIG1 (Suchanek et al. 2005). SCAP is an ER-localised sensor protein for 
cellular sterol levels and in sterol depleted conditions it chaperones the SREBP 
precursor protein to the Golgi for proteolytic processing and release of the active 
SREBP transcription factor domain (Radhakrishnan et al. 2008; Nohturfft et al. 
1999). In sterol rich conditions, SCAP is bound by the ER-retention protein INSIG1, 
and SREBP processing does not occur (L. Sun et al. 2007). The reported interaction 
of PGRMC1 with SCAP and INSIG1 suggests that it may have a functional role in 
the regulation of SREBP processing.  
The HeLa-PHGL cell line was used for the purpose of investigating the effect of 
PGRMC1 on SREBP processing. If PGRMC1 were exerting either a positive or 
negative effect on SREBP processing, this would be reflected by an increase or 
decrease on the SREBP/HMGCR luciferase reporter readout respectively. Thus, 
PGRMC1 over-expression was performed in both FS and LDS conditions, to 
simulate low and high levels of both SCAP and INSIG1. The results indicate that 
over-expression of PGRMC1 alone does not significantly affect SREBP processing 
in FS or LDS conditions. SCAP is a limiting factor in SREBP processing and over-
expression of SCAP increases SREBP/HMGCR luciferase reporter readout. 
PGRMC1 failed to impact on the increase in SREBP processing achieved when 
SCAP is over-expressed in HeLa-PHGL cells in FS conditions. However it did 
marginally but significantly increase SREBP processing a further 9% in LDS. These 
results suggest that PGRMC1 may have a role in increasing the regulation of SREBP 




PGRMC1 has been reported to mediate the anti-apoptotic effects of P4 (Peluso, 
Romak, et al. 2008). The effects of P4 on amplifying PGRMC1s effect on SREBP 
processing were investigated to explore if PGRMC1 was involved in mediating 
regulatory effects of P4 on SREBP processing. In FS conditions, the results indicate 
that P4 alone had no effect on SREBP processing, which is consistent with the 
previous report that P4 failed to influence SREBP1 processing. The observed 
decreases in luciferase reporter readout (Figure 5.3A) were due to the effects of P4 
on cell viability and were deemed not to be specific to SREBP processing. Over-
expressed PGRMC1 failed to rescue the decrease in cell viability induced by P4. 
This is surprising since previous studies have shown that PGRMC1 was required to 
mediate the anti-apoptotic effects of P4 in spontaneously immortalised granulose 
cells (SIGCs) (Peluso, Romak, et al. 2008). Co-expression of PGRMC1 with SCAP 
in the presence of 500 nM P4 did display a slight increase in luciferase readout 
compared to the levels achieved with SCAP alone. However, 500nM P4 caused a 
50% reduction in cell viability, thus the significance of an increase in SREBP 
luciferase reporter readout under these conditions is difficult to interpret. Also, both 
of the lower concentrations (10nM and 100nM) of P4 failed to elicit a significant 
increase in reporter readout under the same conditions. Taken together, these results 
indicate that PGRMC1 does not have any significant effect on SREBP processing in 
FS, and that this is not altered by P4.  
However, somewhat different results were obtained when the same set of 
experiments were performed in LDS. The first interesting finding is that under LDS 
conditions, there was no significant decrease in cell viability induced upon 
incubation with low or high concentrations of P4 alone. However, a role for 




cytotoxicity under LDS conditions was ruled out as over-expression of PGRMC1 
decreased the cell viability in the presence of 500 nM P4 back to the levels seen with 
500 nM P4 alone under FS conditions. Again, this is surprising based on reports that 
PGRMC1 mediates the anti-apoptotic action of P4 (Peluso, Romak, et al. 2008). 
Current literature on the roles of PGRMC1 indicates a proliferative effect and also a 
role in cell survival. However, one group did report in 2003 that PGRMC1 sensitised 
MCF-7 breast cancer cells to death following oxidative stress suggesting that there 
may be a link between this finding and the results presented here (Hand & Craven 
2003). A role for SCAP in the protective response to P4-induced cell death under 
LDS conditions was also ruled out as over-expression of SCAP also caused a 
decreased the cell viability in the presence of 500 nM P4, although not to the same 
extent as PGRMC1. Over-expression of PGRMC1 and SCAP together did not 
enhance the decrease in cell viability in the presence of 500nM P4 beyond that 
achieved with PGRMC1 alone. There was no change in the SREBP/HMGCR 
luciferase reporter readout in the presence of 500nM P4 in response to over-
expression of PGRMC1 that was not caused by the decrease in cell viability.  
The aim of the work in this chapter was to investigate a role for PGRMC1 in the 
regulation of SREBP processing based on its reported interaction with the SREBP 
regulatory proteins, SCAP and INSIG1. The results presented here suggest that 
PGRMC1 neither promotes nor inhibits SREBP processing, and that P4 is not a 
limiting factor required for regulation of SREBP processing by PGRMC1. However, 





 An interesting finding was that culturing HeLa-PHGL cells in LDS induced a 
cellular response which resulted in protection from P4-induced cytotoxicity that is 
seemingly absent in FS conditions. Although PGRMC1 has previously been 
implicated in mediating the anti-apoptotic action of P4, the results presented here 
indicate that it may be involved in mediating a cytotoxic or pro-apoptotic action of 
P4. These findings also suggest a novel role for SCAP in mediating an inhibitory or 
cytotoxic action of P4, which is likely independent of its role in regulating SREBP 
processing. The roles of PGRMC1 and SCAP in mediating the inhibitory or 




























Investigating the Functional Differences between 





















INSIG1 has a central role in regulating cellular lipid homeostasis. In the presence of 
excess lipids, INSIG1 functions as an ER-retention protein for the SREBP family of 
transcription factors which prevents their proteolytic processing. INSIG1 also 
facilitates the degradation of HMGCR, the rate limiting enzyme in cholesterol 
biosynthesis. There are two protein isoforms of human INSIG1 produced through the 
use of two in-frame alternative start sites. However, the functional significance of 
having two INSIG1 proteins produced has not been investigated. Bioinformatic 
analysis indicates that the presence of two in-frame start sites within the 5-prime 
region of INSIG1 mRNA is highly conserved among vertebrate species and that 
production of two isoforms of INSIG1is likely a conserved event. Investigation of 
the functional differences between the two INSIG1 isoforms indicated no observed 
difference in a) negative regulation of SREBP processing and c) facilitation of 
HMGCR degradation. While bioinformatic analysis suggests there is likely a 
regulatory mechanism surrounding translation initiation occurring at one start site 













Under high cellular sterol conditions, the SCAP-SREBP complex is retained in the 
ER through SCAP undergoing a conformational change which a) prevents COPII 
vesicle formation and b) facilitates binding of the SCAP ER-retention protein 
INSIG1 (L.-P. Sun et al. 2007). While it has been identified that the transmembrane 
region (TM1-6) of SCAP is sufficient to bind INSIG and that a mutant SCAP Y298C 
fails to bind INSIG (Yang et al. 2002). The region within INSIG which binds to 
SCAP has not yet been identified. INSIG1 has two known functions. In addition to 
binding and retaining the SCAP-SREBP complex in the ER, INSIG1 also mediates 
the degradation of HMGCR which is the rate limiting enzyme in cholesterol 
biosynthesis. In this case, INSIG1 recruits the ER-resident E3 ubiquitin ligase gp78 
to HMGCR and this initiates the proteasomal degradation of HMGCR, although the 
specific involvement of gp78 is not always clear (Che et al. 2012) (Sever et al. 
2003b). It is believed that INSIG1 mediates its different effects on SCAP and 
HMGCR through whether binding affects its association with gp78. Upon binding to 
SCAP, gp78 is displaced from INSIG1 and thus INSIG1 does not promote the 
degradation of SCAP (Lee, Song, et al. 2006). Upon binding to HMGCR, gp78 
remains associated to INSIG1 and thus promotes the degradation of HMGCR (Song 
et al. 2005).  
Two isoforms of INSIG exist in the vertebrate genome; INSIG1 and INSIG2. 
INSIG1 is located at 7q36 and INSIG2 is located at 2q14.1 (Peng et al. 1997) 
(Bressler et al. 2009). These INSIG proteins have six-transmembrane helices with 
short cytosolic extensions at both the amino and carboxy termini (Feramisco et al. 
2004) (Yabe et al. 2002). They share 59% overall sequence identity (Yabe et al. 




inhibition of SREBP processing and facilitating degradation of HMGCR (Yang et al. 
2002)(Yabe et al. 2002)(Sever et al. 2003b). INSIG2 is believed to mediate 
degradation of HMGCR through recruitment of a different E3 ligase, TRC8 (Jo et al. 
2011). Knockout studies of each have shown that in the absence of INSIG1, INSIG2 
compensates, and vice-versa (Engelking et al. 2005). The two INSIG proteins do 
however differ in their modes of regulation. INSIG2 is constitutively expressed and 
is not subject to sterol-regulated degradation (Lee & Ye 2004). Conversely, INSIG1 
expression is induced by the SREBP transcription factors, which themselves are 
activated in response to low sterol availability, and the INSIG protein is then 
stabilised by sterols when the cellular levels are sufficiently high (Horton et al. 2003) 
(Gong, Lee, Lee, et al. 2006b). INSIG essentially functions to negatively regulate 
cholesterol biosynthesis through a) inhibition of cholesterogenic gene expression via 
ER retention of SREBP-SCAP complex and b) via a more immediate inhibition 
through degradation of HMGCR.  
INSIG1 was originally identified as an insulin-induced gene (Mohn et al. 1991). 
However, it was later discovered that induction of INSIG1 by insulin was indirect.  
INSIG1 expression is induced by the SREBP transcription factors as it contains an 
SRE element in its promoter (Horton et al. 2003). It was discovered that insulin 
stimulates transcription of SREBP-1c and this was responsible for the insulin 
associated increase in INSIG1 (Kim et al. 1998). More recently, insulin has also been 
shown to promote SREBP-1c processing through down regulation of INSIG2 
(Yellaturu, Deng, Cagen, et al. 2009). INSIG1 expression is also regulated by 
members of the peroxisome proliferator-activated receptor (PPAR) family (Kast-
woelbern et al. 2004). PPARs are nuclear hormone receptors which have regulatory 




inducing expression of INSIG1, through interplay with SREBP  (Yoshikawa et al. 
2010). The link of INSIG1 with PPARs provides a more direct link between insulin 
signalling and INSIG1.    
INSIG1 is reported to have two proteins produced from the same mRNA through 
translation initiating from two alternative start sites (Yang et al. 2002). Both start 
sites are in-frame and are located 105 nucleotides apart. This gives rise to two 
proteins that are identical over the transmembrane region of INSIG1 but differ in 
their amino terminal cytosolic extensions by a region of thirty-six amino acids (~4 
kDa). The presence of both isoforms has been confirmed by immunoblot analysis 
(Yang et al. 2002).  The majority of experiments carried out in the literature 
involving INSIG1 utilise the over-expressed gene in a plasmid from which two 
proteins isoforms are produced. Both isoforms have been confirmed by protein 
sequencing analysis and correspond to translation initiation occurring at both 
translation start sites. There are few reports in the literature pertaining to endogenous 
INSIG1 protein expression. Only a single INSIG1 isoform is reported in the human 
liver carcinoma cell line HepG2 (Qin et al. 2008).  Mouse is also reported to have a 
single INSIG1 protein expressed with an approximately molecular weight of 28 kDa 
(Engelking et al. 2004). However expression of two endogenous INSIG1 isoforms in 
hamster cells has been reported (Gong, Lee, Lee, et al. 2006b). Expression of two 
INSIG1 isoforms for other vertebrate species, however, has not been reported. 
Invertebrate species lack a cholesterol biosynthetic pathway since they are 
cholesterol auxotrophic, and therefore lack an INSIG1 homolog for comparison 
(Karlson, P 1986). However, there is a homologous sterol biosynthetic pathway in 
yeast which is primarily responsive to changes in oxygen availability (Bien & 




identity to the human protein, but is believed to have the same basic structure of six 
membrane-spanning helices with amino- and carboxy-terminal cytosolic extensions 
(Hughes et al. 2005). Interestingly, there are also two Ins-1 isoforms produced as a 
result of translation initiating from two in frame start sites located within the region 
encoding the amino-terminal cytosolic extension (Burg et al. 2009). The resultant 
proteins again differ in molecular weight by approximately 4 kDa, and are identical 
after this second start site position. For human INSIG1 over-expression constructs, 
the ratio of expression is in favour of the longer isoform of the protein. However, the 
ratios of expression for the endogenous isoforms appear to vary. In fission yeast, 
over-expression of Ins-1 yields two protein isoforms which appear to be expressed 
strongly and at equal levels. Endogenous Ins-1, however, appears to only have a 
single isoform expressed, but it is not clarified which Ins-1 protein isoform this band 
corresponds to (Burg et al. 2009).  
The first aim of this work was to further explore the likelihood of two INSIG1 
protein isoforms being produced in other vertebrate species through bioinformatic 
investigation of conservation of the two start sites. The second aim of the work was 
to investigate whether the alternate translation start points impart any additional 
function to one isoform over the other.  
A major factor influencing translation initiation occurring at a given AUG sequence 
are its surrounding nucleotides which together comprise the Kozak sequence. The 
importance of the flanking nucleotides in AUG recognition was first recognised by 
Marilyn Kozak (Kozak 1987). Subsequently, a Kozak consensus sequence emerged 




Nucleotides at certain positions relative to the AUG start have more influence over 
translation initiation than others. The most important nucleotides are located at 
positions -3 and +1 of the AUG start (Kozak 1999). In constitutive over-expression 
constructs, the cDNA start site is often placed in an optimal Kozak sequence setting. 
However, expression patterns of endogenous INSIG1 protein isoform ratios suggest 
that this may not be the case.  
Table 5.1. Vertebrate Kozak consensus sequences. Purine bases are represented by 
‗r‘, while ‗n‘ represents any of the four nucleotide bases. ‗AUG‘s are taken together 
as being position 0. Residues at positions -3 and +1 have the most influence on 







The aim of the work described here was to further examine the Kozak sequence 
surrounding each AUG start site in the human INSIG1 mRNA sequence. This 
analysis was then extended to INSIG1 transcripts from other vertebrates. 
Conservation of a second in-frame start site within the region encoding the amino-
terminal cytosolic extension of INSIG1 in other species would highlight an 
importance for having two INSIG-1 isoforms produced. As shown in Table 1, 
nucleotides at the -3 and +1 positions relative to the AUG start site influence the 
strength of translation initiation occurring at a particular start site. Thus conservation 




two translational start sites for INSIG1 and possibly lean towards some sort of 
translational regulatory control over INSIG1 isoform expression.  
While the presence of two human INSIG1 isoforms is accepted, there has been no 
investigation into their individual function. Analysis of each INSIG1 isoform 
function is necessary since the first translational start site is placed within an optimal 
Kozak context in over-expression plasmids used in the majority of INSIG1 
functional studies. This results in translation initiation at the first start site being 
favoured over translation initiation from the second start site, resulting in more of the 
full length INSIG1protein being produced than the shorter isoform. Such expression 
ratios may not reflect in vivo INSIG1 isoform expression. In this chapter, each 
isoform of the human INSIG1 protein has been examined to determine if they exhibit 
the same functional characteristics  in response to a) high cellular sterol levels b) 






 Bioinformatic Analysis 
There are two proteins produced from the INSIG1 mRNA through the use of in-
frame alternative translational start sites within the amino terminal region of the 
protein. Multiple sequence alignment of INSIG1 protein sequences from a wide 
variety of vertebrates was performed and the alignment indicates a strong level of 
sequence conservation over the transmembrane region of INSIG1 (data not shown). 
However there is much less sequence identity within the short cytosolic amino 
terminal region of the protein and it is within this region that the two alternative start 
sites are located (Figure 5.5). Interestingly, despite the lack of sequence identity 
among vertebrate INSIG1 within the translation initiation  region, the presence of a 
second starter methionine thirty-five amino acids downstream from the first starter 
methionine, is highly conserved (Figure 5.5). In rodent species, however, a second 
starter methionine thirty-five amino acids is not present downstream from the first 
starter methionine. There is however a conserved second starter methionine present 
but it is located closer at 25 residues downstream from the first methionine (Figure 
5.5). Two human INSIG1 isoforms are expressed from over-expression constructs 
from two start sites within the amino-terminal of the transcript. The conservation of 
two methionines within the amino-terminal region of the protein sequence among 
vertebrates shown here suggests that production of two INSIG1 isoforms may also 
occur in other vertebrate species. Conservation of two in-frame start sites within this 
poorly conserved region of INSIG1 among vertebrates suggests a potential function 







Figure 5.5. Conservation of a second in-frame start site within the region encoding the 
amino-terminal cytosolic extension of vertebrate INSIG1. Human INSIG1 homologs were 
retrieved from the NCBI database using their protein-protein basic local alignment search 
tool (blastp). Sequences were downloaded to and aligned in MEGA alignment explorer, 
which uses the Clustal W multiple alignment programme. Multiple sequence alignment was 
then edited in GeneDoc. Black=100% residue identity, grey=high level of residue identity, 
white= non-identical residues, yellow=methionine start. 
Human      : *PMPRLHDHFWSCSCAHSARRRGPPRASAAGLAAKVGEM-INVSVSGPSLLAAHGAPDADPAPRGRSAA----MSGPEPGSPYPNTWHHRLLQRSLVLFSVGVVLALVLNLLQIQRNVTLFPEEVIATIFSSAWWVPP : 132 
Gorila     : *PMPRLHDHFWSCSCAHSARRRGPPRASAAGLAAKVGEM-INVSMSGPSLLAAHGAPDADPAPRGRSAA----MSGPEPGSPYPNTWHHRLVQRSLVLFSVGVVLALVLNLLQIQRNVTLFPEEVIATIFSSAWWVPP : 132 
Chimpanzee : *PMPRLHDHFWSCSRAHSARRRGPPRASAAGLAAKVGEM-INVSVSGPSLLAAHGAPDADPAPRGRSAA----MSGPEPGSPYPNTWHHRLVQRSLVLFSVGVVLALVLNLLQIQRNVTLFPEEVIATIFSSAWWVPP : 132 
Orangutan  : *PMPRLHDHFWSCSCAHSARRRGPPRASAAGLAAKVGEM-INASVSGPSLLAAHGAPDADPASRGHSAA----MSGPEPGGPYPNTWHHRLVQRSLVLFSVGVVLALVLNLLQIQRNVTLFPEEVIATIFSSAWWVPP : 132 
Baboon     : *PMPRLHDHFWSCSCAHSARRRGPPRASAAGLAAKVGEM-ISASVSGPSLLAAHGAPDADPAPGGRSAA----MSGPEPGGPYPNTWHHRLVQRSLVLFSVGVVLALVLNLLQIQRNVTLFPEEVIATIFSSAWWVPP : 132 
Macaque    : *PMPRLHDHFWSCSCAHSVRRRGPPRASAAGLAAKVGEM-ISASVSGPSLLAAHGAPDADPAPGGRSAA----MSSPEPGGPYPNTWHHRLVQRSLVLFSVGVVLALVLNLLQIQRNVTLFPEEVIATIFSSAWWVPP : 132 
Marmoset   : *PMPRLHDHFWSCSCAHSGRRRGPPRASAAGLAAKVGEM-INASVSGPSLLAARGASDADPAPGGRSAA----MSGPEPGGPHPNTWHHRLVQRSLVLFSVGVVLALVLNLLQIQRNVTLFPEEVIATIFSSAWWVPP : 132 
Gibbon     : *PMPRLHDHFWSCSCAHSARRRGPPASAPRGLAAKVGEM-INASVSGPSLLAAQGAPDADRAPGGRSAA----MSGPEPGGPYPNTWHHRLVQRSLVLFSVGVVLALVLNLLQIQRNVTLFPEEVIATIFSSAWWVPP : 132 
BrownBat   : *LMPRLDDHFWSCSCAQGARHRGRPAARAGGLAAKVGAM-ITSSVAGPSLRAAHSAPHTDPALGPRSPGEG--ARGQGSGSGHATSWHHHLLQRSLVLFSVGVVLALVLNLLQVQRNVTLFPEEVIATIFSSAWWVPP : 134 
Antelope   : WLMPRLDDHLWRGPCAKGTKHRSHPRASARGLVAKAGEM-INSSGSGPSLLAAHGAPGTDPAHGLQRA-----GVGGQGSSGHVNSWHHHLVQRSLVLFSVGVVLALVLNLLQVQRNVTLFPDEVIATIFSSAWWVPP : 132 
Goat       : KLMPRLDDHLWRGPCAKGTKHRSHPRASARGLVAKAGEM-INSSGSGPSLLAAHGAPGTDPTHGLQST-----DVGGQGSSGHVNSWHHHLVQRSLVLFSVGVVLALVLNLLQVQRNVTLFPDEVIATIFSSAWWVPP : 132 
Horse      : *LMPRLDDHFWSCSCAKGRRHRSHQRTGSGGVAAKVGKM-INSSVPGPSLLVAHSAPDTDPSRGPQSTG----VGGRGASSCHTNSWHHHLVQRSLVLFSVGVVLALVLNLLQVQRNVTLFPEEVIATIFSSAWWVPP : 132 
Sheep      : WLMPRLDDHLWRGPCAKGTKHRSHPRASTRGLVAKAGEM-INSSGSGPSLLAAHGAPGTDPAHGLQST-----GVGGQGSSGHVNSWHHHLVQRSLVLFSVGVVLALVLNLLQVQRNVTLFPDEVIATIFSSAWWVPP : 132 
Cow        : WLMPRLDDHLWRGPCAKGTKHRSHPRASARGLVAKAGEM-INSSGSGPSLLAAHGALGTDPAHGPQSA-----GVGGQGSSSHVNSWHHHLVQRSLVLFSVGVVLALVLNLLQVQRNVTLFPDEVIATIFSSAWWVPP : 132 
Dolphin    : WLMPRLDDHPWSGPCAKGAKHRSHLRASARGLEAKVGEM-ITSSVSGPSPLVAHSARGADPAHGPGSA-----AVGGHGSSGHITSWHHHLVQRSLVLFSVGVVLALVLNLLQVQRNVTLFPEEVIATIFSSAWWVPP : 132 
Pig        : WLMPRLDDHLWSCPCVKGTNHRGHPRASARGQEAKVGEM-ISSSVSGPSLLVAHGAQGPDPSHAPQST-----GMGSHGGSGHTNSWHHHLLQRSLVLFSVGVVLALVLNLLQVQRNVTLFPEEVIATIFSSAWWVPP : 132 
Yak        : WLMPRLDDHLWRGPCAKGTKLRSHPRASARGLVAKAGEM-INSSGSGPSLLAAHGALGTDPAHGPQSA-----GVGGQGSSGHVNSWHHHLVQRSLVLFSVGVVLALVLNLLQVQRNVTLFPDEVIATIFSSAWWVPP : 132 
Alpaca     : --MPRLDDHLWSCPCAKGVKHRSHLRAGAGGLETKVGEM-TTSSVSGPSLLVAHGAGGTDPAPGPQSS-----GLG-------GHSWHHHLLQRSLVLFSVGVVLALVLNLLQVQRNVTLFPEEVIATIFSSAWWVPP : 123 
Camel      : --MPRLDDHLWSCPCAKGVKHRSHLRAGAGGLEAKVGEM-TTSSVSGPSLLVAHGAGGTDPAPGPQSS-----GLG-------GHSWHHHLLQRSLVLFSVGVVLALVLNLLQVQRNVTLFPEEVIATIFSSAWWVPP : 123 
KillerWhal : WLMPRLDDHPWSGPCAKGAKHRSHLRASARGLEAKVGEM-ITSAVSGPSPLVAHSARGADPAHGPGSA-----AVGGHGSSGHITSWHHHLVQRSLVLFSVGVVLALVLNLLQVQRNVTLFPEEVIATIFSSAWWVPP : 132 
Elephant   : --MPRLDDHFWSCSCPASERHKKHLRAGAGGLAAKVEAM-LSPSVSSPSLLVDHGAPHSSPSPRRHSASVSG---HHCSSSRHANSWHHHLVQRSLVLFSVGVVLALVLNLLQIQRNVTLFPDEVIATIFSSAWWVPP : 132 
Rhinoceros : *LMPRLDENFWSCSCADRLRHRSHPRAGAGGLAAKVGEM-INSSASGPSRLMAPRALDTDASRGLRSAG----VGGRGGSSGHTNSWHHHLVQRSLVLFSVGVVLALVLNLLQVQRNVTLFPEEVIATIFSSAWWVPP : 132 
Rabbit     : *PMPRLDQHFWNCSCTTRERHKSHLGSSAAGLAAKVGKM-LNSSVTSSSLVLVGHG--------ALNTDVSNRTTGNNSRRIATNSWHHHLVQRSVVLFAVGVFLALVLNLLQIQRNVTLFPEEVIATIFSSAWWVPP : 128 
TasmanianD : *LMPRLDEHFWSCSCTTRGRHKGNLRAGTARLTEKVGDM-LNPSVSGPSLVLVGQGAINTETTD----TNRNTNTKSNNSRAPSNSWHHHLVQRSVVLFAVGVFLALVLNLLQIQRNVTLFPEEVIATIFSSAWWVPP : 132 
Manatee    : --MPRLDDHFCSCSCPASERHRKQLRAGAGGLAAKVEEM-ISPSVSSPSLLVDHSALNTSPSHRRHSSGHSTGVSVHRCNSSHANSWHHHLVQRSLVLFSVGVVLALVLNLLQIQRNVTLFPEEVIATIFSSAWWVPP : 135 
Armadillo  : *HMPRLDSHFWNCSCASRGRNTTHLTAGAGGPAAKVGEM-IGSSAPGPSLLVDHGGLTTDSSRRVGSTGTNG----HSSSSRHTNSWHHHLVQRGLVLFLVGVVLALVLNLLQIQRNVTLFPEEVIATIFSSAWWVPP : 132 
Dog        : *PMPRLDDHCWSCSCAQGARHRGLPVAGAGGLAAKVGDM-LSPAALAARRGPDPAPAHGPRSPGAGG--------ARGAGGGSPGSWHHHLVRRSLVLFSVGVVLALVLNLLQVQRNVTLFPEEVIATIFSSAWWVPP : 128 
Hedgehog   : --MPRLDDHFWSCSSPASERHKTHSRASSGGLAAKAEEM-ISPSVSRPSLPVDPRAPSVSAHSCSSSS-------------SHTNSWHHHLVQRSLVLFSVGVVLALVLNLLQIQRNVTLFPEEVIATIFSSAWWVPP : 122 
PaintedTur : KPMPRLENCTWSCSCAARGRHKNQLGKTAVGLAAKVGEM-LSSSVSSSPLTLVGH-----GTRSTSSLRSSS-------SSTSSLNLNQHLVQRSLVLFAVGAFMALVLNLLQIQRNVTLFPEEVIATIFSSAWWVPP : 125 
ChineseTur : KPMPRLENCSWSCSCTARGRHKNQLGKTAVGLAARVGEM-LSSSVSSSPRTLVGH---------GTRTPSTSILRSNTSSSNSSLNLNQHLVQRSLVLFAVGAFMALVLNLLQIQRNVTLFPEEVIATIFSSAWWVPP : 128 
Walrus     : *PMPRLDDHCWSCSCAQGARHRGLPGAGAGGLAAKVGDM-LSPATLAARRGPDPDSAPARGPRSP-------GAGGRGAGGGPPGSWHHHLVQRSLVLFSVGVVLALVLNLLQVQRNVTLFPEEVIATIFSSAWWVPP : 129 
Pika       : --MPRLHDHLWGCSYPNSARHQSPPRARAAGLAAGTGDM-SSSPGAGPSLLVAHGAPDTDRSAETSDHRGGGH----------PSSWHHHLVQRSVVLFLVGVVLALVLNLLQIQRNVTLFPEEVIATIFSSAWWVPP : 125 
GroundTit  : KPMPRLERCTWSCSCAARGRHRSQLGDTAAGLAAKVGEM-LSSSVSSPSLALVGR---------GARSPSTSSASSTSSSTCSTLNWSQHLVQRSVVLFVVGAFMALVLNLLQIQRNVTLFPDEVISTLFSSAWWVPP : 128 
Parakeet   : --MPRLENGGWSCSCAARGRHRAQPGDTAAGLAAKVGGM-LSSSGSSPSLTPVGT-----GARSP----------STSTSTSSTLNWSQHLVQRSVVLFVVGAFMALVLNLLQIQRNVTLFPDEVISTLFSSAWWVPP : 120 
Mallard    : RPMPRLESCTWSCSCAARGRHKTQQGDTAT----KAGEM-LSSGGPSQVSAG--------------------HGARSPGGAGSTLNWSRHLVQRSVVLFVVGAFMALVLNLLQVQRNVTLFPEEVIATLFSSAWWVPP : 113 
Falcon     : --MPRLENCAWSCSCTARGRHKTQLGDTAAGLAAKVGEM-LSSSVPSPSLALVGH---------GAHSPSTASASSSTTTTSTLN-LSQHLVQRSVVLFVVGAFMALVLNLLQIQRNVTLFPDEVISTLFSSAWWVPP : 125 
Galagos    : --MPRLHDRFWSCPCAHSARRRGRPRAGAAGPAAKVGEM-IDSSVLDPAPPAAHRAQDPGPAHGG------------PAGFGRASSWHHHLVQRSLVLFLVGVVLALVLNLLQIQRNVTLFPEEVIATVFSSAWWVPP : 123 
Flycatcher : KPMPRLESCAWSCSCTARGRHRRQLGDTAAELAAKVGEM-LGSSVSSPSLARAGR---------GARSPSTSSASSTSSSASSTLNWSQHLVQRSVVLFVVGAFMALVLNLLQIQRNVTSFPDEVISTLFSSAWWVPP : 128 
Mouse      : TPMPRLHDHVWNYPSAGAARPYSLPR----------GMIAAAACPQGPGVPEPEHAPRGQRAGTTGC-------------SARPGSWHHDLVQRSLVLFSFGVVLALVLNLLQIQRNVTLFPDEVIATIFSSAWWVPP : 115 
Vole       : PPMPRLHDHVWSCPSAGAARPYSLPR----------GMIAAARCPQGPGGTEP--SPRVQQAGTSGC-------------SARPGSWHHDLVQRSLVLFSFGVVLALVLNLLQIQRNVTLFPDEVIATIFSSAWWVPP : 113 
GoldenHams : HPMPRLHDHVWGCSSSGAARPYSLSR----------GMIAAARCPQGSGAPEPA-APRSQRAGTAGC-------------GARPGSWHHDLVQRSLVLFSFGVVLALVLNLLQIQRNVTLFPDEVIATIFSSAWWVPP : 114 
JaculusRod : --MPRLHDHFWSCPCAGAARHLSPPRARSAPATRVGGMIAATRSVPAPGAPDAEPEPRSPRA-DAG-------------------SWHRHLVQRSLVLFSVGVVLALVLNLLQIQRNVTLFPDEVIATIFSSAWWVPP : 116 
Hamster    : QPMPRLHDHVWSCSGSGAARPHSLPR----------GMIAAARCPQGSGAPEP--APRSPRAGTAGC-------------GARPGSWHHDLVQRSLVLFSFGVVLALVLNLLQIQRNVTLFPDEVIATIFSSAWWVPP : 113 
PythonIsla : CQMPRLEEHCWSCSTSSKTETK-HPSSGANWLASRAEEMMSIITSVLSSAYISLQDVRTA-----------------------------NLIRRGVVLFTVGVFLALVLNLLQIQRNVTLFPEEVMTTLFSSAWWIPP : 108 
ZebraMbuna : CQMPRLEEHCWSCSTSSKTETK-HPSSGANWLASRAEEMMSIITSVLSSAYISLQDVQTA-----------------------------NLIRRGVVLFTVGVFLALVLNLLQIQRNVTLFPEEVMTTLFSSAWWIPP : 108 
Zebrafish  : CQMPRLEEHCWSCSCSTSVKTK-DLSS-AGWIVCKTGEMMSIITSVLSHAYGSLHSLQSA-----------------------------NLIRRGLVLFIVGVVLALVLNLLQIQRNVTLFPEEVLDTLFSSAWWIPL : 107 
TilapiaFis : CQMPRLEEHCWSCSTSSKTETK-HPSSGANWLASRAEEMMSIITSVLSSAYISLHDVRTA-----------------------------NLIRRGVVLFTVGVFLALVLNLLQIQRNVTLFPEEVMTTLFSSAWWIPP : 108 
GuineaPig  : APMPRLHDHFWSCPC--AARRPSPPR----------ARAALTPGMLVTPAPTAAGVPRSDPVPQSPRV----------------SSWHHDLVQRSLVLFSVGVVLALVLNLLQIQRNVTLFPDEVIATIFSSAWWVPP : 110 
NakedMoleR : ALMPRLHDHFWSCPC--AVRRPSPLR----------ASAAPRLGMLAAPAP--SGLRATDSS--------------PAPRGPRASSGHHDLVQRSLVLFSVGVVLALVLNLLQIQRNVTLFPDEVIATIFSSAWWVPP : 110 
AfricanCla : KQMQTLEEHCWSCSCTRGRDKKGTKVS---------AWLARRVGKAMSSLNSLLSLAYSTLASSEGR----------------------SLIQRSLVLFTVGVFLALVLNLLQIQRNVTLFPEEVIATIFSSAWWVPP : 107 
TropicalCl : KQMQTLEEHCWSCSCTRGRDKKGTRLS---------TWLAQRAAKAMSSLNSLLSLAYHTLASSEGR----------------------SLIRRSLVLFAVGVFLALVLNLLQIQRNVTLFPEEVIATIFSSAWWVPP : 107 
                
                                                                                                                                                                                
Human      : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCIAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATLITQFLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 270 
Gorila     : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCIAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATLITQFLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 270 
Ch mpanzee : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCIAVFV INHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATLITQFLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 270 
Orangutan  : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCIAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATLITQFLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 270 
Baboon     : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCIAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATLITQFLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 270 
Macaque    : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCIAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATLITQFLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 270 
Marmoset   : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCIAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATLITQFLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 270 
Gibbon     : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCIAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATLITQFLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAML : 270 
BrownBat   : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCVAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATLITQLLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 272 
Ant lope   : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCVAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATLITQLLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 270 
Goat       : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCVAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATLITQLLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 270 
Horse      : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCVAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATLITQLLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 270 
Sheep      : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCVAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATLITQLLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 270 
Cow        : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCVAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATLITQLLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 270 
Dolphin    : CCGTAAAVVGLLYPCIDSRLGEPHKFKREWASVMRCVAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATVITQLLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 270 
Pig        : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCVAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGLTIAVLATLITQLLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 270 
Yak        : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCVAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATLITQLLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 270 
Alpaca     : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCVAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATLITQLLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 261 
Camel      : CCGTAAAVVGLLYPCIDSRLGEPHKFKREWASVMRCVAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATLITQLLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 261 
KillerWhal : CCGTAAAVVGLLYPCIDSRLGEPHKFKREWASVMRCVAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATVITQLLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 270 
Elephant   : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCIAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATLITQFLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 270 
Rhinoceros : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCVAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATLITQLLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 270 
Rabbit     : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCIAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATLITQFLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 266 
TasmanianD : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCIAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATLITQFLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 270 
Manatee    : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCIAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATLITQFLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 273 
Armadillo  : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCIAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATLITQFLVYNGVYQYTSPDFLYIRSWLPCI?FSGGVTVGNIGRQLAMG : 269 
Dog        : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCVAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATLITQLLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 266 
Hedgehog   : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCIAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITVAFLATLITQFLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 260 
PaintedTur : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCIAVFVGINHASAKLDFANNIQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATLITQFLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 263 
ChineseTur : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCIAVFVGINHASAKLDFANNIQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATLITQFLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 266 
Walrus     : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCVAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATLITQLLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 267 
Pika       : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCIAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATLITQFLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 263 
GroundTit  : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCIAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFVATLITQFLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 266 
Parakeet   : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCIAVFVGINHASAKLDFANNIQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFVATLITQFLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 258 
Mallard    : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCIAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFVATLITQFLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 251 
Falcon     : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCIAVFVGINHASAKLDFANNIQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFVATLITQFLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 263 
Galagos    : CCGTAAAVVGVLYPCIDSHLGEPHKFKREWASVMRCIAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATLITQFLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 261 
Flycatcher : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCIAVFVGINHASAKLDFANNIQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFVATLITQFLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 266 
Mouse      : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCIAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATLITQFLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 253 
Vole       : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCIAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATLITQLLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 251 
GoldenHams : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCIAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATLITQFLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 252 
JaculusRod : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCMAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATLITQFLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 254 
Hamster    : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCIAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATLITQFLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 251 
PythonIsla : CCGTGAAVIGLLYPCLDSHLGEPHKFKREWASVMRCIAVFVGINHASVKLDFDNNVQLSLTLAALSLGLWWTFDRSRSGFGLGITTAFLATVITQLLVYNGVYQYTSPDFLYVRSWLPCIFFSGGVTVGNIGRQLAMG : 246 
ZebraMbuna : CCGTGAAVIGLLYPCLDSHLGEPHKFKREWASVMRCIAVFVGINHASVKLDFDNNVQLSLTLAALSLGLWWTFDRSRSGFGLGITTAFLATVITQLLVYNGVYQYTSPDFLYVRSWLPCIFFSGGVTVGNIGRQLAMG : 246 
Zebrafish  : CCGTAAAVVGLLYPCLDHHLGEPHKFKREWASVMRCIAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGFGLGLTTALLATLIAQLLVYNGIYQYTSPDFLYVRSWLPCIFFSGGVTVGNIGRQLAMG : 245 
TilapiaFis : CCGTGAAVIGLLYPCLDSHLGEPHKFKREWASVMRCIAVFVGINHASVKLDFDNNVQLSLTLAALSLGLWWTFDRSRSGFGLGITTAFLATVITQLLVYNGVYQYTSPDFLYVRSWLPCIFFSGGVTVGNIGRQLAMG : 246 
GuineaPig  : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCIAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATLITQFLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 248 
NakedMoleR : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCIAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATLITQFLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 248 
AfricanCla : CCGTAAAVVGLLYPCIDSRIGEPHKFKREWASVMRCIAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATLITQFLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 245 
TropicalCl : CCGTAAAVVGLLYPCIDSHLGEPHKFKREWASVMRCIAVFVGINHASAKLDFANNVQLSLTLAALSLGLWWTFDRSRSGLGLGITIAFLATLITQFLVYNGVYQYTSPDFLYIRSWLPCIFFSGGVTVGNIGRQLAMG : 245 
 
                          
Human      : VPEKPHSD*---- : 278 
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Horse      : VPEKPHSD*---- : 278 
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Camel      : VPEKPHSD*---- : 269 
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Elephant   : APEKPHSD*---- : 278 
Rhinoceros : VPEKPHSD*---- : 278 
Rabbit     : VPEKPHSD*---- : 274 
TasmanianD : IPEKPHSD*---- : 278 
Manatee    : VPEKPHSD*---- : 281 
Armadillo  : VPEKPHSD*---- : 277 
Dog        : VPEKPHSD*---- : 274 
Hedgehog   : VPEKPHSD*---- : 268 
PaintedTur : IPEKPHTD*---- : 271 
ChineseTur : IPEKPHTD*---- : 274 
Walrus     : VPEKPHSD*---- : 275 
Pika       : VPEKPHSD*---- : 271 
GroundTit  : IPEKPHND*---- : 274 
Parakeet   : IPEKPHND*---- : 266 
Mallard    : IPEKPHND*---- : 259 
Falcon     : IPEKPHND*---- : 271 
Galagos    : VPEKPHSD*---- : 269 
Flycatcher : IPEKPHND*---- : 274 
Mouse      : VPEKPHSD*---- : 261 
Vole       : VPEKPHSD*---- : 259 
GoldenHams : VPEKPHSD*---- : 260 
JaculusRod : VPEKPHSD*---- : 262 
Hamster    : VPEKPHSD*---- : 259 




Translational start sites have different stringencies of activation depending on their 
context. The context of a translational start site refers to its Kozak sequence for start 
site recognition. Studies have identified that the key nucleotides involved in 
determining the efficiency of initiation at a given ATG start site are the -3 and +1 
nucleotides. Purine bases at these positions indicate a strong initiation site, while 
pyrimidine bases are less favourable. Analysis of the context surrounding the two 
translational start sites found in INSIG1 will inform on which isoform is likely 
expressed in vivo.  
Analysis of the context of the first INSIG1 translational start site at the mRNA level 
in humans shows a cytosine at both the -3 and +1 positions. Having pyrimidine 
nucleotides at both of these positions is considered a very poor context start site. 
Surprisingly, this poor start site context is highly conserved across INSIG1 mRNA 
sequences (Figure 5.6A), with a wide range of vertebrate species retaining the 
cytosine nucleotides at -3 and +1 positions relative to the ATG start.  
Analysis of the Kozak sequence associated with the second ATG start site indicated 
a lot more variability compared to the highly conserved nature of the first start site. 
In the human INSIG1 sequence, the second ATG has a guanine nucleotide at the -3 
position and an adenine nucleotide at the +1 position (Figure 5.6A). Having purine 
nucleotides at both of these positions is considered to be a strong context start site 
for translation initiation. This Kozak motif at the second start site appears to be 
highly conserved among vertebrates, with the guanine at the -3 position being 100% 
conserved. The adenine at the +1 position is also conserved among a large number of 
the INSIG1 mRNA sequences, but in certain sequences a substitution does occur. 
The most common substitution is for a pyrimidine, which is the least favourable 




This substitution is not localised to any one clade of species in particular, as 
highlighted by the phylogenetic tree (Figure 5.7). The relevance of this limited 
conservation of a strong context second translation initiation start site for INSIG1 
among vertebrates will be discussed below.  
Translation initiation occurring from the poor context first start site in human and 
mouse is unexpected based on the strong context of the second start site. However, 
translation from the first start site is known to occur in human, mouse and hamster. 
RNA secondary structures are known to be involved in the regulation of translation 
initiation (Kozak 1986; Kozak 1989). It is a possibility that an RNA secondary 
structure may be causing ribosome stalling at the second start site which could cause 
an increase in translation initiation from the first start site, despite its poor context. 
Therefore, the mRNA sequence surrounding the second start site was analysed for 
the presence of potential secondary structure formation. Preliminary sequence 
analysis suggested two strong stem-loop structures forming in the region of the 
second start site in the human INSIG1 mRNA sequence, with the ATG being 
involved in the base pairing of the second stem (Figure 5.8A, red arrow). This 
structure was conserved in other mammalian INSIG1 mRNA sequences (data not 
shown). If RNA secondary structure formation was a mechanism by which 
translation initiation was occurring at the first start site, then it would be expected 
that secondary structure formation, in which the second ATG start site was involved 
in base-pairing, would be conserved among other vertebrate species. Analysis of the 
nucleotide sequence surrounding the second start site in INSIG1 mRNA sequences 
from frog, fish and rodent species indicate the possibility of stem-loop structure 
formation in which the second ATG start site is involved in base pairing (Figure 




secondary structures with respect to influencing translation initiation at the first poor 
context start site remains to be investigated. 
The overall conservation of two start sites and their initiation contexts among 
vertebrates presented here suggests a functional significance to having two INSIG1 
protein isoforms produced. In this chapter, the function of each INSIG1 isoform was 
investigated with respect to the two known cellular functions of the INSIG1 protein; 















Figure 5.6. Analysis of Kozak sequence surrounding INSIG1 translation initiation start sites 
A) Vertebrate mRNA sequences were retrieved from the NCBI database using the desource 
accessions associated with the INSIG1 protein sequences. Sequences were downloaded to 
and aligned in MEGA alignment explorer, which uses the ClustalW multiple alignment 
programme. Nucleotide positions shown refer to positions in the human INSIG1 mRNA 
sequence. Highlighted in yellow are the ATG start sites, red are cytosines, blue are guanines, 
pink are adenines and brown are thymines B) mRNA and protein sequence of S. pombe Ins-






N  K  M  S  R  K  E  I  Y  E  P  R  P  R  Y  P  D  G  Y  N  G  N  R  A  V  K  K  S    
AATAAAATGAGCAGAAAAGAGATTTACGAACCCCGTCCGCGCTACCCAGATGGTTATAATGGAAATCGAGCGGTCAAGAAGTCC  
L  S  V  L  S  L  D  N  M  K  S  T  L  S  G  L  F  A  P  L  K  L  D  E  E  Q  A  E    
TTGTCGGTACTTTCTTTGGACAATATGAAATCGACACTATCAGGGCTTTTTGCTCCACTTAAATTAGATGAAGAGCAGGCAGAA  
D  D  E  S  L  S  S  Y  E  D  Y  A  S  R  Q  I  D  D  D  L  K  K  Q  R  K  K  G  I  
GATGATGAATCCCTGAGTAGTTATGAAGATTACGCGTCTAGACAGATCGATGATGATTTAAAGAAACAGAGAAAGAAAGGGATA  
T  F  I  D  Y  S  S  L  I  T  F  F  C  K  L  C  V  I  F  G  L  G  F  V  F  T  Y  L   
ACATTTATAGACTATTCATCTTTAATAACTTTTTTTTGTAAGCTTTGTGTTATATTTGGATTAGGGTTTGTGTTTACTTATTTG  
A  E  Q  I  V  Q  D  A  K  L  P  L  L  T  V  N  L  K  S  W  K  F  E  P  P  W  P  A   
GCTGAACAAATTGTGCAAGATGCAAAGCTACCACTTCTGACGGTCAATCTCAAAAGTTGGAAATTTGAGCCCCCATGGCCTGCA  
I  F  G  F  V  A  V  I  L  G  L  S  Y  R  R  M  D  T  K  Y  P  L  G  A  A  P  L  R   
ATTTTTGGCTTCGTTGCTGTCATACTTGGACTCTCTTATCGACGTATGGATACGAAGTATCCTTTGGGAGCTGCCCCTTTACGC  
P  S  Q  S  S  K  W  Q  W  I  S  R  Y  L  A  A  F  A  T  L  L  L  S  M  K  K  L  L   
CCTTCACAATCGTCTAAATGGCAATGGATTTCTCGGTATCTTGCTGCTTTCGCTACATTGCTACTTTCTATGAAGAAATTACTA  
F  I  S  N  S  H  S  I  V  A  L  V  A  S  S  A  S  I  W  Y  I  F  D  R  S  R  N  G   
TTTATTTCGAATTCACACTCCATTGTTGCACTCGTTGCGAGTTCTGCTAGCATTTGGTATATATTTGATCGCTCAAGAAACGGT  
I  I  L  S  T  I  T  S  V  L  G  S  I  L  Y  Y  N  L  V  D  T  S  K  I  E  L  N  G   
ATTATTTTGTCGACAATTACTTCTGTGTTGGGGAGTATCTTATATTATAATTTGGTTGATACCTCAAAAATTGAGTTAAATGGA  
V  E  F  P  E  I  Q  F  R  L  W  I  P  M  I  L  F  S  A  S  T  I  V  G  N  A  G  R  
GTTGAATTCCCTGAAATTCAGTTTCGTTTATGGATTCCTATGATACTTTTCTCCGCTTCTACGATTGTTGGTAACGCTGGTCGT  









Figure 5.7. Phylogenetic tree illustrating the relationship between INSIG1 protein homologs. 
A phylogenetic tree was constructed based on the multiple sequence alignment of vertebrate 
INSIG1 protein sequences using the Neighbour-Joining method in MEGA 4.0. Branch 
values are and indicator of confidence in tree branch topology, as measured using the 






















Figure 5.8. Predicted RNA secondary structures within the 5-prime region of vertebrate 
INSIG1 mRNA sequences. A) Human, B) African clawed frog, C) Zebrafish and D) Mouse. 
Structures represent the lowest free energy structures generated using ‗Fold‘ of the 
RNAstructure Web Server (Reuter and Mathews,2010). The first ATG start site is indicated 

























Investigation of effects of individual INSIG1 isoforms on SREBP retention in the 
ER 
INSIG1 is involved in mediating the inhibitory effects of oxysterols on SREBP 
activation. This inhibitory effect is achieved by INSIG1 binding to the 
transmembrane region of SCAP and anchoring SCAP in the ER which in turn retains 
SREBP in the ER preventing its transport to the Golgi and subsequent activation by 
the site-1 and site-2 proteases. To investigate if either isoform of INSIG1 displayed a 
difference in its ability to inhibit SREBP activity three mutants of INSIG1 were 
generated (Figure 5.9). The first mutant generated was a modification of an INSIG1 
expression plasmid to restore its initiator ATG codons to the same context as the 
native human INSIG1 mRNA. Thus, this mutant INSIG1 construct mimics the native 
mRNA and allows an accurate reflection of the expression ratios from the first and 
second INSIG1 start sites in vivo. This mutant was designated INSIG1WT. The 
second mutant (INSIG12ND-AAA) had the second start site mutated from ATG to AAA 
so that transcription only occurred from the first ATG start site. The size of the 
INSIG1 protein produced from this mutant form should be approximately 30 kDa. 
The third mutant (INSIG11ST-AAA) had the first start site mutated to AAA so that 
transcription only occurred from the second ATG start site and encodes a shorter 








Figure 5.9. Schematic representation of INSIG1 mutants generated. The original construct 
used was purchased from Origene and had the INSIG1 ORF inserted into the vector 
pCMV6-AC-HA Mutant constructs were generated by site directed mutagenesis of the 






The effects of INSIG1WT, INSIG12ND-AAA and INSIG11ST-AAA on25-OHC prevention 
of SREBP processing as measured by SREBP/HMGCR luciferase reporter readout 
were analysed using the HeLa-PHGL cell line which has the SREBP responsive 
promoter HMGCR fused to Gaussia luciferase. Cells were transfected with either 
empty vector (EV) or each of the INSIG1 mutant constructs respectively. Following 
transfection, cells were incubated in the presence or absence of 25-OHC for sixteen 
hours and assayed for secreted luciferase activity (Figure 5.10). Incubation with 25-
OHC alone yielded a 2.38-fold reduction in luciferase readout. As expected, over-
expression of INSIG1WT further increased the fold repression to 4.50. The 
INSIG12ND-AAA mutant increased it further to 5.56 while the increase observed for 
INSIG11ST-AAA increased was 4.55 (Table 5.2). Thus, each mutant INSIG1 protein 
was capable of significantly enhancing the oxysterol inhibitory effect on SREBP 
readout compared to 25-OHC alone (25-OHC vs. INSIG1WT, P=0.0012; 25-OHC vs. 
INSIG12ND-AAA, P=0.0007; 25-OHC vs. INSIG11ST-AAA P=0.0013). However, no 
significant difference was observed when the inhibitory effect between the INSIG1 














Figure 5.10. Comparison of the effects of each INSIG1 isoform on SREBP/HMGCR 
luciferase reporter readout. HeLa-PHGL Cells were transfected with either empty vector 
(EV) or one of the three INSIG1 mutant constructs; INSIG1WT, INSIG12ND-AAA or 
INSIG11ST-AAA, using TurboFect transfection reagent. Following transfection, cells were 
cultured in media containing 10% LDS, in the presence of 25-OHC for 16 hours, after which 
aliquots of media were assayed for luciferase activity.  (** p<0.005, *** p<0.0005, as 
















Table 5.2. Repression of the SREBP/HMGCR luciferase reporter readout in HeLa-
PHGL cells transfected with the different INSIG1 mutants in the presence of 25-
OHC.  
 
Fold repression of HMGCR promoter* 
EV 2.38 (± 0.190) 
INSIG1WT 4.50 (± 0.629) 
INSIG12ND-AAA 5.56 (± 0.290) 
INSIG11ST-AAA 4.55 (± 0.608) 
 
* The values shown represent the average from three independent transfection 

















Table 5.3. Significance of repression of SREBP/HMGCR luciferase reporter readout 
in HeLa-PHGL cells between each INSIG1 mutant in the presence of 25-OHC.  
 
Difference between INSIG mutants in fold repression of HMGCR promoter* 
 INSIG1WT INSIG12ND-AAA INSIG11ST-AAA 
INSIG1WT 1.0000 0.0918 0.9977 
INSIG12ND-AAA 0.0918 1.0000 0.1404 
INSIG11ST-AAA 0.9977 0.1404 1.0000 
 
* The values shown represent the average from three independent transfection 













Effects of individual INSIG1 translation isoforms on HMGCR degradation 
INSIG1 is known to be essential for sterol-induced degradation of HMGCR. A 
population of INSIG1 proteins are known to be constitutively bound by the ER-
resident E3 ligase gp78. Upon sterol-regulated binding of HMGCR by INSIG1, gp78 
is recruited to HMGCR and this triggers the ubiquitin-mediated degradation of 
HMGCR. It has not yet been identified which region of INSIG1 interacts with gp78. 
There are believed to be two portions of INSIG1 within the ER membrane, 
distinguished by whether or not they are bound by gp78. If the two isoforms of 
INSIG1 make up the two populations which are either gp78 bound or not, then they 
would display differences in their ability to mediate the degradation of HMGCR. To 
investigate if there is a difference between the longer and shorter translation isoforms 
of INSIG1 in promoting the sterol-mediated HMGCR degradation, HeLa-PHGL 
cells were transfected with INSIG1WT, INSIG12ND-AAA or INSIG11ST-AAA. Following 
transfection, cells were incubated in the absence or presence of increasing 
concentrations of 25-OHC, which is known to promote the degradation of HMGCR. 
In cells transfected with empty vector, incubation with 25-OHC alone was sufficient 
to induce a rapid decrease in HMGCR at the protein level at the lowest concentration 
used (Figure 5.11). This is mediated by endogenous INSIG1. Over-expression of 
INSIG1WT enhanced the degradation of HMGCR to below detectable levels. Both 
INSIG12ND-AAA and INSIG11ST-AAA displayed the capacity to enhance the sterol-
mediated degradation of HMGCR to below detectable levels, similar to the effects of 
INSIG1WT. These results demonstrate indirectly that both isoforms of INSIG1 must 
be capable of binding gp78 as over-expression of each isoform individually 










Figure 5.11. Comparison of the effects of each mutant isoform of INSIG1 on oxysterol-
mediated degradation of HMGCR. HeLa-PHGL cells were transfected with either empty 
vector (EV) or one of the three INSIG1 mutant constructs; INSIG1WT, INSIG12ND-AAA or 
INSIG11ST-AAA, using TurboFect transfection reagent. Following transfection, cells were 
cultured in media containing 10% LDS, in the absence or presence of increasing 
concentrations of 25-OHC (0.3 µg/ml, 0.6 µg/ml and 0.9 µg/ml) for 20 hours. Whole cell 
extracts were prepared using homemade high SDS lysis buffer, as described in methods. 
Note: The grey in the centre of the INSIG11ST-AAA bands are as result of becoming over-
exposed in attempts to get a signal for INSIG12ND-AAA alongside it for comparison. Please 




















Human INSIG1 has two protein isoforms produced through translation initiation 
occurring from two alternative in-frame start sites (Yang et al. 2002). The work in 
this chapter sought to examine the phylogenetic conservation of these two start sites. 
The work also sought to elucidate if each INSIG1 isoform functioned differently 
with respect to the two known cellular functions of INSIG1; a) repressing SREBP 
processing and b) promoting degradation of HMGCR. 
Multiple sequence alignment of INSIG1 protein sequences from a wide variety of 
vertebrate species indicated a high level of sequence conservation over the entire 
transmembrane domain of the protein. However, there was much less conservation 
within the amino terminus of the protein. Despite the low level of sequence identity 
within this region, the presence of the second initiator methionine is shown to be 
conserved among vertebrates. The production of two proteins from the one INSIG1 
mRNA is only reported for human and hamster INSIG1, but not in other vertebrates 
(Gong, Lee, Lee, et al. 2006b). Mouse is reported as having one INSIG1 isoform, 
corresponding to translation initiation occurring from the first translational start site 
(Engelking et al. 2004). The fission yeast homolog Ins-1 also contains a second 
initiation methionine, located thirty four residues upstream of the first (Burg et al. 
2009). Ins-1 does have two Ins-1 protein isoforms produced corresponding to 
translation initiation occurring from the two in-frame start sites, which is consistent 
with human INSIG1 scenario. 
Analysis of the Kozak sequence surrounding the two methionine residues at the 
nucleotide level was performed in vertebrates to provide insight into whether 




within the Kozak sequence found to influence translation initiation the most are the -
3 and the +1 position relative to the ATG initiation codon (Kozak 1999). 
Pyrimidines are the least favourable nucleotides to have at these positions with 
respect to translation initiation efficiency. Surprisingly, the first start site in human 
INSIG1 has cytosines located at both the -3 and +1 positions, and this context was 
found to be highly conserved among vertebrates. Translation from a start site in this 
context would be expected to be very low but this work and the work of others have 
shown that both the long and short translation isoform are translated in INSIG1 over-
expression constructs. Endogenous INSIG1 expression has shown the longer protein 
isoform to be the main isoform detected, suggesting that initiation is occurring at a 
higher rate from the first start site. There is no immunoblot evidence to indicate 
protein molecular weight for INSIG1 from most of the species present in the 
alignments.  However, for mouse and hamster immunoblot analysis indicates that the 
molecular weight of INSIG1 lies between that of each human INSIG1 isoform at 28 
kDa, which corresponds to translation initiation from the first start site. Our analysis 
indicates that this first start site in rodents is also in poor context. 
 Translation initiation from the first start site appears even less likely when you 
consider the Kozak sequence surrounding the second start site. The second start site 
has purine nucleotides at the -3 and the +1 positions which is considered a good 
context start site. The good context of the second start site is also conserved for the 
most part among vertebrates, including in rodents. However, it is important to 
consider that a purine-pyrimidine substitution occurs in some instances at the +1 
position, which is the least favourable substitution with respect to translation 
initiation and previous findings suggest that this could reduce translation initiation 




INSIG1, the scanning ribosome would be expected to read through the first start site 
and initiate translation at the second (Dr. Ivaylo Ivanov, personal communication). 
However, it is clear that read through of the first translational start site is not 
occurring. Our analysis indicates that translation from the first start site in rodents 
occurs despite the second start site being in better context, which is consistent with 
the human INSIG1 scenario. Thus, it would be reasonable to predict that translation 
occurs from this poor context first start site in INSIG1 from all species shown.  
A possible explanation for translation occurring from a poor context first start site is 
through ribosome stalling at the second site. Ribosome stalling is a possibility when 
you consider the distance between the two start sites is 105 nucleotides and the 
average length covered by a ribosome is 32 nucleotides (Dr. Ivaylo Ivanov, personal 
communication). While this distance is the same for most other vertebrates, in rodent 
species the distance between the two start sites is less and would correspond to just 
over twice the length of a stalled ribosome. A brief analysis of the region 
surrounding the second ATG start sites in human INSIG1 mRNA for potential RNA 
secondary structures which may influence ribosome stalling revealed the possibility 
that the second start site may be occluded within a hairpin structure. Analysis of the 
same region in other species suggested that the second ATG being in stem-loop 
structure appeared to be a conserved event. However, a more detailed investigation 
of conservation of an RNA secondary structure contributing to reduced initiation of 
translation at the second start site would be necessary. It would also be necessary to 
mutate the nucleotides involved this structure formation to confirm its involvement 
in promoting initiation at the first poor context start site. Whether ribosome stalling 
is involved in translation initiation occurring from the first poor context start site was 




Another possibility is that the different translational contexts of the two start sites 
allow recognition by different eukaryotic translation initiation factors (eIFs). In the 
scanning ribosome complex, eIFs are central to selecting translational start sites 
within the 5‘ region of an mRNA transcript. It is has been demonstrated that 
different eIFs have varied affinities for translation start sites depending on their 
Kozak sequence (Ivanov et al. 2010; Loughran et al. 2012). For example, eIF5 has 
been shown to reduce the stringency of start codon selection and induce translation 
from poor context start sites. In contrast, eIF1 has been shown to increase stringency 
of start codon selection and translation initiation from optimal context start sites. The 
cellular signals which regulate which eIFs are present in the scanning ribosome are 
as yet unclear, but are under investigation. INSIG1 having both a poor context and 
an optimal context start site may ensure that if transcription of INSIG1 is induced 
that translation will be initiated regardless of which eIF is present in the scanning 
ribosome. It is also possible that under conditions which induce a change in eIF 
proteins, that this would allow increased expression of one isoform over the other. 
Whether eIFs can alter the ratio of INSIG1 isoform expression merits further 
investigation, but functional significance of such a regulation is unclear and is 
currently under investigation in the lab.   
The production of two INSIG1 isoforms in human from translation occurring from 
two in-frame start sites, and the conservation of two in-frame start sites among 
vertebrates and yeast prompted up to investigate if there was a functional difference 
between the two human INSIG1 isoforms. The effect of over-expression of each 
INSIG1 isoform on mediating sterol-induced inhibition of SREBP activation was 
assessed using the HeLa-PHGL cell line. In this model, HMGCR promoter activity 




assaying for luciferase enzyme levels. The effects of the INSIG1 isoforms were 
compared in the presence of 25-OHC, as certain oxysterols are required to mediate 
INSIG1 effects (Sun et al. 2005). The presence of 25-OHC alone caused a significant 
decrease in SREBP reporter readout, mediated by endogenous INSIG proteins. Over-
expression of all three INSIG1 proteins; INSIG1WT, INSIG12ND-AAA and INSIG11ST-
AAA, significantly enhanced the oxysterol inhibitory effect. However, there was no 
significant difference observed between the level of repression achieved between the 
INSIG1 isoforms or compared to wild-type. Thus, both isoforms appear to possess 
the ability to suppress SREBP activation in the presence of sterols to the same 
degree. While these results give a strong indication towards there being no difference 
between INSIG1 isoforms in this context, the window available to study this effect is 
quite small owing to the large inhibitory effect of oxysterol alone. It would be 




 background to 
remove the effect of the endogenous INSIG. It was not possible to do this here as 
such mutants were not available.  
INSIG1WT, INSIG12ND-AAA and INSIG11ST-AAA were also investigated with respect to 
their ability to mediate the degradation of HMGCR. Due to the presence of 
endogenous INSIG proteins, the presence of 25-OHC alone caused a significant 
decrease in HMGCR at the protein level. Over-expression of all three INSIG1 
proteins; INSIG1WT,  INSIG12ND-AAA and INSIG11ST-AAA, all enhanced the oxysterol 
degradation effect on HMGCR, decreasing protein levels to amounts below the range 
of detection by immunoblot. Thus, both isoforms appear to possess the ability to 
mediate the degradation of HMGCR in the presence of sterols. However, due to the 
large effect that the oxysterol has on inducing HMGCR degradation mediated by 








 background to remove the effect of the endogenous INSIG 
proteins. The results presented here indicate that the function of having two INSIG1 
isoforms produced is not likely to differentially mediate either of the two known 

























Inhibition of SREBP Processing Enhances the 













Statins are a family of drugs which efficiently and specifically inhibit the catalytic 
activity of the rate limiting enzyme in cholesterol biosynthesis, 3-hydroxy-3-
methylglutaryl coenzyme A reductase (HMGCR). Inhibition of HMGCR results in a 
decrease in intracellular cholesterol, as well as essential sterol intermediates. The cell 
compensates by increasing cholesterol biosynthesis and uptake through increasing 
processing of the SREBP2 transcription factor. By this mechanism, statins increase 
LDLR which results in the decrease of serum LDL-cholesterol characteristic of statin 
treatment, but they also increase their own target HMGCR. There is increased 
interest in the potential use of statins as anti-cancer agents based on their ability to 
induce apoptosis. One of the limitations of their potential use in this area is that the 
concentrations required to induce cancer cell death in vitro are much higher than the 
serum concentrations currently achieved with the recommended dosage of 40-80 
mg/day. Higher serum concentrations can be achieved with higher daily doses, but 
this causes adverse effects, including myopathy. Thus lowering the concentrations of 
statin required to induce cancer cell death is of high value.  
The aim of this chapter was to investigate the effect of targeted inhibition of SREBP 
processing on the cytotoxicity induced by statins in cancer cell lines. The results 
indicate that inhibition of SREBP processing using oxysterols significantly enhances 
statin cytotoxicity in HeLa cells, and that this inhibition is related to protein levels of 
active nSREBP2 and HMGCR. The results indicate that this approach is also valid to 
enhance statin cytotoxicity in cancer cells, but may be limited by deregulation of 
SREBP processing and off target effects of statins, which were observed for some of 





Maintenance of cholesterol homeostasis is central to cell viability (Mclean et al. 
2012). Homeostasis is achieved through regulated cholesterol uptake and de novo 
biosynthesis (Davis et al. 2004; Brown & Goldstein 1986). The cholesterol 
biosynthesis pathway comprises multiple enzymes whose expression is regulated by 
the transcription factor (TF) SREBP2 (Horton et al. 2002a). SREBP2 is part of a 
family of transcriptions factors involved in regulating lipid synthesis (Eberlé et al. 
2004; Hua et al. 1995). The other family members are SREBP1a and SREBP1c 
which are both expressed from the SREBF1 gene through the use of alternative first 
exons (Shimomura et al. 1997). SREBP1c primarily regulates genes involved in fatty 
acid biosynthesis, while SREBP1a has been shown to regulate expression of both 
cholesterol and fatty acid biosynthetic enzymes (Horton et al. 2003; Amemiya-kudo 
et al. 2002; Shimano, Horton, et al. 1997). SREBP2 binds to SRE elements within 
the promoter region of key cholesterogenic genes including 3-hydroxy-3-
methylglutaryl coenzyme A synthase (HMGCS), 3-hydroxy-3-methylglutaryl 
coenzyme A reductase (HMGCR), mevalonate kinase and lanosterol synthase 
(Figure 1) (Horton et al. 1998; Horton et al. 2002). The promoters also contain 
transcription factor element binding sites for common TFs such as for SP-1 and NF-
Y (Amemiya-kudo et al. 2002). The availability of active SREBP2 is highly 
regulated. The SREBP proteins are synthesised as inactive precursor proteins where 
the transcription factor domain is tethered to the ER (Hua et al. 1993b; Sakai 1995) . 
When cellular sterols deplete below threshold levels, SREBP2 is transported to the 
Golgi facilitated by the chaperone action of its interacting partner SCAP (Brown et 
al. 2002a). In the Golgi, two endogenous proteases cleave the SREBP2 precursor 




(Duncan et al. 1997a; Duncan et al. 1997b). This sterol regulated release of SREBP2 
allows for rapid induction of the entire cholesterol biosynthetic pathway upon sterol 
depletion within the cell. When cellular sterols return above threshold 
concentrations, transport of the SCAP-SREBP complex does not occur due to 
retention of the complex in the ER, thus preventing excess build-up of cholesterol 
which is toxic to the cell (Radhakrishnan et al. 2008; Adams et al. 2003).  
The cholesterol biosynthesis pathway is also commonly referred to as the 
mevalonate pathway. Mevalonate production is the rate limiting step in cholesterol 
biosynthesis (Brown et al. 1973). Mevalonate is produced by the enzymatic 
reduction of HMG-CoA in the presence of NADPH, by the enzyme HMGCR (Retey 
et al. 1970). As well as cholesterogenesis being essential for new cell membrane 
synthesis, mevalonate has been shown to be essential in many cellular processes 
(Ikonen 2008). As early as 1979, mevalonate was recognised as having an essential 
role in DNA replication (Quesney-huneeus et al. 1979). An increase in HMGCR 
expression co-ordinates with the cell cycle S-phase, and statin-mediated inhibition of 
HMGCR activity prevents S-phase associated DNA synthesis (Tatsuno et al. 1997). 
This statin effect is reversed upon addition of mevalonate but not cholesterol to the 
cells (Tatsuno et al. 1997). It was identified subsequently that the sterol 
intermediates farnesyl pyrophosphate and geranylgeranyl pyrophosphate, which 
cannot be produced in the absence of mevalonate, are essential for post-translational 
modification of proteins essential throughout the cell cycle (Sebti & Hamilton 2000; 
Rilling et al. 1993). Such proteins include nuclear lamins, Ras and other G-proteins 
(Luckman et al. 1998; Lutz et al. 1991). Since mevalonate is upstream of these 
pathway intermediates, their synthesis is dependent on its availability (Rilling et al. 




viability, but also prevents production of other essential pathway intermediates (Kita 
et al. 1980).  
The catalytic activity of HMGCR is specifically and efficiently inhibited by a group 
of drugs called statins (Istvan & Deisenhofer 2001). Statins are the one of the highest 
selling group of drugs in the world today and are widely used in the treatment of 
cholesterol-related diseases including atherosclerosis and hypercholesterolemia 
(Vaughan et al. 2000; Law et al. 2002; Aronow 2013). Statins are a family of drugs 
that differ in their chemical structure and potency, but all competitively bind to the 
catalytic site of HMGCR via their HMG-like moiety, thus preventing binding of the 
HMG-CoA substrate (Istvan & Deisenhofer 2001). The pioneering statin, compactin, 
was discovered in the mid-1970s, isolated from Penicillium citrinium, followed 
closely by the identification of another naturally occurring statin from Aspergillus 
terreus, Lovastatin (Brown et al. 1978; Alberts et al. 1980; Brown & Goldstein 
2004). Natural statins which are currently clinically available are Lovastatin, 
Pravastatin and Simvastatin (compactin failed to pass clinical trials), while synthetic 
statins are also available; Atorvastatin, Cerivastatin and Fluvastatin (Tobert 2003). 
Despite their differences, statins are all metabolised in the liver by Cytochrome P450 
enzymes. Metabolism by P450 enzymes results in statins suffering from low 
bioavailability, as evidenced by low plasma levels detectable following a 40 mg/day 
oral dose ranging from 10ng/ml to 50 ng/ml, depending on the statin (Schachter 
2004). However, the desired site of action for the cholesterol lowering properties of 
statin is in the liver. Thus the low serum levels of statins that result from P450 





Diagram 6.1. SREBP2 target genes (in black) in the cholesterol biosynthesis pathway 
(modified from (Horton et al. 2002b)). 
 
The mechanism of action of statins exploits the tight regulation that governs 
mevalonate pathway activity (Stancu & Sima 2001; Vaughan et al. 2000; Yang et al. 
1994). Expression of HMGCR is regulated by the SREBP family of transcription 
factors, primarily SREBP2 (Vallett et al. 1996; Horton et al. 2002b). When HMGCR 
catalytic activity is inhibited through the use of statins, cellular mevalonate levels 
fall, and thus sterol intermediates and cholesterol decrease (Kita et al. 1980). The cell 
acts to compensate for this decrease by raising the levels of active SREBP2 
transcription factor (Sheng et al. 1995). Depletion of sterols within the cell is sensed 
by the SCAP component of the SREBP pathway via its sterol sensing domain and 
this leads to dissociation of the SCAP-SREBP2 complex from the ER-retention 
protein INSIG (Adams et al. 2003; Brown et al. 2002b). The two proteases required 
for the release of the active SREBP2 transcription factor domain from the inactive 




SCAP-SREBP complex is transported from the ER to the Golgi via COPII vesicles 
facilitated by the interaction of scaffolding proteins with SCAP (Espenshade et al. 
2002). The result is a global increase in SREBP2 target gene expression (primarily, 
but not limited to, genes of cholesterol pathways) to restore the cholesterol balance 
within the cell (Horton et al. 2002b; Amemiya-kudo et al. 2002; Sakakura et al. 
2001). The therapeutic benefit of statins takes advantage of this induction of the 
SREBP pathway as the LDLR is one of these target genes. Increased levels of 
LDLRs on the cell surface increases LDL-cholesterol uptake and clearance from the 
circulation (Law et al. 2002; Goldstein et al. 1979). Once taken into hepatocytes, 
excess cellular cholesterol is converted into bile acids or excreted as free cholesterol. 
The rate limiting step of bile acid synthesis, cholesterol 7-alpha-hydroxylase 
(CYP7A1), is induced under high levels of cholesterol and this enzyme oxidises 
cholesterol for the production of primary bile acids (Li et al. 1990; Russell 2003). 
The latter are then secreted into the intestinal lumen, conjugated to form bile salts, 
which cannot be re-adsorbed from the intestine, and they function to emulsify fats to 
facilitate their excretion (Solaas et al. 2000). Together bile acid formation and 
function act to eliminate cholesterol and fats from the body. Excess cholesterol can 
also be excreted by its conversion to a less absorbed form in the intestine, 
coprostanol, prior to hepatocellular uptake (Kruit et al. 2005; Gérard et al. 2004). 
Gut microbial populations produce a cholesterol reductase enzyme which converts 
cholesterol to coprostanol (Ren et al. 1996; Wilson 1961). 
HMGCR itself is also induced in response to statin treatment (Kita et al. 1980) . The 
doses of statins given to patients in the treatment of hypercholesterolemia (average 
40 mg/day) is sufficient to inhibit HMGCR sufficiently to limit mevalonate 




cell surface LDLR expression (Law et al. 2002). However, the statin-mediated 
inhibition of HMGCR does not outweigh the new HMGCR being produced, thus 
allowing cell viability to be maintained. In fact this property that statins increase all 
SREBP2 target genes is widely used in biochemical and molecular biological studies 
of the HMGCR protein and its regulation (Sever et al. 2003b). Cells cultured in the 
absence of cholesterol in the presence of a high concentration of statin (most often 
compactin) significantly increases expression of all SREBP target genes above basal 
levels. This greatly improves the detection and study capacity of both the SREBP 
and mevalonate pathways. However to achieve this amplification with high 
concentrations of statin cell viability is only maintained with the inclusion of 
exogenous mevalonate in the medium (Sever et al. 2003b).    
In recent years, there have been a growing number of investigations regarding the 
chemotherapeutic potential of statins (Sleijfer et al. 2005). Treatment with statins has 
been shown to induce growth arrest and apoptosis in a variety of cancer cell lines. 
Statins, including atorvastatin and simvastatin have been shown to induce apoptosis 
in myeloma cell lines in a caspase-dependent manner (Cafforio et al. 2005). Recently 
it was shown that sensitivity of acute myeloid leukaemia (AML) cell lines to 
lovastatin induced apoptosis was linked to a deregulated SREBP feed-forward 
response to the statin treatment (Clendening, Aleksandra Pandyra, et al. 2010). AML 
cell lines which were insensitive to statin induced apoptosis retained the ability to 
increase SREBP target genes, including HMGCR. This study also showed that 
primary cells from patients with multiple myeloma expressing a lower level of 
HMGCR were more sensitive to lovastatin and atorvastatin induced apoptosis than 
cells with higher HMGCR expression (Clendening, Aleksandra Pandyra, et al. 




lines (Wächtershäuser et al. 2001). Lovastatin, mevastatin and simvastatin have all 
been shown to induce apoptosis in melanoma cell lines, as well as having inhibitory 
effects on the migration and invasion of these cancer cells (Glynn et al. 2008).  
Prostate cancers have been shown to have high cholesterol content, and a loss of 
cholesterol feedback inhibition of the SREBP pathway has been shown for prostate 
tumours (Pelton et al. 2012; Hager et al. 2006b; Ettinger et al. 2004a; Chen & 
Hughes-Fulford 2001). SREBP-2 has also been implicated as a key transcription 
factor required for elevated cholesterol in prostate cancer tissues (Ettinger et al. 
2004a). An androgen-mediated increase in key lipogenic genes, including fatty acid 
synthase (FASN) and HMGCR, has also been reported (Huang et al. 2012). SCAP 
has also been shown to contain an androgen response element within intron 8 and is 
increased in response to androgen treatments (Heemers et al. 2004). Mevastatin and 
simvastatin have been shown to decrease androgen sensitivity and cell proliferation 
in androgen receptor (AR)-positive prostate cancer cells, but not in AR-negative 
cells (Yokomizo et al. 2011). This decrease in proliferation was linked to statin-
induced proteolysis of the AR protein, which in turn reduced SREBP pathway 
activation in these cells.  
Tumours of simvastatin treated mice have been shown to have increased levels of 
apoptosis compared to untreated control mice, as measured by immune-
histochemical staining of mammary tumour sections for cleaved caspase-3 
(Campbell et al. 2006). Simvastatin also has demonstrated anti-proliferative effects 
on human glioma cells which was rescuable by mevalonate in a dose dependent 
manner, and thus attributable to inhibition of HMGCR (Kikuchi et al. 1997). 




of LDLR. They found an additive cytotoxic effect between simvastatin and a 
peroxidised LDL molecule when they were directly injected into a mouse model of 
glioma.  
However, it has also been reported that lovastatin induced G1 arrest in an epithelial 
cell line, independent of HMGCR inhibition, through inhibition of the proteasome 
and accumulation of cyclin-dependent kinase inhibitors (CKIs) p27 and p21 (Rao et 
al. 1999). They attributed this proteasome inhibition effect to the β-lactone ring of 
the lovastatin pro-drug, although they did show that mevalonate reversed this action.  
The SREBP and mevalonate pathways have also demonstrated links to cancer cell 
survival and progression. Studies have demonstrated the over-expression of the 
HMGCR catalytic domain of was sufficient to enhance the cancer phenotype of 
MCF-7 cells, and to induce transformation of their non-malignant counterparts, 
MCF-10A (Clendening, Aleks Pandyra, et al. 2010). There is also a correlation 
between high mRNA levels of HMGCR and other cholesterol biosynthetic genes 
with poor prognosis for breast cancer patients (Clendening, Aleks Pandyra, et al. 
2010). Elevated levels of cholesterol synthesis and mevalonate pathway gene 
expression have also been detected in brain and prostate cancers (Rudling et al. 
1990; Hager et al. 2006b). A deregulation of SREBP-mediated feedback regulation 
of mevalonate pathway gene expression has also been reported for a subset of 
prostate cancers (Chen & Hughes-Fulford 2001). HMGCR has therefore been 
proposed as a metabolic oncogene, which would fit within one of the emerging 
hallmarks of cancer, namely reprogramming of cellular energy metabolism in order 
to support continuous cell growth and proliferation (Hanahan & Weinberg 2011). 




However, the statin concentrations required to achieve statin induced cell death in 
vitro are in the mid to high micro-molar range. The highest serum concentration of 
statin recorded from the recommended 40 mg/day dosage is in the nano-molar range 
(Chan et al. 2003; Solomon & Freeman 2008; Wong et al. 2002). When it comes to 
translating in vitro experiments to a clinical setting, many are sceptical as to whether 
the doses required to achieve cancer cell death may not be achievable in vivo 
(Bonetti et al. 2003). Achieving high serum concentrations of statins would be 
necessary for use of statins as chemotherapeutic agents, as low concentrations may 
simply act to increase SREBP pathway activity, and this would only prove 
advantageous to the disease. Also, high dose-regimes of statins in the treatment of 
hypercholesterolemia have been documented to have adverse effects on the body, 
including liver damage and  myopathy (Needham & Mastaglia 2014; Wilkinson et 
al. 2014). While the mechanism surrounding myopathy phenotype remains unclear, 
it is believed to be linked to apoptosis induced by statin treatment in the muscle 
(Needham & Mastaglia 2014).  Another proposed mechanism for statin associated 
myopathy is that inhibition of farnesylpyrophosphate synthesis reduces ubiquinone 
(Coenzyme Q10) production which is required for mitochondrial function and energy 
production. The role of mitochondrial dysfunction in statin associated myopathy has 
not been conclusively shown, but clinical trials are underway investigating the 
effects of ubiquinone supplementation on statin associated myopathy (Parker, 
Gregory, et al. 2013).  These distal effects from statin treatment suggest that effects 
beyond the liver can be realised. If the primary aim of the statin treatment was not to 
target increase LDL-cholesterol clearance, then perhaps the drug could be modified 
in a way that allowed direct injection to the region of the cancer, circumventing liver 




be to exploit the property that certain anaerobic bacteria migrate specifically to 
hypoxic tumour sites following oral administration (Cronin et al. 2010). Thus, 
lowering the effective chemotherapeutic concentrations of statins would be highly 
desirable. 
In spite of these reservations, there are ongoing clinical trials in which statins are 
being investigated in the treatment of a variety of cancers. Trials underway where 
statins are being investigated as the primary chemotherapeutic agent include in the 
treatment of multiple myeloma, breast cancer, non-Hodgkin‘s lymphoma and 
chronic lymphocytic leukaemia respectively (Chapter 1; Table 1.4). There are also 
multiple trials, both underway and completed, investigating the effects of statins on 
cancer incidence and effects on other approved cancer therapies (Chapter 1; Tables 
1.2 and 1.3). The advantage of developing statins as an anti-cancer agent is that the 
pharmacokinetic and pharmacodynamic properties of the drug are already known, 
and they have already passed FDA approval for use as a human therapeutic, which 
means the approved doses are safe and give minimal side effects overall. If the 
effective chemotherapeutic concentration of statin could be lowered to ranges 
currently used clinically, then this would be considered a safe effective dose with no 
global adverse effects. 
The hypothesis relating to the statin based research in this chapter is that preventing 
the SREBP-mediated activation of cholesterogenic genes that occurs upon statin 
treatment would reduce the level of the HMGCR gene and protein expression and 
thus reduce the effective statin concentration required to induce cancer cell apoptosis 
via mevalonate starvation and consequently improve the chemotherapeutic potential 




As described earlier, SREBPs are synthesised as inactive precursor proteins and 
release of the active transcription factor domain is regulated by sterols (Hua et al. 
1993b; Wang et al. 1994). Apart from cholesterol, there are many other known 
regulators of SREBP activation, many of which are dietary in origin. These include 
oxysterols and poly unsaturated fatty acids (PUFAs) (Radhakrishnan et al. 2007b; 
Lee et al. 2008; Xu et al. 1999). Modulation of the SREBP pathway is of critical 
importance to several disease areas including hypercholesterolemia, atherosclerosis 
and liver disease (Tang et al. 2011; Miserez et al. 2002; Horton et al. 2002b). Thus, 
the mechanisms of how these dietary oxysterols and PUFAs regulate SREBP 
activation is quite well characterised. Oxysterols, such as 25-OHC, have been shown 
to bind the ER-retention protein, INSIG, and stabilise it through blocking its 
ubiquitination (Gong, Lee, Lee, et al. 2006b; Radhakrishnan et al. 2007b). This 
results in INSIG binding to SCAP and inhibiting the delivery of the SCAP-SREBP 
complex to the Golgi for proteolytic processing (Espenshade et al. 2002). Oxysterols 
also have a direct effect on stimulating degradation of HMGCR. This is also 
achieved through their binding of INSIG1 (Jo et al. 2011). It is believed that PUFAs 
inhibit SREBP cleavage in a similar manner, except that they act following the 
ubiquitination stage of INSIG. Following ubiquitination, INSIG requires removal 
from the ER membrane in order to be degraded by the proteasome, and PUFAs are 
reported to block this extraction (Lee et al. 2008).  Due to the dietary nature of 
oxysterols and PUFAs they are known to be tolerated well at low doses and do not 
exhibit adverse effects on the body (Otaegui-Arrazola et al. 2010). Statin-mediated 
inhibition of HMGCR triggers the cholesterol depletion feed-forward response via 




oxysterols and PUFAs, combined with them being present in the everyday diet, 
make them ideal candidates to investigate to enhance statin induced cell killing.   
This chapter describes: a) The response of the cell line HeLa-PHGL to statin induced 
cytotoxicity under FS and LDS culture conditions with respect to SREBP2 and 
HMGCR, b) How the inhibition of SREBP processing enhances the cytotoxic effects 
of statin in HeLa-PHGL through limiting HMGCR expression, and c) The statin 
induced cytotoxic response in a panel of cancer cell lines under FS and LDS 
conditions. The enhancing effects of SREBP inhibition on statin-associated 
cytotoxicity are also presented for a subset of the cell line panel. The data presented 
in this chapter indicate that prevention of SREBP processing is a viable method for 
enhancing the cytotoxic effects of statins in a sub-set of cancer cell lines.  
The data also highlight a number of key points for consideration for the potential use 
of statins in the treatment of cancer, including: a) the effects of lipid-depletion on the 
cytotoxic effects of statins, b) that deregulation of the sterol-SREBP negative 
feedback loop was observed in half of the cancer cell lines screened, and c) that high 











Lipid depletion increases HeLa-PHGL cell resistance to statin-mediated cell 
killing  
Inhibition of HMGCR catalytic activity by statins depletes the cellular pool of 
mevalonate, thus limiting essential isoprenoid and cholesterol availability. To 
maintain cell viability the cell compensates by increasing SREBP2 target gene 
expression including HMGCR. Culturing cells in the presence of LDS is a well 
documented method to amplify mevalonate pathway activity through promoting 
SREBP processing in response to low lipid availability. A main question addressed 
in this work was to determine if altering the lipid availability to HeLa cells in culture 
would influence their response to statin-mediated cell death. HeLa-PHGL is a cell 
line which stably expresses the HMGCR promoter fused to a secreted Gaussia 
luciferase gene (Chapter 4) was used here, and is used for all subsequent 
investigations in HeLa within this chapter. This luciferase gene reporter assay serves 
as an accurate readout for SREBP activation. HeLa-PHGL cells were seeded in 
medium containing 10% FBS on day 1. The following day, cells were switched to 
fresh medium containing either 10% FBS (FS) or 10% LDS (LDS) supplemented 
with increasing concentrations of Simvastatin. HeLa-PHGL cells cultured in FS have 
a simvastatin ED50 of 2µM (Figure 6.1A).  HeLa-PHGL cells cultured in LDS have a 
much higher simvastatin ED50 of 25µM (Figure 6.1C).  The results indicate that 
HeLa-PHGL cells display an increased resistance to simvastatin induced cytotoxicity 
under LDS culture conditions. Two-way ANOVA analysis of the simvastatin dose 
response curves under FS and LDS conditions indicated that there was a statistically 
significant difference between FS and LDS conditions (Figure 6.1A; p=1.45E-42). 




and effectiveness, and thus comparison was carried out with a synthetic statin, 
Atorvastatin. HeLa-PHGL cells cultured under LDS conditions and in the presence 
of increasing atorvastatin concentrations displayed a similar resistance to statin 
mediated cytotoxicity. HeLa-PHGL cells cultured in FS have an atorvastatin ED50 of 
7µM (Figure 6.1B).  HeLa-PHGL cells cultured in LDS have a much higher 
atorvastatin ED50 of 30µM (Figure 6.1C). Two-way ANOVA analysis indicated that 
the difference in atorvastatin dose-response curves were statistically significant in FS 
and LDS conditions (Figure 6.1B; p=1E-18). Overall, the concentrations of statin 
required to kill half of the cells were higher for both simvastatin and atorvastatin in 
cells cultured in LDS compared to those cultured in FS. The ED50 for simvastatin 
was 12.5-fold higher in LDS compared to FS. Similarly, the ED50 for atorvastatin 
was 4.3-fold higher in LDS compared to FS.  
To investigate if the resistance seen under LDS was due to a SREBP-mediated 
increase in HMGCR expression, secreted luciferase enzyme activity was assayed in 
HeLa-PHGL cells cultured in both FS and LDS conditions. Cells cultured in FS 
displayed a significant increase in HMGCR reporter readout in response to low doses 
of statin over control cells with zero statin added with a maximal and significant 
increase of 2 and 1.7 fold being observed with 1.5µM simvastatin (p=0.009) and 4 
µM atorvastatin (p =0.014), respectively (Figure 6.2A and 6.2B). Cells cultured in 
LDS exhibited a greater response than cells cultured in FS with a maximum 2.6-fold 
increase in HMGCR reporter readout at 2µM simvastatin (p=1.8E-04) and 2.3-fold 
increase at 4µM atorvastatin (p-value=1.50E-04) (Figure 6.2A and 6.2B). The statin-
resistant phenotype of HeLa-PHGL cells in LDS conditions is linked to the larger 




Cell death induced by statins is likely to result from limiting the availability of the 
HMGCR product, mevalonate. If this is the case then addition of exogenous 
mevalonate to the cells grown in FS culture should confer resistance to cells under 
these conditions to the same extent (or higher) than when the cells are grown in LDS. 
Figure 6.3A shows that this indeed is the case, with mevalonate conferring statin 
resistance on the cells grown in FS (Figure 6.3A). Mevalonate also has the capacity 
to rescue statin-mediated cell death for cells cultured under LDS conditions (Figure 
6.3B). However, unlike in FS conditions, 50µM mevalonate fails to completely 
rescue cytotoxicity at simvastatin concentrations higher than 40 µM. A concentration 
of 70 µM simvastatin is required to achieve a 100% decrease in cell viability in LDS, 
and the presence of 50 µM mevalonate increases cell viability to 50% (p=1.46E-04).  
Increasing mevalonate to 100µM slightly improved on the rescue observed at 50 µM 
and 60 µM simvastatin, but again failed to completely rescue the cytotoxic effects of 
simvastatin. In the presence of 70 µM simvastatin, 100 µM mevalonate fails to 
increase cell viability above 60% (p=7.37E-05). Concentrations of mevalonate 
higher than 100 µM were not used in these studies as it has previously been shown 
that high concentrations of mevalonate negatively affect the activity of HMGCR 
through increasing degradation of the HMGCR protein and decreasing translation of 
HMGCR mRNA. This lack of complete rescue of simvastatin induced cytotoxicity 
suggests that the cytotoxicity occurring at high statin concentrations is likely to be 








   
 
 
Figure 6.1. HeLa-PHGL cells display an increased resistance to statin-mediated cell death in 
LDS versus FS culture conditions. HeLa-PHGL cells were treated with increasing 
concentrations of either (A) Simvastatin or (B) Atorvastatin under FS or (C) LDS 
conditions. . (D) The ED50 values for Simvastatin and Atorvastatin were calculated using the 
Excel plug-in ED50 plus v1.0. Experiments were performed in triplicate and error bars 
represent ± SD. Significance of statin resistance in FS versus LDS was compared for 
simvastatin (p<0.05)  and atorvastatin (p<0.05 ) using two-way ANOVA. 
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Figure 6.2. SREBP luciferase reporter expression in response to statin treatment. HeLa-
PHGL cells were cultured in the presence of increasing concentrations of either (A) 
Simvastatin or (B) Atorvastatin in both FS and LDS conditions. Following a 48 hour 
incubation period, media samples were assayed for luciferase activity. Experiments were 
performed in triplicate and error bars represent ± SD. Significance of the maximum point 














Figure 6.3. Mevalonate rescues statin induced cell death under both FS and LDS conditions. 
HeLa-PHGL cells were cultured in the presence of increasing concentrations of Simvastatin 
under either (A) FS or (B) LDS conditions, in the absence or presence of mevalonate at the 
indicated concentrations. Experiments were performed in triplicate and error bars represent ± 











Inhibition of the SREBP pathway enhances statin sensitivity in HeLa-PHGL cells 
 
Culturing cells under LDS conditions confers a resistance to statin-mediated cell 
death in HeLa-PHGL cells, and the data shown indicate that the mechanism 
underlying this relates to a SREBP-mediated increase in HMGCR expression. Thus, 
in the absence of this feed-forward SREBP mediated increase in HMGCR, the 
sensitivity of the cells to statin mediated cytotoxicity would be expected to increase. 
To investigate this possibility, a panel of known inhibitors of the SREBP pathway 
were first screened to identify the most potent as measured by  reducing HMGCR 
reporter expression and the effect of such inhibitors on statin mediated cytotoxicity 
was evaluated. The compounds screened were 25-OHC, cholesterol and also a more 
recently identified regulator of SREBP activation called betulin. Betulin is a 
naturally occurring compound derived from birch bark, and has been shown to 
negatively regulate SREBP by promoting binding of INSIG by SCAP. 19-OHC was 
used as a negative control oxysterol as it has been reported that 19-OHC does not to 
bind SCAP or INSIG, and does not affect SREBP cleavage. 19-OHC has been used 
in previous studies as a suitable control for SREBP feedback inhibition studies. The 
stable HeLa-PHGL cell line was treated with increasing concentrations of each 
inhibitory compound. The maximal repression of HMGCR promoter activity was 
achieved using 25-OHC at 1 µg/ml and cholesterol at 10 µg/ml under LDS 
conditions (5-fold and 5.5-fold, respectively) (Figure 6.4A and 6.4B). Betulin was 
less effective at reducing HMGCR promoter readout, with a maximum decrease of 
1.8-fold achieved in LDS prior to any cell death occurring (Figure 6.4C). No 
significant decrease in luciferase reporter readout was observed for betulin under FS 
conditions at non toxic concentrations. Unexpectedly, these dose-response screens 




control but the results indicate that 19-OHC displays a dose-dependent regulation of 
the HMGCR promoter at higher concentrations (Figure 6.4D). A concentration of 1 
µg/ml 19-OHC resulted in a 1.15 and 1.34-fold decrease in luciferase reporter 
readout under FS and LDS conditions, respectively. Based on these results, 25-OHC, 
cholesterol and betulin were brought forward to the next stage of experiments. 19-
OHC was also brought forward with a view to identifying if this oxysterol was 
indeed having an effect on SREBP activation and that the results observed here were 
















Figure 6.4. Inhibitors of SREBP processing. Increasing concentrations of a panel of SREBP 
processing inhibitors were incubated with the HeLa-PHGL cell line and secreted luciferase 
activity was measured 48 hours after addition of 25-OHC, Cholesterol, Betulin or 19-OHC. 
Cell viability was measured for the same experiments using the MTT assay. All sterols, with 
the exception of cholesterol, were prepared in EtOH. Cholesterol was prepared in MβCD as 








To investigate the hypothesis that blocking the induction of SREBP activity would 
increase the sensitivity of HeLa-PHGL cells to statin induced cytotoxicity, cells were 
cultured in the presence or absence of an SREBP inhibitor, in the presence of 
increasing concentrations of statin. The inhibitor chosen was 25-OHC as this was 
deemed the most potent with respect to inhibition of SREBP activation (Figure 6.4). 
ED 50s were calculated for HeLa-PHGL cells for simvastatin and atorvastatin in the 
absence and presence of 1μg/ml 25-OHC (Figure 6.5 and Table 6.1). The presence of 
25-OHC reduced the ED50 for cells grown in FS treated with simvastatin from 2.5 
μM to 1.5 μM (Figure 6.5A) and reduced the ED50 for cells grown in LDS treated 
with simvastatin from 25 μM to 2 μM (Figure 6.5B). Similarly, the presence of 25-
OHC reduced the ED50 for cells grown in FS treated with atorvastatin from 7 μM to 
3 μM (Figure 6.5C) and reduced the ED50 for cells grown in LDS treated with 
atorvastatin from 30 μM to 3 μM (Figure 6.5D). Thus the presence of 25-OHC 
significantly improved the  cytotoxic effect of both statins under FS and LDS culture 
conditions, and for both statins the maximum enhancing effect of 25-OHC was 
observed for statin-treated cells cultured under LDS conditions.  
Addition of exogenous mevalonate (50 μM) rescued cells from the enhancing effect 
of the 25-OHC on simvastatin treated cells (Figure 6.5E) Mevalonate rescue was 
considered to be similar for atorvastatin and as such, mevalonate rescue of cells 
treated with atorvastatin and 25OHC was not performed. Mevalonate rescue restored 
HeLa-PHGL cell viability in cells treated with simvastatin and 25-OHC to within the 
range of simvastatin alone treated cells. The presence of 1 μg/ml 25-OHC is 
sufficient to reduce SREBP luciferase reporter readout approximately 5-fold (Figure 
6.4A). The ability of mevalonate to rescue cell cytotoxicity in the presence of 




which remains in the presence of 25-OHC permits sufficient expression of 
cholesterogenic genes to utilise this exogenous mevalonate to produce essential 
isoprenoids and sterols required to maintain cell viability. 
Betulin significantly inhibited SREBP readout in the initial screen (Figure 6.4C) and 
therefore was also investigated for its effectiveness in enhancing simvastatin 
cytotoxicity.  Incubation of HeLa-PHGL cells with simvastatin in the presence of 
betulin under LDS conditions reduced the ED50 1.4 fold compared to cells treated 
with simvastatin alone (Figure 6.6). Betulin was less effective than 25-OHC at 
reducing the ED50 of simvastatin-mediated cytotoxicity for cells cultured in LDS, 
only reducing the ED50 from 35 µM to 25 µM (Figure 6.6). This is consistent with 
betulin having less effect on SREBP processing, as measured by luciferase reporter 
readout compared to that achieved with 25-OHC (Figure 6.4A vs. 6.4C). The 
presence of betulin was sufficient to significantly improve the cytotoxicity induced 
by simvastatin overall compared to HeLa-PHGL cells treated with simvastatin alone, 
as measured by two-way ANOVA (p=1.78E-11).  
Cholesterol also significantly inhibited SREBP readout in the initial screen (Figure 
6.4B) and therefore was investigated for its effectiveness in enhancing simvastatin 
cytotoxicity. Co-incubation of cholesterol with simvastatin decreased the statin ED50 
from 25 µM to 1.25 µM (Figure 6.7A). The presence of cholesterol significantly 
improved the cytotoxicity induced by simvastatin overall compared to HeLa-PHGL 
cells treated with simvastatin alone, as measured by two-way ANOVA (p=9.28E-
18).While this finding is consistent with the hypothesis, 25-OHC did not behave as 
expected in this experiment (Figure 6.7A). This can be explained by the following: 




methyl-β-cyclodextrin (MβCD) is a commonly used vehicle. Therefore, cholesterol 
was prepared as a sterol-MβCD complex and 25-OHC was prepared in the same way 
as a positive control, as described under materials and methods. Measurement of 
SREBP/HMGCR luciferase reporter activity in response to each sterol with or 
without MβCD indicated that 25-OHC/MβCD was less effective at lowering SREBP 
reporter readout below that of the vehicle treated control compared to 25-OHC alone 
(Figure 6.7B).  However, the data indicate that this decreased effect of 25-OHC is 
due to the presence of MβCD alone causing a 2-fold increase in SREBP reporter 
readout compared to vehicle treated control. The 25-OHC/MβCD complexes do 
significantly reduce SREBP reporter activity below that of MβCD alone (Figure 
6.7B). Cholesterol/ MβCD is capable of reducing SREBP reporter readout below the 
levels of vehicle treated control, despite the increase caused by MβCD. Thus 
cholesterol is potentially a stronger inhibitor of SREBP processing than 25-OHC. 
However, further experiments focused on 25-OHC as data interpretation is clearer 
and the effects of cholesterol may be confounded by the effects of MβCD.   
19-OHC was also investigated for its effectiveness in enhancing the cytotoxicity of 
simvastatin. 19-OHC had less of an inhibitory effect on the SREBP luciferase 
reporter compared to 25-OHC (Figure 6.4A vs. 6.4D). However, this oxysterol was 
brought forward with a view to further characterising if 19-OHC was indeed have 
some regulatory effect on the SREBP pathway. Interestingly, co-treatment of HeLa-
PHGL cells with simvastatin and 19-OHC in LDS yielded a similar enhancement of 
statin mediated cytotoxicity to that observed with simvastatin and 25-OHC co-
treatment. Incubation of HeLa-PHGL cells with simvastatin in the presence of 19-
OHC reduced the simvastatin ED50 in LDS to 3 µM compared to that of 25 µM for 




induced by simvastatin overall compared to HeLa-PHGL cells treated with 
simvastatin alone, as measured by two-way ANOVA (p=1E-14). The concentration 
of 19-OHC used here was 1 µg/mL. The SREBP luciferase reporter readout for the 
19-OHC dose-response indicated that higher concentrations of 19-OHC may have 
been used (Figure 6.4D). The 1 µg/mL concentration of 19-OHC was chosen to 
match the concentration used for 25-OHC. 19-OHC has been used in previous 
studies as a negative control for 25-OHC. Using these two oxysterols at the same 
concentration would allow for direct comparison between the effects seen with 19-
OHC to those seen with 25-OHC. The slightly reduced effect of 19-OHC compared 
to 25-OHC on enhancing  simvastatin ED50 in HeLa-PHGL cells cultured under LDS 
conditions is consistent with the reduced inhibitory effect of 19-OHC on SREBP 
processing compared to that achieved with the same concentration of 25-OHC 
(Figure 6.4A vs. 6.4D). 
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Figure 6.5. Inhibition of SREBP activity with 25-OHCenhances statin-induced cytotoxicity. 
HeLa-PHGL cells were incubated with increasing concentrations of either Simvastatin(A, 
B,)  or Atorvastatin(C, D)  under FS or LDS conditions, in the absence or presence of 25-
OHC (1µg/ml) and cell viability was measured using the MTT assay E) Cells were 
incubated with increasing concentrations of simvastatin in the absence or presence of 25-
OHC (1µg/ml) or 25-OHC (1µg/ml) plus mevalonate  (50 µM). Experiments were 















Figure 6.6. Inhibition of the SREBP pathway with betulin enhances statin-mediated 
cytotoxicity, HeLa-PHGL cells were incubated with increasing concentrations of simvastatin 
in the absence or presence of 1 µg/ml Betulin. Cell viability was measured using MTT assay. 
Experiments were performed in triplicate and error bars represent ± SD. Significance of 






Figure 6.7. Cholesterol enhances statin-mediated cytotoxicity. (B)HeLa-PHGL cells were 
incubated with increasing concentrations of simvastatin in the absence or presence of 10 
µg/ml cholesterol/ MβCD or 1 µg/ml 25-OHC/MβCD for 48 hours. Cell viability was 
measured using MTT assay (C) HeLa-PHGL cells were incubated with the indicated sterols 
either alone or complexed with MβCD  (25-OHC(1 µg/ml); cholesterol (10 µg/ml)).(D) Cell 
viability in response to the indicated sterol alone or sterol/ MβCD  complexes, measured 
using MTT assay. Experiments were performed in triplicate and error bars represent ± SD. 
Significance of enhancement of statin induced cytotoxicity was measured using two-way 














Figure 6.8. 19-OHC enhances statin-mediated cytotoxicity, HeLa-PHGL cells were 
incubated with increasing concentrations of simvastatin in the absence or presence of 1 
µg/ml 19-OHC. Cell viability was measured using MTT assay. Experiments were performed 
in triplicate and error bars represent ± SD. Significance of enhancement of statin induced 











Inhibition of the SREBP pathway enhances statin sensitivity in HeLa-PHGL cells 
through preventing statin-mediated increases in nSREBP2 and HMGCR levels 
The previous results show that 25-OHC was the most effective agent of the panel 
tested at reducing the ED50 for simvastatin. Therefore, 25-OHC was used extensively 
in subsequent experiments on statin cytotoxicity. 19-OHC was also further 
investigated with respect to its association with SREBP processing and enhancement 
of statin efficacy in reducing cell viability. 
To further investigate that the oxysterols are enhancing statin-mediated cell death 
through blocking of SREBP mediated increases in HMGCR, the levels of HMGCR 
and SREBP2 proteins in HeLa-PHGL cells were analysed by immunoblot. Cells 
were cultured with simvastatin in the presence and absence of either 25-OHC or 19-
OHC, in both FS and LDS culture conditions. Western blot analysis showed that 
cells cultured in the presence of simvastatin alone under FS conditions increased the 
levels of both HMGCR and nSREBP2 at the protein level (Figure 6.9, more sensitive 
exposure; lane 1 vs. 2). This increase in both HMGCR and nSREBP2 was 
completely blocked in the presence of simvastatin plus 25-OHC in FS (Figure 6.9, 
lane 2 vs. 3). The presence of 19-OHC (1μg/ml) did not significantly affect the levels 
of nSREBP2 produced in FS (Figure 6.9, SREBP2 more sensitive exposure; lane 2 
vs. 4). This is consistent with the low inhibitory effect of 1μg/ml 19-OHC on the 
SREBP luciferase reporter (Figure 6.4D). Interestingly, the presence of 19-OHC 
completely blocked the statin-induced increase in HMGCR in FS (Figure 6.9, lane 2 
vs. 4). This data suggests that 19-OHC is having a greater effect on HMGCR 
stability than on repressing nSREBP levels. 
Similar results were observed for HeLa-PHGL cells cultured under LDS conditions. 




and nSREBP2 were both increased (Figure 6.9, lane 5 vs. 6). This increase in both 
HMGCR and nSREBP2 was completely blocked in the presence of simvastatin plus 
25-OHC in FS (Figure 6.9, lane 6 vs. 7). The presence of 19-OHC (1μg/ml) did not 
significantly affect the levels of nSREBP2 produced in LDS (Figure 6.9, lane 6 vs. 
8). This is consistent with the low inhibitory effect that 1μg/ml 19-OHC has on the 
SREBP luciferase reporter under LDS conditions also (Figure 6.4D). Consistent with 
the findings in FS, the presence of 19-OHC completely blocked the statin-induced 
increase in HMGCR in LDS (Figure 6.9, lane 6 vs. 8). This data further suggests that 















Figure 6.9. Western blot analysis of HMGCR and SREBP2 in HeLa-PHGL cells treated with 
simvastatin in the absence and presence of oxysterols. Cells were cultured for 24 hours with 
0.5 µM simvastatin in FS or 10 µM simvastatin in LDS in the presence and absence of either 
25-OHC (1 µg/ml) or 19-OHC (1 µg/ml). All culture conditions contained 50 µM 
mevalonate to maintain cell viability. Lanes: 1-4; FS, Lanes: 5-8; LDS. Lanes: 1 and 5; 
Vehicle, 2 and 6; Simvastatin, 3 and 7; Simvastatin+25-OHC, 4 and 8; Simvastatin+19-
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Over-expression of constitutively active nSREBP2 partially rescues cell death 
induced by combined statin and oxysterol treatment in HeLa-PHGL cells 
The results indicate that the oxysterol enhancement of statin mediated cytotoxicity is 
via repression of SREBP processing. If this is the case, the enhancement effect 
should be reversed if the activation domain of SREBP2 (nSREBP2) is supplied in 
trans. To test this, cells were transfected with nSREBP2 which is constitutively 
active and is not subject to the regulation of the SREBP precursor protein as it lacks 
the transmembrane and regulatory domains. Expression of the nSREBP2 in 
transfected cells was confirmed by immunoblotting in the presence and absence of 
25-OHC (Figure 6.10A).  Over-expression of nSREBP2 increases the SREBP 
luciferase reporter readout 1.42-fold (42% increase) compared to empty vector 
(p=0.0285) following a 48-hour incubation period (Figure 6.10B). The presence of 
25-OHC results in a 3.35-fold decrease in luciferase reporter readout (p=3.05E-04). 
While over-expression of nSREBP2 fails to restore this 25-OHC mediated decrease 
in luciferase reporter activity back to control levels, it does restore it 1.85-fold which 
corresponds to 47% rescue, which is similar to the activation achieved by nSREBP2 
in the absence of 25-OHC (p=0.0066) (Figure 6.10B). Another possible explanation 
for this limited rescue of nSREBP2 in the presence of 25-OHC possibly lies in the 
transient transfection of the over-expression plasmid. The HeLa-PHGL cell line was 
used and thus all cells contain the luciferase reporter plasmid. The 25-OHC 
treatment affects all cells present, and its effects are active following the 48 hour 
incubation period on day four. However, the over-expression plasmid lacks a 
mammalian origin of replication and so is not replicated with every cell division. 
Thus, taking into account the doubling time of HeLa is approximately 24 hours, one 
would expect only approximately one quarter of the final cell population to express 




on day 2. The level of nSREBP2 rescue in the presence of 25-OHC observed in 
Figure 6.10B is consistent with this explanation. Nonetheless, over-expression of 
nSREBP2 was capable of significantly, although not completely, reverting the 
oxysterol enhanced statin cytotoxicity back towards the more resistant phenotype, as 
compared by two-way ANOVA (statin vs. statin+25-OHC+EV, p=3.07E-32; statin 
vs. statin+25-OHC+nSREBP2,p=8.22E-23) (Figure 6.10C). It is noteworthy that the 
rescue up to 1µM simvastatin is a 40% rescue, back up to 100% viability, and that 
this 40% rescue is maintained right up 3µM. The lack of capability of nSREBP2 to 
rescue up to 100% viability is likely attributable to the activation capacity of 
nSREBP2 alone in the presence of 25-OHC without any statin present, as shown in 

















Figure 6.10. Over expression of constitutively active nSREBP2 partially rescues cell death 
induced by simvastatin plus 25-OHC. (A) Immunoblot of over-expressed Flag-nSREBP2 in 
HeLa-PHGL cells: lane 1, empty vector; lane 2, Flag nSREBP2; lane 3, Flag nSREBP2 plus 
25-OHC. (B) Luciferase readout from the HeLa-PHGL stable cell line transfected with Flag-
nSREBP2 +/-  25-OHC (1 µg/ml). (C) HeLa-PHGL cells were transfected with empty vector 
or Flag and treated with increasing concentration of simvastatin. Cell viability was measured 
by MTT. Experiments were performed in triplicate and error bars represent ± SD. 
Significance of SREBP luciferase reporter activation or repression were measured using 
Student‘s t-Test (p<0.05). Significance of enhancement or rescue of statin induced 













HeLa-PHGL cells co-treated with statin and oxysterol undergo apoptosis 
Statins are known to induce apoptosis in a variety of cell lines, including HeLa cells. 
In previous experiments the effect of statins and oxysterol on HeLa-PHGL cells has 
been measured using the MTT assay which measures cell viability and cell 
proliferation. While this assay is a standard assay for cytotoxicity, it was important 
to confirm by a separate means that apoptosis was occurring in the cells treated with 
statin alone or with statin plus oxysterol. Propidium iodide (PI) is a common 
fluorescent dye used to measure cellular DNA content and facilitates cell cycle 
analysis using FACS. PI fluorescence is proportional to the DNA content of the cell. 
As apoptotic cells are characterised by fragmented DNA, this method can also be 
used to identify cells undergoing apoptosis (Nicoletti et al. 1991). Thus FACS 
analysis of PI labelled DNA was used here to compare the extent of apoptosis 
induction by simvastatin in cells grown in FS or in LDS in the presence and absence 
of 25-OHC.  4 µM simvastatin has been previously shown to be sufficient to kill all 
HeLa-PHGL cells cultured under FS conditions following a 48 hour incubation 
period while 4 µM simvastatin has no effect on HeLa-PHGL cells under LDS 
conditions.  
For analysis of apoptosis, HeLa-PHGL cells were cultured with 4 µM simvastatin for 
24 hours to allow induction of apoptosis, either in the absence or presence of 25-
OHC. Cells were then harvested and stained with PI for analysis by FACS. Using PI 
staining with FACs analysis normal cells display  characteristic peaks corresponding 
to diploid (2n) or tetraploid (4n) DNA content while apoptotic cells can be 
distinguished by increased fluorescence detected below these peaks (sub-G1, <2n) 
due the presence of fragmented DNA. For HeLa-PHGL cells cultured with 4 µM 




compared to the untreated control (Figure 6.11A and 6.11B). Conversely under LDS 
conditions, 4 µM simvastatin increases the sub-G1 population by only 7.2% 
compared to the untreated control (Figure 6.11C and 6.11D). However cells cultured 
under LDS conditions with 4 µM simvastatin in the presence of 1 µg/ml 25-OHC 
display a 55.3% increase in the sub-G1 population compared to cells treated with 25-
OHC alone (Figure 6.11E and 6.11F). This data demonstrates that the level of 
fragmented DNA in the sub-G1 population (which is indicative of apoptosis) is at 
similar levels for simvastatin treated cells cultured in FS conditions and in LDS 






Figure 6.11. Measurement of apoptosis induced by simvastatin in FS conditions and LDS 
conditions in the absence and presence of 25-OHC. Cells were cultured in FS or LDS 
conditions in the presence of the indicated compounds for 24 hours. Cells were then 
harvested, permeabilised using ethanol, and DNA was stained using PI as described under 
materials and methods. Cells were then analysed by FACS. A, FS conditions without 
simvastatin; B, FS conditions with 4 µM simvastatin; C, LDS conditions without 
simvastatin; D, LDS conditions with 4 µM simvastatin; E, LDS conditions with 1 µg/ml 25-







Investigation of oxysterol-mediated SREBP feedback and statin cytotoxicity in a 
panel of cancer cell lines  
Cell lines derived from other cancer types were tested to see if they had similar 
oxysterol-mediated SREBP feedback and statin cytotoxicity to HeLa-PHGL cells. 
Dose-response curves for simvastatin treated A-498 (kidney carcinoma), DU-145 
(prostate carcinoma), MeWo (malignant melanoma), MCF-7 (breast 
adenocarcinoma), HepG2 (hepatocellular carcinoma), KYSE-70 (oesophageal 
squamous cell carcinoma) and HT-29 (Colorectal adenocarcinoma) cell lines were 
determined for both FS and LDS conditions (Figure 6.12A). Two-way ANOVA 
analysis revealed that A-498, DU-145 and MCF-7 cell lines did not have 
significantly different dose-responses to simvastatin under FS and LDS conditions 
(p=0.973, 0.126 and 0.401, respectively) while MeWo, HepG2, KYSE-70 and HT-
29 cell lines had significantly different dose-responses to simvastatin under FS and 
LDS conditions (p=1.55E-06, 3.22E-09, 0.045 and 4.71E-33, respectively). The dose 
response curves were then used to calculate the ED50 values for each cell line (Figure 
6.12B). The ED50 values varied widely across the cell lines tested from 5 µM to 50 
µM in FS and from 16 µM to 69 µM in LDS reflecting different sensitivities across 
the cancer cell lines to statin induced cytotoxicity. In agreement with the two-way 
ANOVA analysis of the cell line dose-response curves, A-498, DU-145 and MCF-7 
cell lines did not display significant difference in their simvastatin ED50 values in FS 
and LDS (p=0.219, p=0.172, p=0.079, respectively (student‘s t-test)), while KYSE-
70, HepG2, MeWo and HT-29 cell lines were significantly different in FS vs. LDS  
(p=9.37E-04, p=1.51E-03, p=0.034 and p=9.41E-06, respectively). 




To investigate if the cell lines displayed a sterol regulated feedback response of the 
SREBP pathway, each cell line (A-498, DU-145, MeWo, MCF-7, HepG2, KYSE-70 
and HT-29) was transiently transfected with the SREBP luciferase reporter plasmid 
promHMGCR-GLuc. To achieve this, transfection for each of the cell lines required 
optimisation. Luciferase activity of a constitutively active luciferase reporter 
plasmid, pCMV-GLuc, was used to compare the transfection efficiency achieved 
using three commercial transfection reagents; Lipofectamine 2000, TurboFect and 
Xtremegene (Figure 6.13). Maximal transfection efficiency was achieved using 
Lipofectamine 2000 for A-498, KYSE-70, and MeWo and Xtremegene for DU-145, 
HT-29, and MCF-7. For HeLa-PHGL there was no significant difference observed 
across the three transfection reagents used, and thus TurboFect was used due to 
simplicity of use and cost effectiveness. The levels of transfection of HepG2 with 
Xtremegene and TurboFect were 9.08-fold and 3.96-fold higher than HeLa-PHGL 
cells respectively and the TurboFect method was deemed sufficient for use with the 
HepG2 cells. The results indicated that a 1:2 ratio of plasmid DNA to transfection 
reagent (µg:µl) was optimal in all cases. The optimal transfection conditions were 
then used to transiently transfect each cell line with promHMGCR-pGLuc and the 
cell lines were screened for a sterol feedback response using the SSLR method 
described in chapter 4. 
The cell lines A-498, DU-145, MeWo and MCF-7 did not display any decrease in 
luciferase reporter activity in response to increasing concentrations of 25-OHC (data 
not shown), and thus were not followed up any further for the purpose of this 
investigation. However, the lack of a sterol feedback response in these cells lines is 
interesting and merits further investigation. The cell lines KYSE-70, HepG2 and HT-




to 25-OHC, thus confirming that sterol regulated feedback is present in these cell 
lines (Figure 6.14). Interestingly, HT-29 and KYSE-70 displayed significantly 
different responses to oxysterol induced cytotoxicity under FS compared to LDS 
conditions. HT-29 and KYSE-70 cells were more sensitive when cultured in LDS 
(Figure 6.14A and 6.14C). In contrast, HepG2 cells displayed a similar response to 
oxysterol induced cytotoxicity under both FS and LDS conditions (Figure 6.14B). 
Based on the presence of a sterol feedback response in these cell lines, HT-29, 
KYSE-70 and HepG2 were further investigated to see if co-treatment of simvastatin 










   








Figure 6.12. Simvastatin cell viability dose-response curves for a panel of cancer cell lines 
under FS and LDS conditions. A) All cell lines were cultured in the presence of increasing 
concentrations of simvastatin under FS and LDS conditions for 48 hours. Cell viability was 
assessed using MTT assay. B) Simvastatin ED50 of the different cell lines under FS and 









Figure 6.13. Optimising transfection of cell lines. Cells were transfected according to 
manufacturers guidelines for Lipofectamine 2000 (Lipo     ), TurboFect (Turbo      ) or 
Xtremegene (Xtreme     ) transfection reagents. The amount of pCMV-GLuc reporter 
plasmid transfected was kept constant at 0.5 µG and the transfection reagents were used at 
either 1:2 or 1:3 (µG/ µL) ratios. Transfection efficiency was assessed by measuring 
















Figure 6.14. SREBP feedback response to 25-OHC treatment in cell lines. Cells were 
incubated in the presence of increasing concentrations of 25-OHC under both FS and LDS 
conditions. Media was sampled after 48 hours and assayed for secreted luciferase activity. 













Investigation of inhibition of the SREBP pathway and statin sensitivity in HT29, 
HEPG2, KYSE70 cells  
The effect of co-treatment of 25-OHC or 19-OHC and statins in enhancing cancer 
cell death was investigated and yielded mixed results. For HT-29 cells cultured in FS 
conditions, co-treatment of simvastatin with either 25-OHC or 19-OHC reduced the 
ED50 6-fold from 6µM to less than 1µM (Figure 6.15A). The presence or absence of 
25-OHC and 19-OHC on statin cytotoxicity was compared. The presence of 25-OHC 
and 19-OHC significantly enhances the cytotoxicity caused by increasing 
concentrations of simvastatin in FS, (p=1.87E-26 and p=1.78E-26, respectively (two 
way ANOVA)). Analysis of the SREBP activation readout using the HMGCR 
promoter luciferase reporter in the same experiment showed that 25-OHC and 19-
OHC reduced SREBP readout 3 fold and 2.8 fold respectively (Figure 6.15B). This 
indicates that the enhancement of statin-mediated cell death is due to the inhibitory 
effects that 25-OHC and 19-OHC   have on HMGCR promoter activation. HMGCR 
promoter activation is significantly repressed by both 25-OHC and 19-OHC in the 
presence of increasing statin concentrations. Thus, this confirms that there is an 
active SREBP-feedback response in the HT-29 cell line. However, when cells were 
cultured in LDS rather than FS conditions and were treated with simvastatin in the 
presence and absence of oxysterols, the same degree of oxysterol enhancement of 
statin ED50 did not occur (ED50=15 μM for all in LDS) (Figure 6.15A and 6.15C) 
although analysis of the dose-response curves by two-way ANOVA indicated that 
the presence of 25-OHC did significantly improve the overall cytotoxicity induced 
with increasing concentrations of simvastatin (p=0.0012) compared to conditions 
where 25-OHC was absent, while no difference was observed with 19-OHC  
(p=0.491). Analysis of the SREBP activation readout using the HMGCR promoter 




enhancement may by the oxysterols is likely to be to the much lower inhibitory 
effect of the oxysterols on HMGCR promoter activity under LDS conditions 
compared to FS (Figure 6.15B and 6.15D). In LDS conditions, 25-OHC reduced the 
luciferase reporter readout 1.26-fold while 19-OHC reduced it 1.34-fold. These 
differences were not significant over conditions where the 25-OHC and 19-OHC 
were absent (p=0.179 and p=0.115, respectively (student‘s t test)).  
Immunoblot analysis of HT-29 cells revealed an induction of both SREBP2 and 
HMGCR in response to statin treatment in FS conditions (Figure 6.16, lane 2). This 
induction is inhibited by both 25-OHC and 19-OHC, although to a lesser extent by 
19-OHC (Figure 6.16, lane 3, 4). By contrast, there is a substantial level of induction 
of both HMGCR and SREBP2 under LDS conditions in the presence of simvastatin 
(Figure 6.16, lane 6). Again this induction is inhibited by 25-OHC and to a lesser 
extent by 19-OHC. Overall the levels of induction or repression of SREBP correlate 
with the levels of HMGCR detected and correlate with the statin cytotoxicity 
observed in the absence and presence of the sterols under FS conditions. Under LDS 
conditions, the trend remained the same. However, while the 25-OHC repressed 















Figure 6.15. Analysis of the effect of oxysterols on cell viability and SREBP readout in HT-
29 cells grown in FS or LDS conditions. Cells were cultured in the presence of increasing 
amounts of simvastatin in the absence or presence of oxysterols under both FS and LDS 
conditions. Cell viability was measured using MTT assay (A and C). Media was sampled 















   
 
Figure 6.16. Western blot analysis of HMGCR and SREBP2 in HT-29 cells treated with 
simvastatin in the absence and presence of oxysterols. Cells were cultured for 24 hours with 
1µM simvastatin in FS or 3 µM simvastatin in LDS in the presence and absence of 25-OHC 
(FS=3 µg/ml, LDS=0.25 µg/ml) or 19-OHC (FS=3 µg/ml, LDS=0.25 µg/ml). 50 µM 
mevalonate was included in the growth media to maintain cell viability. FS conditions lanes 
1-4 and LDS conditions lanes 5-8. Lanes 1-8: vehicle, simvastatin, simvastatin plus 25-OHC 
FS, simvastatin plus 19-OHC, vehicle, simvastatin, simvastatin plus 25-OHC, simvastatin+ 
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The effect of co-treatment of oxysterols and statins in enhancing cancer cell death 
was next investigated for HepG2 cells. Co-treatment of HepG2 cells with simvastatin 
and 25-OHC significantly improved the ED50 2.3-fold from 35µM to 15 µM in the 
ED0-ED50 region of the graph. However, this was not sustained across the whole 
dose response range, and did not affect the simvastatin concentration required to 
decrease cell viability 100%, which remained at approximately 100 µM (Figure 
6.17A). 19-OHC had a similar, but slightly less effect than 25-OHC (Figure 6.17A, 
17C). SREBP/HMGCR luciferase reporter readout analysis for the same experiment 
indicated that19-OHC reduced the luciferase reporter readout 1.53-fold compared to 
the 2.12-fold decrease achieved with 25-OHC (Figure 6.17B). In the presence of 
simvastatin, overall repression of luciferase reporter activity remained statistically 
significant for 25-OHC and 19-OHC compared to statin alone, as compared by two-
way ANOVA (p=6.37E-14 and p=6E-07, respectively).  A similar effect was seen in 
for HepG2 cells co-treated with simvastatin and oxysterols under LDS conditions 
(Figure 6.17C). 25-OHC and 19-OHC significantly enhanced simvastatin induced 
cytotoxicity overall in LDS conditions, as compared by two-way ANOVA (p=1.36E-
07 and p=0.005, respectively). However, consistent with what was observed for 
HepG2 under FS conditions this enhancement was observed at lower simvastatin 
doses but not at higher ones. Analysis of the SREBP readout luciferase reporter 
activity for the same experiment showed a 4.41-fold decrease achieved with 25-OHC 
and a 1.63-fold decrease achieved with 19-OHC (p=1.19E-04 and p=0.002, 
respectively). In the presence of simvastatin, overall repression of luciferase reporter 
activity remained statistically significant for 25-OHC and 19-OHC compared to 
statin alone, as measured by two-way ANOVA(p=5.11E-20 and p=1.09E-10, 




SREBP luciferase reporter repression achieved with each oxysterol was related to the 
level of oxysterol enhancement of the statin effect on cell viability. Immunoblot 
analysis of HMGCR and SREBP2 protein levels indicated that there was an increase 
in both proteins in response to simvastatin treatment, and that the increase was 
higher under LDS conditions (Figure 6.18, lane 2, 6). This is consistent with what 
was seen in HeLa-PHGL and HT-29 cells, but was unexpected as unlike the HeLa-
PHGL and HT-29 cells, HepG2 cells have the same simvastatin ED50 in both FS and 
LDS conditions. The presence of 25-OHC completely prevented the statin-mediated 
increase in both HMGCR and nSREBP2, with 19-OHC having a lesser effect, under 
both FS and LDS conditions (Figure 6.18, lane 3, 4, 7, 8).  
A similar set of experiments were carried out on KYSE-70 cells and results were 
very similar to results with HepG2. Co-treatment of KYSE-70 cells with simvastatin 
and 25-OHC reduced the ED50 5.2-fold from 58 µM to 10 µM in FS conditions 
(Figure 6.19A). However, the 50% decrease in cell viability achieved with 10 µM 
simvastatin in the presence of either 25-OHC or 19-OHC does not decrease any 
further from 10 µM up to 40 µM simvastatin. Similar to HepG2 cells, 25-OHC and 
19-OHC significantly enhanced simvastatin induced cytotoxicity overall in FS 
conditions over simvastatin alone (p=1.5E-10 and p=3.52E-11, respectively (two-
way ANOVA)). Analysis of the SREBP luciferase readout for the same experiment 
showed that 25-OHC and 19-OHC reduced secreted luciferase with 19-OHC having 
a stronger effect than 25-OHC (Figure 6.19B).  For KYSE-70 cells co-treated with 
simvastatin and oxysterols under LDS conditions, similar results were observed. 25-
OHC significantly enhanced simvastatin induced cytotoxicity overall in LDS 
conditions, (p=0.02 (two-way ANOVA)) while 19-OHC did not have a significantly 




reporter activity for the same experiment indicated that the 19-OHC was only 
marginally effective in inducing SREBP feedback by comparison with 25-OHC in 
KYSE-70 cells under LDS conditions (Figure 6.19D) and explains why the 19-OHC 
did not significantly enhance simvastatin cytotoxicity under these conditions.  
In the presence of simvastatin, overall repression of luciferase reporter activity 
remained statistically significant for 25-OHC and 19-OHC compared to statin alone 
(p=1.9E-09 and p=1E-05, respectively (two-way ANOVA). However, consistent 
with what was observed for HepG2 under LDS conditions the enhancement of 
simvastatin induced cytotoxicity by 25-OHC was not sustained across the whole 
dose response range, and did not affect the concentration required to decrease cell 
viability to 100% levels, Consistent with results from HeLa-PHGL, HT-29 and 
HepG2, the level of SREBP luciferase reporter repression achieved with each 
oxysterol correlated with the level of oxysterol enhancement of the statin effect on 
cell viability.  
Immunoblot analysis of HMGCR and SREBP2 protein levels indicated that there 
was an increase in both proteins in response to simvastatin treatment, and that the 
increase was substantially higher under LDS conditions (Figure 6.20, lane 2, 6). This 
is consistent with what was seen in HeLa-PHGL, HT-29 and HepG2 cells. The 
presence of 25-OHC completely prevented the statin-mediated increase in both 
HMGCR and nSREBP2, with 19-OHC having a lesser effect under FS and 
practically no effect under LDS conditions (Figure 6.20, lane 3, 4, 7, 8).  
Overall, the data from the analysis of the simvastatin cytotoxicity in HepG2 and 
KYSE-70 in the presence and absence of oxysterols suggest that the simvastatin cell 




by oxysterol induced reduction of HMGCR while the loss of cell viability at higher 
statin concentrations appears to be by a different mechanism since the oxysterols are 
ineffective at the higher statin concentrations. To further explore this idea, the ability 
of mevalonate to rescue the statin-mediated cell death in HT-29, HepG2 and KYSE-
70 cell lines was investigated. Full rescue of statin-mediated cytotoxicity in the three 
cell lines occurred when 100 μM mevalonate was included in the growth media (50 
μM mevalonate had and intermediate to full rescue effect depending on the cell line) 
(Figure 6.21) at or under simvastatin concentration of 40 to 60 μM. However, when 
the simvastatin concentration were higher than this, mevalonate rescue was no longer 
effective indicating that the decrease in cell viability at the higher statin 



















Figure 6.17. Analysis of the effects of oxysterols on simvastatin cytotoxicity under both FS 
and LDS culture conditions in HepG2 cells. Cells were cultured in the presence of increasing 
simvastatin concentrations under both FS and LDS conditions. Cells were co-treated with or 
without 25-OHC (2 µg/ml) or 19-OHC (2 µg/ml) as indicated. Cell viability was measured 
using MTT assay (A and C). Media was sampled after 48 hrs and assayed for secreted 















Figure 6.18. Western blot analysis of HMGCR and SREBP2 in HepG2 cells treated with 
simvastatin in the absence and presence of oxysterols. Cells were cultured for 24 hours with 
10 µM simvastatin in FS or 10 µM simvastatin in LDS in the presence and absence of 25-
OHC (2 µg/ml) or 19-OHC (2 µg/ml).  50 µM mevalonate was included in the growth media 
to maintain cell viability. FS conditions lanes 1-4 and LDS conditions lanes 5-8.Lanes 1-8, 
Vehicle, Simvastatin, Simvastatin plus 25-OHC, Simvastatin plus 19-OHC,  Vehicle, 

















Figure 6.19. Analysis of the effect of oxysterols on cell viability and SREBP readout in 
KYSE-70 cells grown in FS or LDS conditions. Cells were cultured in the presence of 
increasing amounts of simvastatin in the absence or presence of oxysterols (FS=5 µg/ml, 
LDS=0.5 µg/ml) under both FS and LDS conditions. Cell viability was measured using 
MTT assay (A and C). Media was sampled after 48 hrs and assayed for secreted luciferase 
















Figure 6.20. Western blot analysis of HMGCR and SREBP2 in KYSE-70 cells treated with 
simvastatin in the absence and presence of oxysterols. Cells were cultured for 24 hours with 
10 µM simvastatin in FS or 10 µM simvastatin in LDS in the presence and absence of 25-
OHC or 19-OHC (FS=5 µg/ml, LDS=0.5 µg/ml).   50 µM mevalonate was included in the 
growth media to maintain cell viability. FS conditions lanes 1-4 and LDS conditions lanes 5-
8.Lanes 1-8, Vehicle, Simvastatin, Simvastatin plus 25-OHC, Simvastatin plus 19-OHC,  

















Figure 6.21. Mevalonate rescue of statin treated HT-29, HepG2 and KYSE-70 cells under 
FS and LDS culture conditions.  Cells were incubated with increasing concentrations of 
simvastatin in the presence and absence of 50 μM or 100 μM mevalonate over a 48 hour 












The work described in this chapter tested the hypothesis that preventing the SREBP-
mediated activation of cholesterogenic genes that occurs upon statin treatment would 
reduce the level of the HMGCR gene and protein expression, which in turn would 
reduce the effective statin concentration required to induce cancer cell apoptosis via 
mevalonate starvation and consequently improve the chemotherapeutic potential of 
the statins. 
Initially the investigation involved looking at the effect of statin cytotoxicity in 
HeLa-PHGL cells in full vs. lipid depleted serum. Interestingly, HeLa-PHGL cells 
grown in LDS were significantly more resistant to statin induced cytotoxicity than 
when grown in FS. This response was observed with both a naturally occurring statin 
simvastatin (12.5-fold difference) and a synthetic statin atorvastatin (4.3-fold 
difference). Simvastatin and atorvastatin are the two most commonly used statins on 
the market used for the treatment of high cholesterol related disease. The differences 
in efficacy between simvastatin and atorvastatin in inducing cytotoxicity were not 
unexpected because although statins all target the active site of HMGCR, they differ 
in their pharmacokinetic properties (Schachter 2004). This result of an increased 
resistance to statin cytotoxicity in LDS has not been seen previously.  Despite the 
extensive amount of research on statins, all previous work on statin cytotoxicity has 
been focused on cells in FS. The simplest explanation for this is that cholesterol is 
depleted in LDS. Therefore cells in LDS would be expected to have increased 
SREBP processing and therefore increased transcription of downstream SREBP 
target genes including HMGCR (Nohturfft et al. 1999; Vallett et al. 1996).  Analysis 
of SREBP/HMGCR luciferase reporter readout confirmed that there was a direct 




statins has been reported to be due to HMGCR inhibition limiting the production of 
essential mevalonate derived protein modification substrates including 
geranylgeranyl pyrophosphate and farnesyl pyrophosphate (Stancu & Sima 2001). 
Consistent with the cytotoxicity being related to SREBP/HMGCR down-regulation, 
mevalonate rescued the cells from statin induced cytotoxicity, with full rescue 
occurring in FS and rescue ranging from 60-90% occurring in LDS. The difference 
in rescue is likely linked to the higher statin concentration required to achieve 
cytotoxicity in LDS compared to FS. For these higher concentrations of statin, it is 
likely that cytotoxicity for a large part is due to HMGCR inhibition but that other 
mechanism(s) may also be involved.  
These findings show that increasing HMGCR levels increases resistance to statin 
cytotoxicity and suggest that a strategy whereby agents are used to reduce HMGCR 
would increase the cytotoxicity of statins and increase their potential for use as 
chemotherapeutic agents. In this work three previously characterised sterol feedback 
response agents that decrease SREBP processing were evaluated (cholesterol, 25-
OHC and betulin) and 19-OHC was used as a negative control. Using the 
SREBP/HMGCR luciferase reporter assay, cholesterol and 25-OHC were highly 
effective in reducing reporter readout, and betulin was less effective. Interestingly, 
19-OHC was found to have an effect on SREBP/HMGCR luciferase reporter 
readout, whereas previous reports all show that 19-OHC does not interact with 
INSIG or SCAP and is commonly used as a negative control (Sun et al. 2005; 
Radhakrishnan et al. 2007a). Consistent with previous reports, use of 19-OHC in the 
same concentration range as 25-OHC had little effect on SREBP/HMGCR luciferase 





The statin cytotoxic effects were significantly enhanced when used in combination 
with cholesterol or 25-OHC and to a lesser extent with betulin. In LDS, 25-OHC and 
cholesterol reduced the simvastatin ED50 by 12.5-fold and 20-fold, respectively, 
while betulin reduced it only 1.4-fold. This is consistent with betulin having less of 
an effect on SREBP/HMGCR luciferase reporter readout. Clinical trials to date using 
statin as chemotherapeutic have used statin treatment regimes in the order of 40-
80mg/day, which translates into low serum concentrations (Solomon & Freeman 
2008). Low serum concentrations may be only partially effective in inducing cell 
death, while in vitro studies show micromolar concentrations are required to achieve 
significant cancer cell death. The work reported here provides a potential solution to 
achieving higher cell death with lower statin concentrations, namely by co–
administration with 25-OHC or cholesterol.  One interesting prospect not 
investigated here is whether a combination of cholesterol and 25-OHC would give 
further enhancement of statin cytotoxicity.  The justification for this is that 
cholesterol binds SCAP and 25-OHC binds INSIG and promotes degradation of 
HMGCR (Radhakrishnan et al. 2007a).  The reason that the combination treatment, 
and indeed cholesterol itself was not followed up here was that the cyclodextrin 
delivery vehicle (MβCD) for cholesterol had an effect on increasing 
SREBP/HMGCR luciferase reporter readout. This is not unexpected as other 
cyclodextrins are used to deplete cellular membranes of cholesterol (Christian et al. 
1997). This depletion in cholesterol would cause an increase in SREBP/HMGCR 
luciferase reporter readout. This limitation could be circumvented by using LDL-
cholesterol but this was not available for this work.  
Given that 19-OHC unexpectedly had a repressive effect on SREBP/HMGCR 




similar concentrations (1µg/ml) it is comparable with 25-OHC with respect to 
enhancing statin cytotoxicity. This was a surprising finding as at this concentration 
19-OHC has a very small effect on SREBP/HMGCR luciferase reporter readout in 
the region of 10% reduction. These results indicate that 19-OHC may not be exerting 
its effect by suppression of HMGCR transcription at this concentration. More insight 
into the mechanism by which 19-OHC works was provided by immunoblot analysis, 
which is discussed below.  
While the SREBP/HMGCR luciferase reporter readout is a measure of SREBP 
transcription activity and HMGCR promoter activity, analysis of HMGCR and 
SREBP at the protein level is required for a comprehensive analysis of these proteins 
under the different conditions studied (Figure 6.9). Consistent with the 
SREBP/HMGCR luciferase reporter readout and the statin resistance of the HeLa-
PHGL cells in LDS, immunoblot analysis showed that both nSREBP2 and HMGCR 
were higher in LDS compared to FS.  In the presence of simvastatin HMGCR and 
nSREBP2 were induced to a very high level in HeLa-PHGL cells in LDS compared 
to FS, further explaining the significant resistance of HeLa-PHGL cells to the 
simvastatin cytotoxicity. 25-OHC was very effective in reducing both HMGCR and 
nSREBP2 in both FS and LDS, presumably reflecting its ability to prevent SREBP 
processing and stimulate degradation of HMGCR.  
The results with 19-OHC were somewhat surprising. At the concentration used 19-
OHC only had small effect on SREBP/HMGCR luciferase reporter readout 
compared to 25-OHC, but was as effective as 25-OHC in enhancing the cytotoxic 
effect of simvastatin. The immunoblot analysis offers an explanation for this as it 




HMGCR. This indicates that 19-OHC is less effective than 25-OHC in repressing 
SREBP processing but is very effective in promoting HMGCR degradation. Previous 
reports on 19-OHC have only investigated 19-OHC binding to SCAP or INSIG and 
this was shown to be negative at the concentration used (Radhakrishnan et al. 
2007a). Thus this work has shed new light on a common dietary oxysterol and 
indicates that it is a novel regulator of HMGCR protein stability.  
The results indicate that the mechanism by which 25-OHC enhances statin 
cytotoxicity is mediated by its effect on preventing SREBP processing. This was 
confirmed by the processed form of SREBP2 (nSREBP2) rescuing the cell from the 
enhanced statin cytotoxicity in the presence of 25-OHC. The rescue observed using 
nSREBP2 was about 40%. The lack of capability of nSREBP2 to rescue up to 100% 
viability is likely to be partially accounted for by the fact that all of the cells contain 
the luciferase construct and 25-OHC treatment affects 100% of the cells. However 
nSREBP2 is transiently transfected into the cells and the transfection is not likely to 
have surpassed more than 80%.  
Statins are known to induce apoptosis in a variety of cell lines (Cafforio et al. 2005; 
Clendening, Aleksandra Pandyra, et al. 2010; Wächtershäuser et al. 2001; Glynn et 
al. 2008). The MTT assay used here for the majority of experiments measures 
mitochondrial dehydrogenase activity which is a measure of respiring cells. Thus the 
MTT assay is a measure of cell viability and cell proliferation. While this assay is a 
standard assay for cytotoxicity, FACS analysis of PI-stained DNA confirmed that 
induction of apoptosis was occurring at a high level with simvastatin in FS and with 
the simvastatin combination with 25-OHC in LDS, and was consistent with the MTT 




The oxysterol enhancement of statin cytotoxicity worked very successfully using 
HeLa cells. However, cancers are very heterogeneous and it was important to 
investigate other cancer cell lines to determine if they responded the same way as the 
HeLa cells. The cell lines investigated reflected a number of different cancer types. 
Investigation of the statin induced cytotoxicity in these cell lines showed a broad 
range of ED50 concentrations. Statin sensitivity differs in HeLa cells in FS vs. LDS. 
The cell lines KYSE-70, HepG2 and HT-29 were similar to HeLa in this respect 
while no significant difference was observed with the other cell lines (A-498, DU-
145, MCF-7 and MeWo). To explore this difference further, all cell lines were tested 
for the presence of a sterol feedback response. This response was present in the cell 
lines which showed different statin sensitivity in FS vs. LDS, while it was absent in 
the other cell lines.  
Loss of sterol feedback was reported very early on in liver cancer models, although 
sterol feedback remains present in HepG2 cell line (Siperstein & Fagan 1964). The 
sterol feedback response has been investigated the most with respect to prostate 
cancer. Absence of a sterol feedback response has previously been reported for DU-
145 and PC-3 cells, and deregulated processing of SREBPs is associated with 
progression to androgen-independence (Chen & Hughes-Fulford 2001; Ettinger et al. 
2004b).  However, a conflicting report shows the presence of a sterol feedback 
response in PC-3 and LNCaP prostate cancer cell lines, although DU-145 cells were 
not investigated in this study (Krycer et al. 2009). Whether the sterol feedback 
response is intact in other cancer cell lines has not been investigated. The absence of 
this response would be advantageous to the cancer cell as it ensures a consistent high 
level supply of mevalonate and other essential sterol intermediates to support 




shown here is interesting and indicates that this may be a regular feature in cancer. 
The analysis here did not give any insight into the mechanism underlying the 
absence of the sterol feedback response and was not pursued in this work.  It would 
be interesting to determine if this lack of feedback correlates with a more aggressive 
cancer phenotype, however this aspect was not pursued here. 
The sterol feedback response was evident in HT-29, HepG2 and KYSE-70 but the 
response differed between the cell lines. HT-29 were unusual in several respects by 
comparison with HeLa cells. Like HeLa, HT-29 cells were more resistant to statin 
cytotoxicity in LDS vs. FS and they exhibited sterol feedback response in FS 
conditions. However in LDS conditions, HT-29 cells were highly sensitive to 
cytotoxicity induced by 25-OHC. The reason for this increased sensitivity to 
oxysterol cytotoxicity seen here compared to in HeLa is unclear.  
In FS, enhancement of statin cytotoxicity with 25-OHC in HT-29 cells was 
significant and correlated with the reduction of SREBP/HMGCR luciferase reporter 
readout by 25-OHC. Enhancement of statin cytotoxicity with 25-OHC in HT-29 in 
LDS was also investigated, but because of the heightened sensitivity to 25-OHC 
induced cytotoxicity, a low concentration of 25-OHC or 19-OHC was used. This 
concentration was not sufficient to reduced the SREBP/HMGCR luciferase reporter 
readout (Figure 6.15D), and the inclusion of this concentration of the oxysterols had 
little impact in enhancing the statin cytotoxicity (Figure 6.15C). Immunoblot 
analysis of HT-29 in FS was as expected with respect to HMGCR and nSREBP2. 
Both were increased in response to statin and this increase was blocked by 25-OHC 
with 19-OHC being less effective. The result from the immunoblot analysis of HT-




in response to statin, however the presence of the low amount of 25-OHC decreased 
nSREBP2 to background levels but had only a minor effect on HMGCR levels. 
Given that nSREBP2 is virtually absent, SREBP/HMGCR luciferase reporter 
readout should be highly suppressed but this was not the case (Figure 6.15D). This 
indicates in LDS conditions that the sterol feedback response in HT-29 is intact with 
respect to SREBP processing but that SREBP2 regulation of HMGCR is uncoupled 
at the transcriptional level, as evidenced by the SREBP/HMGCR luciferase reporter 
readout. There is also the possibility that HMGCR protein stability is also being 
deregulated. The implication of this finding is that certain cancers may be able to 
adapt to changing dietary conditions with respect to HMGCR regulation and further 
investigations will be necessary to explore the different HMGCR response in FS vs. 
LDS.  
HepG2 did not exhibit any difference to 25-OHC induced cytotoxicity between FS 
and LDS and the sterol feedback response in relation to 25-OHC and 19-OHC was 
evident in both culture conditions. The oxysterols enhance statin cytotoxicity at low 
to medium concentrations of simvastatin in both FS and LDS, but at higher statin 
concentrations in FS and LDS, the oxysterols appeared to have a slightly protective 
effect. The reasons for this are unclear but given that high statin concentrations are 
used, it is possible that the cytotoxicity induced at the higher concentrations is due to 
a mechanism(s) outside of HMGCR inhibition, especially as the statin cytotoxicity at 
higher concentrations was only rescued to a limited extent with mevalonate (Figure 
6.21C and 6.21D). Immunoblot analysis of HMGCR and nSREBP2 in HepG2 cells 
in FS and LDS in the presence or absence of oxysterol yielded somewhat similar to 
HeLa cells, in that 25-OHC blocked the statin induced increase in HMGCR and 




reduced HMGCR to background levels. This supports the idea discussed earlier that 
19-OHC is primarily affecting the stability of HMGCR protein.  Overall, the 
enhancing effects of oxysterols on statin cytotoxicity observed in HepG2 at lower 
statin concentrations are consistent with the enhancing effects of oxysterols seen in 
HeLa, and seen in HT-29 in FS only. However, further investigation is required to 
elucidate the mechanism(s) of statin cytotoxicity at higher statin concentrations.  
The response of KYSE-70 cells was similar to HepG2 in FS, in that the oxysterols 
enhance statin cytotoxicity at low to medium concentrations of simvastatin but to a 
lesser extent at the higher statin concentrations. Also similar to HepG2, the statin 
cytotoxicity at higher concentrations was only rescued to a limited extent with 
mevalonate in KYSE-70 (Figure 6.21E and 6.21F). This supports the idea that the 
cytotoxic effects of statins are not limited to inhibition of HMGCR at higher 
concentrations. In LDS, the KYSE-70 cells were more similar to HT-29 in that they 
had an increased sensitivity to cytotoxicity induced by 25-OHC, which meant that a 
low concentration of 25-OHC or 19-OHC was used to investigate oxysterol 
enhancement of statin cytotoxicity with in LDS. This concentration used was not 
sufficient to reduced the SREBP/HMGCR luciferase reporter readout (Figure 
6.19D), and the inclusion of this concentration of the oxysterols had little impact in 
enhancing the statin cytotoxicity in LDS (Figure 6.19C). Immunoblot analysis in 
KYSE-70 for simvastatin and 25-OHC was as expected in FS, with 25-OHC 
reducing both nSREBP2 and HMGCR. However, the 19-OHC appeared to behave 
differently in the FS compared to HepG2 and HeLa, as nSREBP2 processing was 
reduced to almost the same extent as with 25-OHC while HMGCR was also 
substantially reduced. The results for KYSE-70 in LDS were more surprising. 25-




was not well reflected in the statin cytotoxicity results in the presence of 25-OHC. 
The response to 19-OHC in LDS was almost absent. This was very different to 25-
OHC and also different to what was observed in FS. Overall, the enhancing effects 
of oxysterols on statin cytotoxicity observed in KYSE-70 in FS are consistent with 
the enhancing effects of oxysterols seen in HeLa and HepG2, and in HT-29 in FS 
only. Similar to HepG2, due to the limited rescue of mevalonate on statin 
cytotoxicity in KYSE-70, further investigation is required to elucidate the 
mechanism(s) of statin cytotoxicity at higher statin concentrations.  
The results presented here show that different cancer cell lines have related yet 
different responses to statin induced cytotoxicity and enhancing of statin cytotoxicity 
with oxysterol. Results in HeLa, HT-29, HepG2 and KYSE-70 show that lowering 
statin sensitivity using oxysterols is a valid approach in FS conditions. However, the 
different responses of the cell lines in LDS indicate that dietary influences may have 
a significant impact on the efficacy of this approach. The results presented here give 
significant new insight into the potential use of statins as anticancer agents and 
indicate approaches to enhance their efficacy. Further elucidation of the mechanisms 
underlying the deregulated response in cells where the feedback is absent and in cells 
where the feedback is altered in LDS conditions will provide additional insights and 





























The SREBP family of transcription factors are central to regulating de novo 
cholesterol and fatty acid biosynthesis. The aims of this thesis were to gain further 
insight into the regulatory aspects surrounding SREBP processing and also to 
investigate the potential of exploiting the SREBP pathway in the treatment of cancer.  
The interaction between SCAP and SREBP is essential for both SREBP protein 
stability and in regulating SREBP processing. The interaction has been localised to 
the respective CTDs of each protein, but has not been elucidated. Mapping the exact 
binding site of the SREBP CTDs within SCAP would give valuable insight into the 
control and regulation of SREBP processing and would shed light on the regulation 
surrounding differential activation of SREBP1 and SREBP2. The knowledge could 
also contribute to development of an inhibitor of the SREBP-SCAP interaction. 
Inhibiting this interaction has major relevance to disease including cancer as 
blocking the interaction could enhance cell killing. Blocking this interaction could 
also reduce lipid biosynthesis and prove beneficial in the treatment of obesity. 
Significant obstacles were encountered in purifying recombinant SREBP CTDs and 
limited the prospect of mapping the site on SCAP to which SREBP1 and SREBP2 
bind. Preliminary peptide array analysis using SREBP2CTD-His6 identified peptides 
in SCAPCTD that could potentially be key in the interaction. However, these results 
were not reproduced in a repeat peptide array. The reason for this is not clear but 
may be related to the difficulty in preparing good quality native SREBP. However, 
peptide array analysis using SREBP1CTD-His6 identified multiple amino acid 
stretches in SCAPCTD that could potentially be key in the interaction, and these were 
reproduced in a repeat peptide array. Attempts to narrow down the SREBP1CTD-His6 
binding site in SCAP further using alanine scanning arrays of the identified amino 




candidate residues in the context of the full length SCAP protein is required to assess 
their impact on the SCAP-SREBP interaction. Due to the limitations presented in 
preparing good quality native SREBP, time constraints did not permit these 
functional studies to be performed within the scope of this thesis. 
PGRMC1 was clearly identified as interacting directly with SCAP and INSIG1 by 
Suchanek et al in 2005 using photo cross-linking of proteins and this prompted an 
investigation of PGRMC1s influence on SREBP reported in this thesis, in particular 
with respect to regulation of SREBP processing. Investigation of PGRMC1 as a 
putative regulator of SREBP processing indicated that it did not have any effect 
under the conditions tested here that could be attributed to direct regulation of 
SREBP processing,.  However, while the results indicated that PGRMC1 did not 
affect SREBP processing, and P4 did not appear to impact on this, our studies did 
highlight novel roles for both PGRMC1 and SCAP in mediating cytotoxic actions of 
P4 under lipid depleted conditions as at high concentrations of P4 LDS protected 
against cell killing whereas the protection was absent in the presence of over-
expressed PRGMC1 or SCAP. A role for SCAP in P4-induced cytotoxicity is a 
novel finding, and suggests a role for SCAP in cell response to P4 in addition to its 
role in SREBP processing. These novel findings in relation to P4 were not followed 
up within the scope of the aims of this thesis, but the significance of this finding 
merits further investigation.  
INSIG1 is a well characterised protein with respect to its role in negative regulation 
of both SREBP processing and HMGCR protein stability. However, there are two 
INSIG1 isoforms produced from INSIG1 mRNA through the use of two alternative 




investigate the reason for the evolutionary conservation of the two in-frame start 
sites present within the INSIG1 transcript, and to discern the functional significance 
of the generation of two INSIG1 isoforms through alternate translation start sites. 
The results indicate that the presence of the two start sites is highly conserved among 
vertebrates and is also present in the fission yeast homolog, Ins-1. Conservation of 
the Kozak sequence surrounding the two start sites suggests translation initiation in 
other vertebrate species is likely to occur similarly to the human INSIG1scenario. 
The results presented indicate that there are no significant functional differences 
between the two human INSIG1 isoforms with respect to the current known 
functions of INSIG1 protein, but novel function(s) of the isoforms could not be ruled 
out. Bioinformatic analysis suggested a possible regulatory mechanism surrounding 
isoform expression involving ribosome stalling, but confirmation of such regulation 
remains to be established. However, without a functional difference between the two 
isoforms, the significance of having such a regulation is unclear.   
During the course of this research, 19-OHC was identified as a novel negative 
regulator of SREBP processing and HMGCR protein stability. The ability of 19-
OHC to decrease HMGCR at the protein level was achieved at concentrations below 
that required to inhibit of SREBP processing and HMGCR promoter activity. The 
action of 19-OHC is different than cholesterol with respect to SREBP feedback as 
the latter does not affect HMGCR stability. The action of 19-OHC is similar to 25-
OHC in that it promotes degradation of HMGCR and at higher concentrations 
reduces SREBP activity to a certain extent. The data suggests that its efficacy in 
promoting degradation of HMGCR is similar to 25-OHC but its efficacy in reducing 
SREBP processing is lower. In previous reports 19-OHC has been used as a control 




for 25-OHC or other oxysterols affecting HMGCR stability or SREBP processing. 
Further characterisation of 19-OHC with respect to INSIG-mediated regulation of 
SREBP processing and HMGCR degradation is necessary to confirm that it is 
working in a similar manner to 25-OHC. 19-OHC is reported as a common oxysterol 
found in cholesterol-rich foods, however how 19-OHC is produced remains 
unknown and a functional role for 19-OHC has not been reported. Regulation of 
cholesterol biosynthesis by 19-OHC adds to the knowledge on oxysterol and dietary 
regulation of SREBP processing. It would be interesting to see if 19-OHC would 
also function similarly to other oxysterols in other manners, such as in LXR 
signalling.  
One of the most interesting findings in this thesis is that targeted inhibition of 
SREBP processing is a viable means of enhancing statin cytotoxicity and thus 
lowering the statin concentration required to kill cancer cells. The potential use of 
statins as anti-cancer agents is limited by the high concentrations of statins required 
to induce cell death. The results presented here indicate that the inherent ability of 
statins to increase their own target HMGCR contributes significantly to this 
resistance to statin cytotoxicity.  Previous studies whereby HMGCR was targeted 
post-transcriptionally with tocotrienols showed that lowering HMGCR protein had 
synergistic effects with statin in inducing cytotoxicity. In the approach presented a 
superior effect was considered achievable since targeted inhibition of SREBP2 
processing would reduce HMGCR at both mRNA and protein levels, but would also 
prevent essential cholesterol uptake through preventing the statin-associated increase 
in LDLR. Although not assessed in the work presented here, inhibition of SREBP 
processing could also negatively impact on the expression of other genes essential to 




The finding that half of the cancer cell lines screened here displayed an increased 
resistance to statin cytotoxicity under lipid depleted conditions has important 
implications for considering the impact of diet on both clinical trials for potential use 
of statins as anti-cancer agents but also in interpreting the data from epidemiology 
studies investigating links between cancer incidence and the use of statins.  
The finding that the other half of the cancer cell lines screened here displayed a lack 
of sterol feedback response in SREBP processing is consistent with reports for a 
subset of AML and prostate cancers so far. However, this finding suggests that 
evading this feedback response is a more common event than previously expected 
and now extends to cell lines from breast, renal and melanoma cancer types. 
Deregulation of the SREBP pathway is presumably advantageous to cancer cell 
survival as it provides a sustained increase in mevalonate levels. Understanding the 
mechanisms underlying this deregulation is important to consider with respect to the 
potential use of statins as anti-cancer agents. While cell lines lacking a feedback 
response were not explored in the current investigation, oxysterols may also be 
capable of enhancing statin cytotoxicity in these cell lines, by promoting HMGCR 
degradation, but this remains to be investigated.  
Another key finding from this research is that mevalonate does not rescue 
cytotoxicity induced at higher concentrations of statins in the cancer cell lines 
screened (40-100 µM dose range). This would suggest that statin cytotoxicity is 
occurring via a mechanism outside of mevalonate limitation at higher concentrations 
and thus is independent of HMGCR activity. This is an important finding with 
respect to the potential use of statins as anti-cancer agents as understanding the 




potential side effects. Thus further investigation of the mechanisms underlying statin 
cytotoxicity at high concentrations is necessary. 
Overall, the work presented here supports the potential use of statins as anti-cancer 
agents and has raised some important issues for consideration for the use of statins in 
this context. This work has also presented targeted inhibition of SREBP processing 
as a viable method of lowering statin doses required for cancer cell death. However 
this work has also highlighted that this approach may be limited if the statin induced 
















Summary of Thesis Achievements 
The first aim of this thesis was to investigate the possibility that SREBP1 and 
SREBP2 bound distinct sites within the CTD of SCAP through mapping their 
interaction sites. Progress in bringing this aim to completion was limited by 
difficulties in obtaining high quality purified SREBPCTD proteins. However, 
significant steps were taken towards achieving this aim by identifying candidate 
SREBP binding residues within SCAPCTD. Interestingly, the preliminary results 
presented in this thesis suggest that SREBP1 and SREBP2 may actually bind to a 
common site within the CTD of SCAP. The residues identified here require follow 
up by SDM within the full length SCAP protein and functional analysis with respect 
to their role in binding SREBP.  
The second aim of this thesis was to further characterise proteins which interact with 
the SCAP:SREBP complex with respect to their roles in regulating SREBP 
activation and cholesterol biosynthesis. Two proteins were investigated; PGRMC1 
and INSIG1. The results presented in this thesis indicate that PGRMC1 does not 
regulate SREBP processing. However, the experiments performed have highlighted a 
potential role for both PGRMC1 and SCAP in mediating the cytotoxic action of 
progesterone under lipid depleted conditions, which merits follow up investigation. 
INSIG1 has two protein isoforms produced through the use of two in-frame 
translational start sites. The aim was to investigate if the isoforms served different 
purposes with respect to the two known functions of INSIG1, which are negative 
regulation of SREBP processing and HMGCR protein stability under high sterol 
conditions. The results presented in this thesis conclude that the two isoforms of 




response to sterols as both isoforms were individually capable of inhibiting SREBP 
processing and promoting HMGCR degradation. 
The final aim of this thesis was to investigate inhibition of SREBP processing as a 
means to lower the concentration of statin required to induce cancer cell death. The 
results presented in this thesis show that inhibition of SREBP processing using 
sterols is a viable method to enhance statin induced cancer cell death and thus lower 
the statin concentration required to achieve cancer cell death. This has important 
implications for the use of statins as a chemotherapeutic drug since their use is 
currently limited by inability to achieve serum concentrations high enough to 
achieve cancer cell death.  Lowering the effective cytotoxic concentration of statins 
may also limit adverse side effects which are associated with high statin doses. The 
work from this thesis has also highlighted a number of key issues which require 
consideration for the use of statins as a chemotherapeutic, including a) the potential 
influence of diet as a number of cancer cell lines were found to be more resistant to 
statin induced cell death in lipid depleted conditions, and b) that high concentratons 
of statins may be inducing cell death by mechanism(s) outside of inhibiting the 
catalytic activity of HMGCR.  
Overall, the work presented in this thesis has contributed to the knowledge base 
surrounding regulation of SREBP proteins and has offered a means to further the use 
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